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ABSTRACT 
Ribavirin, 1-ß-D-ribofuranosyI-1,2,4-triazole-3-carboxamide, is a broad 
spectrum antiviral agent active against both DNA and RNA viruses. A 
range of 1,2,3-triazole, 1,2,4-triazole and benzotriazole analogues of 
ribavirin was synthesised using a crude extract of N- 
deoxyribosyltransferases from Lactobacillus leichmannii in the 
chemoenzymatic synthesis of nucleoside analogues with potential 
antiviral activity. N-Deoxyribosyltransferase catalyses the transfer of the 
2-deoxyribose sugar between purine and pyrimidine bases. Of thirty two 
bases synthesised, twelve were found to act as acceptors in the N- 
deoxyribosyltransferase reaction. Nine 2'-deoxyribofuranosyl-1,2,4- 
triazole nucleoside analogues were isolated and characterised. Only one 
nucleoside showed any significant antiviral activity. 
2'-Deoxyribavirin was found to possess antiviral activity against the 
influenza virus. Attempts were made to synthesise the nucleoside 
chemically from ribavirin on a larger scale, but without success. 
However, 5'-iodo-5'-deoxyribavirin and 5'-deoxyribavirin were 
synthesised, the former showed slight antiviral activity. 
The specificities of the N-deoxyribosyltransferases for purine, pyrimidine 
and triazole bases are discussed, gathering together the 
findings of 
previous workers with the results presented in this thesis. 
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CHAPTER 1 
INTRODUCTION 
General Background 
In developed countries up to sixty per cent of all illness is caused by viral 
infections such as influenza, herpes, hepatitis, rabies and mumps 
compared to only fifteen per cent resulting from bacterial infection. 1 
Industry and government had been relatively inactive in preventing or 
alleviating the effects of viral infection by chemotherapy until acquired 
immune deficiency syndrome (AIDS)2 brought unprecedented finance, 
manpower and determination to bear on solving problems associated with 
the human immunodeficiency virus (HIV), identified in the early 1980s. 3 
Treatment of viral diseases is largely limited to prevention, i. e. 
vaccination, rather than cure, forestalling the infection by stimulating 
the immune system in advance rather than by attacking the virus 
directly. This is short-sighted considering the latency of herpes virus, 
infecting eighty per cent of the population, and the high antigenic 
variation of others such as the common cold. 
Viruses were first identified in plant cells in the 1890s, 4 when it was 
shown that bacteria-free filtrates of tobacco plants infected with tobacco 
mosaic disease virus could produce the disease in healthy plants. In the 
same year the mammalian virus causing foot and mouth disease was 
identified. 5 
Viruses are packets of DNA or RNA contained in a protein coat. To 
replicate, the virus must first enter the cell by penetrating the cellular 
membrane, then commandeer the host cell's own genetic machinery to 
replicate itself, assemble the new virus particles and release them to 
1 
infect other cells. This intimate relationship with the biochemical 
mechanism of the host cell means that there are few unique functions for 
selective attack, that do not harm the host cell. In the replication of viral 
nucleic acids, there are certain enzymes which are specifically coded for 
by the virus. Most potential antiviral drugs (Table 1.1), the majority 
nucleoside analogues, target these enzymes and interrupt nucleic acid 
synthesis. 
DRUG VIRUS 
Amantidine Influenza A 
Rimantidine Influenza A 
5-Iodo-2'-deoxyuridine HSV 
5-Trifluoromethyl-2'deoxyuridine HSV 
Adenine arabinoside HSV 
Acyclovir HSV, VZV 
Gancyclovir Cytomegalovirus 
5-Ethyl-2'-deoxyuridine HSV (Germany) 
5-Iodo-2'-deoxycytidine HSV (France) 
Ribavirin Respiratory syncytial virus 
3'-Azido-2', 3'-dideoxythymidine HIV-1 
2', 3'-dideoxyinosine HIV-1 
Penciclovir HSV, VZV 
Famciclovir HSV, VZV 
Table 1.1 Licensed antiviral drugs 
Viruses and Antiviral Chemotherapy 
Herpes viruses are double-stranded DNA viruses causing diseases such as 
2 
cold sores, chicken pox and genital sores. There are many nucleoside 
analogues targetted at this virus as it codes for many of the enzymes 
required in its own replication. The most successful is acyclovir6 3 (Fig. 
1.1) which is now marketed by Wellcome as an over-the-counter drug. 
O 
HN 
CH3 
ON 
HO 
N3 
1 
AZT 
2 
ddl 
3 
Acyclovir 
Fig. 1.1 The chemical structures of some antiviral nucleosides 
All the nucleoside analogues are phosphorylated to the triphosphate in 
the cell where they can act as chain terminators, 7'9 inhibit viral capping 
enzymes 10-12 or act as suicide substrates for some polymerases. 13 
The influenza viruses A, B and C of the family orthomyxoviridae provides a 
case where prevention by vaccination is not the complete answer. The 
protein coat of this enveloped RNA virus varies greatly due to point 
mutations or recombination of RNA between species making control by 
vaccine at best one step behind the virus. 
Amantidine hydrochloride 14 4 (Fig. 1.2), is a narrow spectrum agent, 
active only against influenza A virus. In 1966 it was the first antiviral 
drug approved by the FDA for the use against Asian influenza in the USA. 
Rimantidine hydrochloride 5 (Fig. 1.2), an analogue with fewer side 
effects, is widely used in Russia 
15 , 16 and is shortly to be licensed in the 
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HN N 
HO 0 
0 
N 
I 
HI-p 
ý/0 V 
3 
USA, for the treatment of influenza A virus. 17 
4 5 
Amantidine hydrochloride Rimantidine hydrochloride 
Fig. 1.2 Drugs used in the treatment influenza 
Both influenza drugs prevent infection by raising the pH of the 
endosomal/lysosomal compartments. The virus attaches to the cell as 
normal but once inside the secondary uncoating of the virus core is 
inhibited. 18' 19 This prevents RNA from reaching the nucleus where 
replication normally occurs. 
20 Treatment works in seventy per cent of 
cases with influenza A, but neither drug is effective against influenza B. 
The potential neurotoxicity of amantidine hydrochloride and the rapid 
formation of resistant strains precludes their widespread use. 
Ribavirin 7 is the next most effective inhibitor of influenza A and B 
replication and infection. 
21 
Ribavirin 
Ribavirin (1-0-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) 7 (Fig. 1.3), 
the first broad spectrum antiviral agent, was reported in 1972 as part of a 
program to prepare broad spectrum antiviral agents. 
12, 22,23 Since then, 
it has been studied in more animals and against more viruses than any 
other antiviral agent, but has the most pronounced activity against 
4 
NH2 HCI 
M 
NH. HCI 
orthomyxoviruses and paramyxoviruses. 24 It inhibits a wide range of DNA 
and RNA viruses in vitro and in vivo, 22' 25, 26 showing activity in cell 
culture against about eighty per cent of all viruses studied, with little 
cellular toxicity. 27 However VirazoleTm, marke ted by ICN Pharmaceut icals, 
is only approved in the USA against severe respiratory syncytial virus 
(RSV) in young children. 28 It has shown teratogenicity in rats and 
29 hamsters,, 30 though not in baboons. 26,31,32 
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Fig. 1.3 Similarity of ribavirin to guanosine and adenosine 
0 
N FINN 
HO O 
CIO OH 
8 
Guanosine 
Ribavirin has a multipronged mode of attack (Scheme 1.1). 21 X-ray crystal 
studies show the striking similarity to guanosine 8 (Fig. 1.3), or on 
rotation about the amido group, to adenosine 6 (Fig. 1.3). 3 3 The inhibition 
of inosine monophosphate (IMP) dehydrogenase by ribavirin-5'- 
monophosphate (RMP), which has an affinity 70 times greater than IMP, 
results in a depletion of cellular GTP pools. 34 Ribavirin-5'-triphosphate 
(RTP), the most abundant form of ribavirin, can then more effectively 
competitively inhibit the viral specific RNA polymerase of some viruses 
by acting as a GTP or ATP substrate analogue. 
359 36 RTP inhibits the viral- 
specific mRNA capping enzymes, guanyltransferase and N7- 
methyltransferase, interrupting viral protein synthesis3 
7 and inhibits 
5 
initiation and elongation of viral mRNA. 
38 Resistance has only been 
detected recently in Sindbis virus mutates with an altered RNA 
guanyltransferase. 39 Ribavirin is not incorporated into the DNA or RNA of 
either mammalian or viral systems. Ribavirin is effective against viruses 
in plants, such as potato virus X, and in man, such as infectious hepatitis 
A40 and potentiates the anti-HIV activity of dideoxynucleosides, e. g. 
dideoxyinosine. 41,42 
The success of ribavirin has stimulated the chemical synthesis and 
antiviral testing of a large number of glycosides of related 5-membered 
heterocycles. 26,43 
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Scheme 1.1 Proposed mechanism of action of ribavirin' 
7 
Nucleoside Synthesis 
Chemical Synthesis 
There are three main strategies for the chemical synthesis of nucleoside 
analogues: 45,46,47 
" the modification of a preformed nucleoside; 
0 the formation of the glycosidic bond by the fusion of a preformed base 
onto a sugar; or 
0 the de novo synthesis of a heterocyclic base onto a preformed nitrogen 
or carbon substituent at C-1 of the sugar moiety. 
Formation of the Glycosidic Bond 
Koenigs-Knorr Procedure 
This reaction uses the presence of an acyloxy substituent at C-2 to produce 
selectively only the 0 -ribonucleosides. The initial sugar halide is formed 
from the reaction of the D-ribofuranose tetraacetate with hydrogen 
bromide in acetic acid to give 2,3,5-tri-O -acetyl-a-D-ribofuranosyl 
bromide. 
Heavy metal salts of the bases catalyse the nucleophilic displacement of 
the halogen substituent from the C-1 of the protected sugar to give the 1,2 
trans product, even though the reaction is unimolecular. Only the ß- 
product is formed because the neighbouring trans-acetoxyl group at C-2 
shields the a-face of the sugar (Scheme 1.2). 
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Scheme 1.2 Koenigs-Knorr displacement of halide 
When the C-2 group is absent a mixture of a- and ß-anomers results, 
confirming the stabilisation of the carbonium ion by neighbouring group 
participation (Scheme 1.3). 
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Scheme 1.3 Formation of both a- and ß- anomers in the absence of a 
functional group at C-2 
For the synthesis of 2'-deoxynucleosides and 2', 3'-dideoxynucleosides other 
methods are, therefore, favoured. 
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Scheme 1.4 Pyrimidine nucleoside synthesis 
Hilbert-Johnson and Silyl Procedures 
O -Substituted pyrimidines are sufficiently nucleophilic to react 
with halogeno-sugars without the need for electrophilic catalysis. 
directly 
In the 
10 
BzO 
alkylation of a 2-alkoxypyrimidine with a halogeno-sugar the initial 
product is a quaternary salt which can then be used to give several 
nucleosides with different base moieties. Even with a ribose derivative an 
anomeric mixture is produced (Scheme 1.5). 
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Scheme 1.5 Hilbert-Johnson synthesis of nucleosides 
This method was significantly improved by the introduction of silylated 
bases which are easily prepared, give homogeneous reaction mixtures and 
allow conversion of the intermediate products into a wide variety of 
nucleosides with modified bases. The early use of mercuric oxide gave way 
to other Lewis acid catalysts such as tin (IV) chloride and mercuric 
acetate, which were superseded by silyl esters of strong acids e. g. 
trimethylsilyl triflate (Scheme 1.6). These Friedel-Crafts-catalysed 
reactions are fast and high yielding. 
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Scheme 1.6 Friedel-Crafts-catalysed nucleoside synthesis51 
With ribose sugars the ß-nucleoside is formed exclusively. In the synthesis 
of 2'-deoxynucleosides a nonpolar 
mechanism giving predominantly the 
solvent will promote the SN2 
0-nucleosides. 52 Many nucleoside 
analogues have been made in this way, 53 but the lack of regioselectivity 
and stereoselectivity and the need for protecting groups can reduce yields. 
12 
Transglycosylation 
Transglycosylation is the transfer of a sugar residue from one base to 
another. It is most effective for transferring sugars from pyrimidines 
(which are n -deficient heterocycles) to the more basic purines (n - 
excessive heterocycles), by an SN 1 reaction mechanism (Scheme 1.7). 54 
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Scheme 1.7 Synthesis of nucleosides by transglycosylation 
Fusion 
A melt of the 1-acetoxy sugar and a suitable base in vacuo, with a trace of 
acid catalyst gives the nucleoside in acceptable yields. This method is best 
for weakly basic heterocycles having a low melting point and has been 
used in many convergent syntheses of triazole nucleoside analogues 
(Scheme 1.8). 55-57 
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Scheme 1.8 Fusion synthesis of nucleosides58 
Construction of the Base onto the Sugar at C-1 
31% 
The advantages of building the base on to the sugar moiety are that the 
position of attachment of the glycosyl residue is unambiguous and the ß- 
configuration at C-1 will usually be conserved in the product nucleoside. 
However, anomerisation of glycosyl azides has been reported. 59 This route 
is often employed for the synthesis of C-nucleosides and carbocyclic 
nucleosides which can therefore be derived from starting materials other 
than sugars or other carbohydrates (Scheme 1.9). 45,60 
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Scheme 1.9 Synthesis of a nucleoside by building the base onto the sugar 
Modification of Nucleosides 
Hundreds of reactions have been used to transform the base of a 
preformed nucleoside. 
46,61,62,63 Unfortunately modification of the 
sugar moiety often necessitates multistep procedures involving protection 
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d 
N( 
N 
0 
TolO 
Td0 
0 TolO 
ToK) N-N 
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14 
sugar moiety often necessitates multistep procedures involving protection 
and deprotection to control stereoselectivity and regioselectivity. 47' 64 
Enzymatic Synthesis 
Many nucleoside analogues are difficult to synthesise chemically because 
of the need for both modified base and sugar residues. The multistage 
processes are often difficult and time consuming giving mixtures of 
products in poor yields. The advantages of enzymatic methods over purely 
chemical methods are their efficiency, selectivity and the mildness with 
which they catalyse reactions. The broad substrate specificities of some 
enzymes allow reactions to be performed on analogues of natural 
substrates in both aqueous and non-aqueous solvents. Enzymes can be used 
to replace existing chemical processes or in combination with chemical 
steps to improve existing methods. Difficulties may arise in scale-up 
production due to the concentration of substrates or of the presence of 
other species in the reaction solution. Immobilisation on a support 
material can stabilise the enzyme and a small quantity of enzyme can be 
used repeatedly to synthesise substantial amounts of product and, it is 
recoverable at the end. A large range of products can be prepared under 
these mild conditions in good yields making it a convenient method for the 
small scale synthesis of nucleoside analogues in screening 
programmes. 
65-69 
Enzymatic Synthesis of Nucleoside Analogues 
Enzymatic Modification of Sugar or Base Residues 
Enzymes can be used to modify existing nucleosides by selective protection 
15 
and deprotection of hydroxyl groups. 7 073 By far the most useful 
applications have been the resolution of racemic nucleoside analogues by 
sugar modification74 
deaminase. 75,76 
Glycosyl Transfer Reactions 
and base modification using adenosine 
Two main classes of enzyme have been used to synthesise nucleoside 
analogues by transferring glycosyl residues from a donor nucleoside to an 
acceptor base: nucleoside phosphorylases and N- 
deoxyribosyltransferases. 69 
Nucleoside Phosphorylases 
Nucleoside phosphorylases catalyse the reversible phosphorolysis of 
ribonucleosides or deoxyribonucleosides affording ribose-1-phosphate or 
deoxyribose-1-phosphate and a purine or pyrimidine base. Addition of an 
acceptor base can lead to the formation of a new nucleoside with the 
equilibrium lying well in favour of nucleoside formation. Since the 
discovery of nucleoside phosphorylase and a general description of the 
mechanism 77 this method of nucleoside synthesis has been widely used. 
Both pyrimidine and purine nucleoside phosphorylases are known. They 
can be obtained from mammalian and bacterial sources and their substrate 
specificities can vary with the source. 78 
16 
Two strategies have generally been used (with ribose as the sugar moiety 
in the example of Scheme 1.10). The first involves isolation of the ribose- 
1-phosphate from a nucleoside donor and a high concentration of 
phosphate. This intermediate is then used as the glycosyl donor with 
respect to an added pyrimidine or purine base. 
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Scheme 1.10 Two-stage synthesis of nucloesides using nucleoside 
phosphorylases 
The second strategy involves a one-pot exchange of one base for another 
in the presence of a catalytic amount of inorganic phosphate without the 
isolation of the intermediate ribose- 1-phosphate (Scheme 1.11). 
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Scheme 1.11 One-pot synthesis of nucleosides using nucleoside 
phosphorylases 
Both methods have been used in the small scale production of a variety of 
nucleoside analogues. 69 The first strategy is the most general. The 
second 79 has limitations. For example, an equilibrium mixture of starting 
and product nucleosides can be formed from which the desired nucleoside 
must be separated. In other cases, the base released by the glycosyl donor 
may act as a competitive inhibitor of the enzyme and prevent the base 
analogue from binding. The problem of inhibition can be avoided by 
using a pyrimidine nucleoside as the glycosyl donor and a purine base as 
the acceptor, but both a pyrimidine and a purine nucleoside 
phosphorylase are then required. 
Both methods have disadvantages as they either require the presence of 
both pyrimidine and purine nucleoside phosphorylases or the isolation of 
the intermediate ribose-1-phosphate. These problems can be overcome 
and the yields of the coupled enzymatic reaction can be greatly increased 
by the use of an irreversible donor nucleoside. 8° By using the salt of 7- 
methylguanosine, as the glycosyl donor, the first stage of the 
18 
phosphorolysis reaction is made irreversible. The cleavage of the glycosyl 
bond produces a neutral base molecule which lacks a tautomeric proton on 
N-7. The formation of the positively charged nucleoside in the reverse 
direction would be highly unfavourable. Therefore, the 7-methylguanine 
does not function as an acceptor base in the reverse reaction and so the 
intermediate ribose-1-phosphate formed is available exclusively for the 
formation of product nucleoside. Only one of the nucleoside 
phosphorylases, not both, is required and as the 7-methylguanine is very 
insoluble, purification of the product nucleoside is very easy. The 
effectiveness of this approach was demonstrated in the synthesis of 
ribavirin using 1,2,4-triazole-3-carboxamide (TCA) as the acceptor base 
(Scheme 1.12). 
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Scheme 1.12 Use of 7-methylguanosine as an irreversible donor in the 
synthesis of nucleoside analogues80 
The nucleoside phosphorylases have been found to accept a wide range of 
19 
nucleoside and base analogues as substrates. The enzymes are able to 
tolerate a high degree of modification in the base component but only a 
limited amount of modification of the sugar moiety. So far nucleoside 
analogues have been synthesised with D-arabinofuranosyl, 2- 
aminoribose, 2-deoxy-3-aminoribose, and 5-deoxyribose as the sugar 
moiety. The nucleoside analogues which have been made by nucleoside 
phosphorylases have been reviewed. 69 
Recently, a new route to the enzymatic synthesis of nucleoside analogues 
has been described which involves the coupling of nucleoside 
phosphorylase with phosphopentomutase (Scheme 1.13). 81 The advantage 
of this method is that the pentose-5-phosphate is easier to prepare and 
more stable than the corresponding ribose-1-phosphate. This method is 
limited by the mutase which only accepts 2-deoxyribose-5-phosphate (the 
natural substrate), D-ribose and D-arabinose-5-phosphate. 
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Scheme 1.13 Synthesis of nucleosides using nucleoside phosphorylase 
and phosphopentomutase 
N-Deoxyribosyltransferases 
The other class of enzymes used in nucleoside synthesis are the N- 
20 
deoxyribosyltransferases which were first reported by MacNutt. 82 These 
enzymes were shown to catalyse deoxyribosyl transfer from 2'- 
deoxyribonucleosides to free purines and pyrimidines without the need 
for phosphate ions. The reaction involves the direct transfer of the 2- 
deoxyribose group from one heterocyclic base to another without the 
formation of a 2-deoxyribose-1-phosphate intermediate (Scheme 1.14). The 
use of 2-deoxyribose-1-phosphate as the glycosyl donor did not result in 
the formation of any 2-deoxyribonucleosides. Further experiments were 
performed to show that the reaction mechanism did not involve hydrolysis 
of the glycosidic bond followed by resynthesis with the donor heterocyclic 
base to give the new nucleoside8 2, nor the transamination of 2'- 
deoxyinosine to produce 2'-deoxyadenosine. 83 The reaction catalysed was 
in fact trans-N-glycosylation. 
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Scheme 1.14 Reaction of N-deoxyribosyltransferase 
An extensive screening programme has been undertaken to investigate 
the occurrence and specificity of this enzyme. 
84 Nucleoside 
deoxyribosyltransferase s are present in appreciable levels in some 
organisms, notably the family lactobacillacae, which do not contain 
high 
levels of the nucleoside phosphorylase enzymes and require N- 
deoxyribosyltransferases to produce 2-deoxynucleosides for growth. This 
activity has been found in Lactobacillus helveticus, 
85 L. delbruecki, 86 L. 
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acidophilius87 and L. lactis, 88 but is not present in extracts of L. casei, 88 
other microbes or animals. 8 9 However, recently a purine-2'- 
deoxyribosyltransferase activity has been purified from a protozoa, 
Crithidia luciliae. 90 
Many procedures for the purification or partial purification of the N- 
deoxyribosyltransferases from various lactobacilli have been reported. 86, 
87-89,91,92 The presence of two distinct enzymes in L. helveticus was first 
shown by Beck. 88 These were isolated using affinity chromatography with 
two types of ligand. 92,93 N-Deoxyribosyltransferase I catalysed the 
transfer of 2-deoxyribose residues exclusively between purine bases, 
whereas N -deoxyribosyltransferase II catalysed the transfer of 2- 
deoxyribose residues between purine and pyrimidine bases (Fig. 1.4). 
N-Deoxyribosyltransferase I 
dRib-Pur(1) + Pur(2) dRib-Pur(2) + Pur(1) 
N-Deoxyribosyltransferase II 
dRib-Pur(1) + Pur(2) dRib-Pur(2) + Pur(1) 
dRib-Pur + Pyr dRib-Pyr + Pur 
dRib-Pyr(1) + Pyr(2) dRib-Pyr(2) + Pyr(1) 
dRib = 2-deoxy-D-ribose 
Pur = Purine 
Pyr = Pyrimidine 
Fig. 1.4 Activities shown by the two transferase enzymes 
Detailed kinetic studies of both transferase enzymes from L. helveticus 
were performed and the initial velocity studies showed that the 2- 
22 
deoxyribosyl transfer reactions both proceed via a ping-pong bi-bi 
mechanism (Fig. 1.5). 94 The kinetic mechanism is ping-pong because the 
first product is released before the second substrate combines with the 
enzyme and it is bi-bi because the reaction is bimolecular. 95,96 
dRib-Base(1) Base(l) Base(2) dRib-Base(2) 
Enz-dRib 
Fig. 1.5 Ping-pong bi-bi mechanism of N-deoxyribosyltransferase 
The donor nucleoside combines with the enzyme and the glycosyl bond is 
cleaved. The base is released, leaving a glycosyl-enzyme intermediate. The 
acceptor base enters the active site and combines with the glycosyl- 
enzyme intermediate. Finally, the new nucleoside is released leaving the 
free enzyme. This mechanism assumes the existence of a stable glycosyl- 
enzyme intermediate in which the 2-deoxyribosyl moiety undergoes a 
double inversion. 
A detailed study of the substrate specificities of the N-deoxyribosyl- 
transferases from L. helveticus has been described. 97 A wide range of 
heterocyclic bases were accepted by the enzyme but only a very limited 
number of nucleosides with modified sugar residues were accepted as 
donors. 
Two distinct N-deoxyribosyltransferase activities were purified from 
Lactobacillus leichmannii and their substrate specificities were 
investigated. 98 As with Lactobacillus helveticus, these enzymes were 
23 
capable of accepting a wide number of heterocyclic bases as substrates but 
showed little tolerance towards donor nucleosides with modified sugar 
residues. The transfer reaction proceeded via a ping-pong bi-bi 
mechanism and kinetic and radiolabelling experiments provided 
preliminary support for the existence of a covalent glycosyl intermediate. 
Chemical modification of N-deoxyribosyltransferase II with specific 
chemical reagents suggested that histidine and/or carboxyl residues may 
participate in binding and catalysis at the active site of the enzyme. A 
proposed mechanism was suggested that is consistent with the information 
ascertained so far and highlights the double-inversion of the 2- 
deoxyribosyl moiety to produce ß-nucleosides exclusively (Scheme 1.15). 98 
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Scheme 1.15 Proposed mechanism of N-deoxyribosyltransferase98 
N -Deoxyribosyltransferase has been purified and characterised from 
Leuconostoc mesenteroides subspecies cremoris. 99 A single 
multifunctional enzyme capable of carrying out the transfer of the 2- 
deoxyribosyl moiety from either pyrimidine or purine nucleosides to 
either pyrimidine or purine bases was isolated. Kinetic studies carried out 
on the purified enzyme showed that the transfer reaction proceeded via a 
ping-pong bi-bi mechanism. Further evidence for the existence of a 
25 
glycosyl intermediate was provided by radiolabelling studies. 
Microcrystals of nucleoside deoxyribosyltransferase obtained from 
Lactobacillus helveticus have been reported, 8 5 but these were not of 
sufficient quality to be used for X-ray studies. Crystals of recombinant N- 
deoxyribosyItransferase from Lactobacillus leichmannii have been 
grown from ammonium sulfate, 100 though the type of reaction it catalysed 
was not specified. Molecular weight studies revealed a molecular weight 
for the intact enzyme of about 110,000 and a subunit molecular weight of 
about 18,000. Thus, the enzyme is a hexamer of six identical subunits. 
Function of N-Deoxyribosyltransferase Activity 
Within cells, nucleosides can be synthesised either: by the de novo 
synthesis or by the salvage pathway. In the de novo pathway the purine 
and pyrimidine bases are constructed onto the ribose moiety in several 
steps. This, overall, is a high energy process. A much more efficient 
method is the salvaging of bases produced by the hydrolysis of nucleic 
acids and nucleotides. The metabolic function of the N- 
deoxyribosyltransferase is believed to be part of nucleic acid synthesis. 101 
The effects of varying vitamin B 12,2'-deoxyribonucleoside or free purine 
and pyrimidine bases have been investigated. It was shown that vitamin 
B12 participates in the reduction of ribonucleosides to 2'- 
deoxyribonucleosides. 102-106 The N-deoxyribosyltransferase activity 
serves as an alternative pathway for 2'-deoxynucleoside synthesis in the 
absence of vitamin B12 (Fig. 1.6). 
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N -Deoxyribosyltransferases in the Synthesis of Nucleoside 
Analogues 
The N-deoxyribosyltransferases offer an alternative route to nucleoside 
phosphorylases for the synthesis of nucleoside analogues. 68 For the 
synthetic prepanalion of nucleosides with possible antiviral activity the 
transferases from Lactobacillus helveticus and Lactobacillus leichmannii 
are usually u as crude preparations without separation of the two 
discrete transferase activities. 107 This is a very convenient method as the 
minimum purification is required. As with the nucleoside phosphorylases, 
the N-deoxyribosyltransferase reaction is a very regioselective and 
stereoselective process; the glycosyl bond is formed at only one nitrogen 
within the heterocc base in a ß-configuration. 108 
The use of cruk enzyme preparations simplifies the synthetic procedure, 
but side reactions catalysed by contaminating hydrolytic and/or 
deamination activities in the crude enzyme preparation can occur when 
27 
long reactions times are used. Addition of water-miscible organic solvents 
to the reaction inhibit this degradation. It was found that the glycosyl 
transfer reaction was not effected if the concentration of the organic 
solvent was kept low. The best results were achieved by the addition of 10% 
(v/v) ethylene glycol to the reaction which inhibited any contaminating 
enzyme while allowing the transfer reaction to proceed as normal. 109 
In the transferase reactions, thymidine or 2'-deoxycytidine are the most 
effective glycosyl donors. The transferases will only accept 2'-deoxy-, 
2', 3'-dideoxy- and 2', 5'-dideoxynucleosides as the donors: no other sugar 
modifications have yet been found which are tolerated. As with nucleoside 
phosphorylases a wide range of heterocyclic bases are accepted as 
substrates, as in the synthesis of 2'-deoxyadenosine 110 and imidazole-2'- 
deoxynucleoside1 11 derivatives. The reaction is ideal for the preparation 
of radiolabelled compounds as the radiolabel is found exclusively in either 
the base or the sugar moiety of the product with no contamination in 
other parts of the nucleoside. 1.12,113 
More recently the transferases have been used in the synthesis of 2', 3'- 
dideoxynucleosides with antiviral activity. ' 12 A vast range of base 
modified 2', 3'-dideoxynucleosides have now been synthesised by enzymatic 
means for screening as potential anti-HIV drugs. 65,114-118 
Recently 1,4-anhydro-2-deoxy-D-erythro-pent-l-enitol (D-ribal), a glycal 
of ribose, was shown to be formed in the enzymatic reactions. In the 
absence of acceptor bases, the N-deoxyribosyltransferase catalyses the 
slow hydrolysis of the 2'-deoxynucleosides to generate spontaneously D- 
ribal which only disappears later as 2'-deoxynucleoside hydrolysis 
approaches completion (Scheme 1.16). 
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Scheme 1.16 Mechanism of nucleoside and D-ribal formation by N 
deoxyribosyltransferase 
In the absence of heterocyclic bases, the N- deoxyribosyltran sf erase 
catalyses the hydration of D-ribal, but when the bases are present it 
catalyses the synthesis of 2'-deoxynucleosides. This new method eliminates 
the substrate nucleoside from the reaction mixture, facilitating 
purification, but as yet only the synthesis of natural substrates has been 
reported. The stereochemistry of the nucleoside formation from D-ribal 
supports previous evidence for the presence of a deoxyribosyl-enzyme 
intermediate. 
To summarise, the N-deoxyribosyltransferases have practical application 
in the synthesis of a wide range of nucleoside analogues. The transferases 
29 
tolerate minor modification in the sugar moiety and a great variety of 
heterocyclic bases. The N-deoxyribosyltransferases have an advantage 
over nucleoside phosphorylases in that only one enzyme is required for 
the transfer of the glycosyl residue between purines and pyrimidines in 
the synthesis of a whole range of analogues, thus making it a more 
general and simpler method giving a cleaner reaction. 
Triazole Nucleoside Analogues 
The success of ribavirin has stimulated the synthesis and antiviral testing 
of a large number of glycosides of related 5-membered heterocycles. 120, 
25,26,43,121,120 Analogues (Fig. 1.7), such as, FICAR (5-fluoro-1-0-D- 
ribofuranosylimidazole-4-carboxamide), tiazofurin, EICAR (5-ethynyl-1-0- 
D-ribofuranosylimidazole-4-carboxamide)122 and selenazofurin123, these, 
along with other 5-halogenated and 5-alkynyl imidazole-4- 
carboxamides, 1 24 are all active 
paramyxoviruses and arenaviruses. 
against orthomyxoviruses, 
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Various 1,2,3-triazole nucleoside analogues have been synthesised, most 
show little antiviral activity. 59,125-130 1-ß-D-2'-Deoxyribofuranosyl-1,2,3- 
triazole-4-carboxamide 8 has been reported to have antiviral activity. 57 A 
range of 1,2,4-triazole nucleosides with sugars other than D-ribose, a- and 
0-arabinofuranosyl, 58,131 various thio-, 132 fluoro-, 133 deoxy- and 
dideoxyribofuranosyl derivatives, 1349 135 and other sugars136-139 have 
been synthesised. The majority show little' antiviral activity. 2'- 
Deoxyribavirin has been patented as antivira1140 though Witkowski et 
a! 5 8 reported it as inactive. 2', 3'-Dideoxyribavirin again shows no activity 
against the HIV retrovirus, 135 but is patented as a virucidal agent. 118 The 
2', 3', 5'-tri-O-acetate of ribavirin has been prepared as a lipophilic prodrug 
and appears to cross the blood brain barrier. 141 Any modification of the ß- 
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D-ribofuranosyl moiety other than phosphorylation or acetylation leads to 
loss of activity. 26 The heterocycle of ribavirin, 1,2,4-triazole-3- 
carboxamide (TCA), is reported to have antiviral activity. The base is 
converted enzymatically to ribavirin in vivo. 142 The carboxamidine of 
ribavirin is active against both DNA and RNA viruses, but the 
thiocarboxamide is only active against DNA viruses. 55 Other disubstituted 
carboxamidine ribavirin derivatives were found to inhibit nucleoside 
phosphorylases. 56 Any other changes in the carbamoyl group reduced or 
lost the antiviral activity of the nucleoside. 12,55,143,144 Structure 
activity analysis145 confirms that the carboxamide group, 146 the 1,2,4- 
triazole ring, 147 and the ß -D-ribofuranosyl moiety are essential for 
antiviral activity. Theoretical studies on the conformation of ribavirin 
have been . reported (Fig. 1.8). 
1 45 Ribavirin crystallises in two 
polymorphic forms, VI and V2.33 VI exhibits a glycosyl torsional angle 
x (O(1')-C(1')-N(1)-C(5 )) of 10.4° denoted as high syn and the ribose 
conformation is 3'endo-2'exo. V2 has ax value of 119.0° referred to as high 
anti and a 2'-exo-1'-endo ribose conformation (Fig. 1.8). Ribavirin exists 
in solution in the high syn conformation, but this was considered not to be 
the active form of the drug. The inactive 5-methyl and 5-chloro 
derivatives, 14 8 which also exist in the high syn forms, lack an energy 
minimum in the high anti region. Ribavirin does have a second minimum 
energy corresponding to the high anti conformation, and it has been 
suggested that the active conformation of ribavirin at the enzyme site is 
the high anti form (Fig. 1.8). 
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Enzymatic Synthesis of Triazole Nucleoside Analogues 
H 
The enzymatic synthesis of ribavirin was first reported by Ochiai et a1149 
in 1976 from a whole cell culture of mutant Bacillus subtilis KY 4540, but 
the productivity was low. A two step reaction using purified purine 
nucleoside phosphorylase from Enterobacter aerogenes AJ 11125 has been 
used to synthesise ribavirin where the glycosyl donor was inosine 
(Scheme 1.17). The initial step involved the production of ribose-l- 
phosphate from the enzymatic phosphorolysis of the purine 
nucleoside . 
15 0 The ribose-1-phosphate was isolated by ion exchange 
chromatography before it was combined with 1,2,4-triazole-3-carboxamide 
(TCA). A transribosylation reaction then produced the nucleoside virazole. 
TCA has a low affinity for the purine nucleoside phosphorylase as 
compared to that of the hypoxanthine base. If the hypoxanthine base is 
retained in the reaction, it competes with TCA for the enzyme. 
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Scheme 1.17 Two step synthesis of ribavirin with nucleoside 
phosphorylases 150 
Shirae and co-workers have carried out an extensive screening 
programme to find microorganisms that produce ribavirin directly from 
TCA and pyrimidine nucleosides 151,152 or TCA and purine nucleosides by 
whole cell culture and thus ribose-l-phosphate need not be isolated 
(Scheme 1.18). 153,154 One of each type was purified and characterised. 
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phosphorylases 
The purine nucleoside phosphorylase from Brevibacterium acetylium 
ATCC 954 was purified and ribavirin was synthesised directly from TCA and 
guanosine or inosine. 155 The uridine/oritidine nucleoside phosphorylase 
and the pyrimidine nucleoside phosphorylase activities from Erwin ia 
ca rto vo ra AJ 2992 were purified. 156 The orotidine phosphorylating 
enzyme could hydrolyse orotidine but could not produce ribavirin in the 
presence of TCA. Likewise, the purine nucleoside phosphorylase could not 
split orotidine. However, the synthesis of ribavirin from TCA and oritidine 
was possible when both enzymes were used. Thus, both enzyme catalysed 
reactions are irreversible and, together, give good yields of ribavirin. A 
combination of microorganisms was used to increase the productivity of 
the whole cell ribavirin reaction. 1 57 The enzymes from Erwinia 
ca ro to vo ra AJ 2992 catalysed the phosphorolysis of inosine, and those from 
Bacillus brevis the ribosylation of TCA. This proved to be a more efficient 
and productive system than the one using whole cells of Enterobacter 
35 
aerogenes AJ 11125 alone. 
The syntheses of ribavirin, 15 8 -160 2'-deoxyribavirin 140,161 and 2', 3'- 
dideoxyribavirin 118 with nucleoside phosphorylases have been reported. 
A range of 1,2,4-triazole adenine dinucleotides has been made by the 
nicotinamide adenine dinucleosidase (NAD nucleosidase) catalysed trans- 
ade nosinediphosphate-ribosyIation with nicotinamide adenine 
dinucleotide (NAD). Treatment with phosphodiesterase (PDE-1) and 5'- 
nucleotidase gave the corresponding mononucleoside (Scheme 1.19). 162 
All the 3-substituted 1,2,4-triazole bases gave the N-1 substituted product 
exclusively. The parent 1,2,4-triazole base gave the N-1 and N-4 ribosylated 
product. 
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Previous to this, a number of benzotriazole and related triazoles were ADP 
ribosylated using a crude enzyme extract of porcine brain NADase by the 
same methodology (Scheme 1.20). 163 In all cases only the N-1 ribosylated 
product was formed. 
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The synthesis of nucleoside analogues 
deoxyribosyltransferases has yet to be reported. 
of ribavirin using N- 
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CHAPTER 2 
SYNTHESIS OF TRIAZOLE BASES 
Background 
The discovery of ribavirin with its broad spectrum of antiviral activity 
has stimulated the synthesis of a wide range of 1,2,3-triazole and 1,2,4- 
triazole nucleoside analogues. Ribavirin and a few ribavirin analogues 
have been made using nucleoside phosphorylases and NAD nucleosidase, 
as already mentioned in Chapter One, but no synthesis using N- 
deoxyribosyltransferase has yet been reported. The parent compounds 
1,2,4-triazole and benzotriazole (Fig. 2.1) are known to act as acceptors in 
the transglycosylation reaction catalysed by N-deoxyribosyltransferase 
from Lactobacillus leichmannii. 98 
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Fig. 2.1 The structures of the parent triazole bases 
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In this work, series of triazoles were synthesised as base substrates for the 
enzymatic synthesis of triazole nucleoside analogues. All the triazoles 
were synthesised by methods published in the literature. All but one of the 
N-substituted triazole carboxamides are new compounds. 
Results and Discussion 
Synthesis of 1,2,4-Triazole Bases 
All of the 1,2,4-triazole derivatives were synthesised from the parent 
compound 5-amino-1,2,4-triazole-3-carboxylate 10 (Scheme 2.1). This was 
made from aminoguanidine bicarbonate and oxalic acid via the oxalic acid 
monoguanylhydrazide 9 in almost quantitative yield. 164,165 However, 5- 
amino-1,2,4-triazole-3-carboxylic acid is now commercially available. 
Treatment of the triazole 10 with sodium nitrite in acid166 gave the 
diazonium salt, which is explosive when dry. The damp solid was suspended 
in methanol and heated to 40°C, when an exothermic reaction occurred 
yielding 1,2,4-triazole-3-carboxylate 15. The impure acid was used for the 
esterification, as recrystallisation from water caused decarboxylation 
reducing the yield. 
From 5-amino-1,2,4-triazoIe-3-carboxyIate 10 and 1,2,4-triazole-3- 
carboxylate 15 a range of 1,2,4-triazole esters and carboxamides were made 
(Scheme 2.1) (Table 2.1). The methyl 11,16 and ethyl esters 12,17 were 
synthesised by esterifying the acid at room temperature in the 
appropriate alcohol saturated at 0°C with hydrogen chloride gas. 
164,166, 
167 
The 1,2,4-triazole-3-carboxamides were synthesised by dissolving the 
triazole esters neat in the required amine, sometimes methanol was added 
to homogenise the solution and left to react at room temperature or 50°C 
39 
(Scheme 2.1) (Table 2.1). Reactions at the lower temperature were slower 
but were easier to purify by recrystallisation. 
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Scheme 2.1 Synthesis of 1,2,4-triazole bases 
The reactions were followed by reverse phase HPLC on a Techsphere 5C8 
40 
or Techsphere 100DS column (25 cm x 4.6 mm and a precolumn, 5 cm x 4.6 
mm), using a mobile phase of acetonitrile and double distilled water (5: 95, 
v/v) at a flow rate of 1.0 ml/min with detection by UV at 214 nm. When the 
reactions were completed, the solvent was removed and in most cases all 
that was required for purification was recrystallisation. 
Typical IH NMR and 13C NMR spectral data of triazoles are shown in Fig. 
2.2: 
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Fig 2.2 1H and 13C NMR data for 1,2,3-triazole-4-carboxamide and 1,2,4- 
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One of the difficulties encountered at the beginning of this investigation 
was the detection and characterisation of the triazoles synthesised. Most 
only absorb at low UV wavelengths, typically 220 nm, and have few 
protons for 1H NMR analysis (Fig. 2.2). A range of thin layer 
chromatography (TLC) sprays were screened to find a generally 
applicable, sensitive spray reagent for the triazole ring, but without 
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success. 168-172 
Accordingly, attempts were made to synthesise the unknown benzyl 1,2,4- 
triazole-3-carboxylate 27, use of which would solve the dual problems of 
solubility and detection. The benzyl ester group would increase the 
solubility of the triazole in organic solvents. In addition, it would also be a 
good marker as it is UV-active at 254 nm and its disappearance in the 
amidation reactions could be monitored by TLC. Classical methods, 
employing dicyclocarbodiimide in dimethylformamide, benzenesulfonic 
acid or boron trifluoride as catalysts, formation of the acyl chloride using 
thionyl chloride or oxalyl chloride or diphenylphosphoryl chloride gave 
no detectable product (Scheme 2.2 and 2.3). The problems of solubility, 
even in dimethylformamide and dimethylsulfoxide and the known ease 
with which triazole carboxylic acids undergo decarboxylation173 could 
account for these failures. Difficulties in using thionyl chloride have 
been reported, 174 where sulfur containing triazole products were isolated. 
This was avoided by using oxalyl chloride to form the acid chloride instead. 
Unfortunately, on repeating this procedure no benzyl 1,2,4-triazole-3- 
carboxylate was formed. 
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Finally, using POC13 and PC15181 a small amount of the desired ester 27 was 
formed, but in poor yield (Scheme 2.4). Investigation of this synthesis was 
discontinued as the other method, using the ethyl or methyl ester in the 
amidation reaction and following the reaction by HPLC, was found to be 
satisfactory. 
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Table 2.1 1,2,4-Triazoles synthesised 
Synthesis of 1,2,3-Triazole Bases 
Synthesis of 1,2,3-Triazole-4-carboxamide 
Two previously published approaches were investigated for the synthesis 
of 4-monosubstituted-1,2,3-triazoles. In the first, a novel ring contraction 
of 5-diazouracil to 1,2,3-triazole-4-carboxamide reported by Thurber et al 
was tried (Scheme 2.5). 182-184 In this synthesis, which was repeated 
exactly as published, 5-aminouracil 28 is diazotised and recrystallised from 
45 
methanol. The methanol adduct 29 formed can be stored at room 
temperature indefinitely. 
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Scheme 2.5 Synthesis of 1,2,3-triazole-4-carboxamide from 5- 
aminouracil182,184 
When the diazo compound 29 is heated in a sealed vessel at 130°C in a 
solution of 5% aqueous acetonitrile it undergoes hydrolysis with ring 
opening. This is followed by ring contraction and loss of carbon dioxide. 
Using 18 0 labelling studies 18 4 Thurber et al showed that the ring 
contraction occurred without the exchange of the C-2 oxygen atom. No 
detectable traces of triazole were found if the proton on N-3 was replaced 
by a methyl group. In 5% methanolic acetonitrile the N-carbamate 33 of 
30 was isolated. The following mechanism was proposed to explain these 
observations (Scheme 2.6) on the cyclisation of 5-diazo-l-methyluracil-6- 
methanolate in 5% methanolic acetonitrile 31 (Scheme 2.6). 184 The 
cyclisation of 32 has precedence in the literature. 185-187 
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This reaction gave yields varying from 42% to 85% owing to the 
difficulties of maintaining a constant temperature in the autoclave. This is 
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in contrast to the 98% yield reported by Thurber et al for the same 
reaction. 184 
The methyl ester 35 of the carboxamide 30 was synthesised by gently 
refluxing the carboxamide and Amberlyst 15, a strong acid cation 
exchange resin, in methanol in a method adapted from Greenlee et al 
(Scheme 2.7). 188 
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Scheme 2.7 Synthesis of methyl-1,2,3-triazole-4-carboxylate from the 
carboxamide188 
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A more direct route to the same triazole ester 35 was the 1,3-dipolar 
cycloaddition of trimethylsilyl azide to methyl propiolate in an autoclave 
at 1300C. 189 Addition of methanol to the cooled reaction mixture brought 
about the smooth hydrolysis of the trimethylsilyl group, giving the 
methyl-1,2,3-triazole-4-carboxylate 35 in 83% yield (Scheme 2.8). The 
reaction is very regioselective and only the 4-substituted ester is formed. 
Compared to the direct addition of hydrazoic acid or sodium azide to 
alkynes, trimethylsilylazide provides a much safer route. The initial 
product is the 1-trimethylsilyl-methyl-1,2,3-triazole-4-carboxylate 36 but 
this rearranges to the 2-substituted isomer 37189 and is very labile to 
hydrolysis. 
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Scheme 2.8 Synthesis of methyl-1,2,3-triazole-4-carboxylate from an 
organic azide and acetylene 189 
The N-methyl- and N-ethyl-1,2,3-triazole-4-carboxamides 38 and 39 of the 
methyl ester 35 were synthesised by the same methods previously 
described for the 1,2,4-triazoles-3-carboxamides (Scheme 2.9). 
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Scheme 2.9 Synthesis of 1,2,3-triazole-4-carboxamides 
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Synthesised from 1,2,3-triazole-4-carboxamide188 (Scheme 2.7) 
$ 
Synthesised from trimethylsilyl azide and methyl propiolate 189 
(Scheme 2.8) 
Table 2.2 4-Monosubstituted-1,2,3-triazoles synthesised 
Synthesis of 1-N-Protected-4,5-disubstituted-1,2,3-triazole Bases 
Sulfonyl azides 40 are used as a source of the diazo group where the 
dinitrogen is exchanged in a one-step reaction for two protons of an 
active methylene compound 41 in the presence of a base. The p- 
toluenesulfonamide 42 is generally separated from the newly formed diazo 
compound 43 as a salt 44 (Scheme 2.10). 
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0R 
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Scheme 2.10 Transfer of diazo groups from sulfonylazides 
Reaction of the sulfonyl azide with malononitrile exhibits a novel 
reaction, where in aqueous sodium hydroxide or ethanol and potassium 
ethoxide a very stable 1: 1 p-toluenesulfonylazide adduct is formed. 191 This 
adduct was eventually shown to be the 5-tosylamine-l-H-1,2,3-triazole-4- 
carbonitrile 48 (Scheme 2.11). 192 The 5-tosylamine 48 derivative is the 
more stable isomer formed in a Dimroth rearrangement of the initially 
formed intermediate, 5-amino-l-N-tosyl-1,2,3-triazole-4-carbonitrile 45. 
The strongly electronwithdrawing effect of the tosyl group favours ring 
cleavage to form the diazo isomer 45-46 and the more nucleophilic 
amidine nitrogen, the one without the tosyl group, attacks the electron 
deficient terminal diazo nitrogen causing ring closure 47-48. Though the 
reaction is reversible in pyridine193 the facile rearrangement proved to 
be a problem and use of this sort of protecting group was abandoned. 
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Scheme 2.11 Synthesis of 5-amino-l-N-tosyl-1,2,3-triazole-4-carbonitrile 
followed by a Dimroth rearrangement 
The base-catalysed condensation of the azides with activated methylene 
compounds is a well established route to 1-H-triazoles. 194 It is ideal for the 
regiospecific synthesis of 1,2,3-triazoles with an amino or hydroxy 
substituent at the 5 position and a carbonyl or aryl function at C-4. The 
stepwise mechanism of the reaction is best revealed by the anomerisation 
of the glycosyl azides on reaction with activated methylene compounds 
(Scheme 2.12). 59 
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Scheme 2.12 Anomerisation of a glycosyl azide during a condensation 
reaction59 
The proposed intermediates have been detected in solution or have been 
isolated from the solutions of reacting azides with aliphatic ketones. 195 
A versatile N-protecting group for the synthesis of 1-N-substituted-1,2,3- 
triazoles has been developed by Buckle et al, 196,197 Protecting groups 
such as N-benzyl are too difficult to remove 
19 8 and destroy the triazole 
53 
ring or substituents with the forcing conditions required. Others are too 
labile, as with the tosyl group199 and trimethylsilyl group. 200 The 4- 
methoxybenzyl group, on the other hand, is stable under a wide range of 
experimental conditions but is sufficiently labile to be removed by 
solvolysis in trifluoroacetic acid in the presence of a variety of functional 
groups. 197 
The synthesis by Buckle et al incorporated the base-catalysed 
condensation with the 4-methoxybenzyl protecting group. The method was 
followed exactly as described to synthesise the 5-substituted-ethyl-1,2,3- 
triazole-4 -carboxylates (Scheme 2.13). 
197 The 4-methoxybenzylazide 49 
was easily prepared from the corresponding 4-methoxybenzyl chloride 
and sodium azide. Condensation of 4-methoxybenzylazide 49 and 
diethylmalonate in the presence of a base gave the 5-hydroxyl--I-(4- 
methoxybenzyl)-ethyl-1,2,3-triazole-4-carboxylate 50 in moderate yields. 
Treatment of the hydroxyl triazole with phosphorous pentachloride in dry 
toluene gave the chloro derivative 51 and this in turn was displaced by 
the cyanide ion to give the carbonitrile triazole 5 2. Each reaction gave 
yields of about 60%. 
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Scheme 2.13 Synthesis of Nprotected-4,5-disubstituted-1,2,3-triazole 
bases197 
Having followed the procedure of Thurber et al to its conclusion 19 7 the 
respective amides 5 3,5 4 of the protected chloro 51 and cyano 52 
derivatives were synthesised using methanolic ammonia or aqueous 
ammonia (Scheme 2.14). 
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Scheme 2.14 Synthesis of Nprotected-5-substituted-1,2,3-triazole-4- 
carboxamide bases 
The amide of the hydroxyl compound, protected or unprotected, could not 
be formed, possibly due to enolisation or hydrogen-bonding between the 
carbonyl group of the ester and the 5-hydroxyl group preventing 
nucleophilic attack (Fig. 2.3). 
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55R=H 
Fig. 23 Hydrogen bonding in ethyl-1,2,3-triazole-4-carboxylate 
preventing attack by ammonia 
The 4-methoxybenzyl group was readily removed by solvolysis with 
trifluoroacetic acid at 65°C in yields ranging from 46% to 90% (Scheme 
2.15,2.16). 
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Scheme 2.15 N-Deprotection of the 5-hydroxyl-1,2,3-triazole base with 
trifluoroacetic acid 
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Scheme 2.16 N-Deprotection of the 5-cyano-1,2,3-triazole bases with 
trifluoroacetic acid 
Neither the deprotection of the protected 5-cyano-1,2,3-triazoIe-4- 
carboxamide 54 nor the ammonolysis of ethyl 5-cyano-1,2,3-triazole-4- 
carboxylate 56 gave the required product 57 (Scheme 2.16). A gave the 
same result. Treatment of the unprotected ethyl-5-chloro-1,2,3-triazole-4- 
carboxylate 59 with methanolic ammonia gave the 5-amino-1,2,3-triazole- 
4-carboxamide 60, whereas the protected chloro derivative 51 gave only 
one product, the protected chloro carboxamide 53 (Scheme 2.17). 
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Scheme 2.17 N-Deprotection of the 5-chloro-1,2,3-triazole bases with 
trifluoroacetic acid 
This slow displacement of the 5-chloro group of methyl 1-benzyl-1,2,3- 
triazole-4-carboxylate by ammonia or methylamine has been previously 
reported. The only products isolated were the amides, leaving the chloro 
group untouched. 201 
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Table 2.3 4,5-Disubstituted-1,2,3-triazoles synthesised 
Synthesis of Benzotriazole Bases 
Little investigation has been conducted in the 
nucleosides. The first chemical 
area of benzotriazole 
synthesis of benzotriazole-2'- 
60 
deoxynucleosides was reported by Kazimierczuk et al in 1990.202 
Benzotriazole 6198 and benzimidazole 62111 can function successfully as 
substrates for N-deoxyribosyltransferases from Lactobacillus leichmannii, 
but the benzotriazole nucleoside was not isolated (Fig. 2.4). 
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Fig. 2.4 Acceptor bases for N-deoxyribosyltransferases from 
Lactobacillus leichmannii 
4-Nitrobenzotriazole 63203 and 4-aminobenzotriazole 64202 were 
synthesised as described by standard methods in 84% and 70% yields, 
respectively (Scheme 2.18). 
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Scheme 2.18 Synthesis of 4-substituted benzotriazole bases 
61 
The parent compound 61 was the only one found to act as an acceptor for 
the N-deoxyribosyltransferase, as will be dicussed in Chapter Three so the 
synthesis of other benzotriazoles was not pursued. 
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Table 2.4 4-Substituted benzotriazole bases synthesised 
The results of the bases synthesised as acceptors for the reaction catalysed 
by the N-deoxyribosyltransferases from Lactobacillus leichmannii will be 
discussed in Chapter Three. 
The results of Chapter Two are summarised in the following Tables 2.1 and 
2.5 
62 
N-( 
R 
H2N NN 
N-( 
R 
NN 
H 
R= Yield R= 
Yield 
% R= 
Yield 
10 
O 
/)\ 98 15 
0 
/)\ 94 21 
0 
A 
I\ l OH OH N \ 72 
H 
11 
p 
A 
O 78 16 
O 
/ 
)\ 
89 22 
O 
AN/\\//\\ 
79 
O/ H 
12 
O 
A 
53 17 
0 
%` 
50 23 
0 
ANISýý 
37 O O 
H 
27 
p 
O 15 18 
0 
//ýNH2 94 24 
0 
/\O 
N 25 
0 
90 19 
0 
81 25 
0 
68 13 NH2 N 
14 
0 
A 
97 20 
H 
0 
N 92 26 
0 
N 40 
N 
H H 
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Table 2.5 Summary of 1,2,3-triazoles synthesised 
Ar = 4-CH3OC6H4CH2-, Ts = CH3C6H4SO2- 
t 
Synthesised from 
$ 
Synthesised from 
(Scheme 2.8) 
1,2,3-triazole-4-carboxamidel88 (Scheme 2.7) 
trimethylsilyl azide and methyl propiolate189 
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CHAPTER 3 
ENZYMATIC SYNTHESIS OF NUCLEOSIDES 
Background 
Synthesis of Triazole Nucleoside Analogues 
There are numerous routes to the synthesis of triazole nucleosides by 
either modification of an existing nucleoside, fusion of a sugar and base to 
form the nucleoside or the de novo synthesis, building the base onto the 
sugar. As discussed in Chapter One, these procedures have difficulties and 
much interest has been directed towards the development of enzymatic 
methods for the synthesis of nucleoside analogues where precise 
stereochemical and regiochemical control is possible without the use of 
protecting groups on reactive residues. N-Deoxyribosyltransferases are 
specific and glycosylate only one nitrogen in a heterocyclic base to give a 
nucleoside with a ß- configuration. Several enzymatic syntheses of 
nucleoside analogues have been described65, 108-111,114 using a crude 
nucleoside N-deoxyribosyltransferase from Lactobacillus leichmannii. 
This route is complementary to one involving a combination of purine and 
pyrimidine phosphorylases. The availability of enzymatic synthetic 
methods means that a range of novel nucleosides is now accessible. 
N-Deoxyribosyltransferases from Lactobacillus leichmannii 
In this chapter, exploration of the use of N-deoxyribosyltransferases 
specifically from Lactobacillus leichmannii will be discussed in more 
detail. Lactobacillus leichmannii is a member of the subdivision of 
65 
obligately homofermentative lactobacilli which ferment glucose almost 
entirely to lactic acid. These lactic acid bacteria occur as regular, non- 
sporing, gram-positive rods with rounded ends (0.5-0.8 x 2-9 mm). The 
cells of Lactobacillus leichmannii occur singly, in pairs and in short 
chains, and can be isolated from milk, cheese, compressed yeast and grain 
mash. They require not only carbohydrates as energy and carbon sources, 
but nucleotides, amino acids and vitamins which are essential for 
growth. 204 Both N -deoxyribosyltransferase I and N- 
deoxyribosyltransferase II have been purified from Lactobacillus 
leic hm annii ,98 but for the synthetic reactions a crude preparation of the 
enzyme is employed. 
It has been shown that a wide range of bases act as competent acceptors 
with N-deoxyribosyltransferases but only very minor modifications on the 
sugar moiety are tolerated (Fig. 3.1). 88,98,107,110 Analogues that lack an 
hydroxyl group in the 3'- or 5'-position are accepted by the enzyme as 
glycosyl 9 donors. 3,114,205 However, transfer of the 2,3-dideoxyribosyl 
moiety occurs at a much slower rate than the natural 2-deoxyribosyl 
substrate. ' 12,206 
Base 
HO 
/ 
R 
R=H, OH 
Emse 0 
R 
HO 
R= H, OH, F, Cl, I 
Fig. 3.1 Sugar moieties accepted as glycosyl donors by N- 
deoxyribosyltransferase 
Enzymatic Synthesis of Nucleoside Analogues 
66 
Purification of Nucleoside 
(E. C. 2.4.2.6) from Lactobacillus leichmannii 
N -Deoxyribosyltransferases 
Bacteria are one of the most favoured sources of enzymes and the 
purification of a crude preparation of N-deoxyribosyltransferases from 
lactic acid bacteria was fairly simple. Lactobacillus leichmannii was 
grown for 24 hours at 37°C. The cells were then harvested by 
centrifugation during their stationary phase, when the highest levels of 
N-deoxyribosyltransferases are present. The cells were broken open by 
the use of a French pressure cell, which forces the cell suspension 
through a restricted orifice at high pressure. After cell breakage, the cell 
debris was removed by centrifugation. The resulting yellow liquid was 
dialysed to remove salts and thus yielded the crude preparation of enzyme. 
This preparation contained a multitude of different enzymes which could 
interfere with the transfer reactions. To remove the need for any further 
purification steps a technique, whereby the other enzymes, such as 
hydrolases and deaminases, in the crude preparation are inhibited by the 
addition of 10% (v/v) ethylene glycol, has been developed. 109 This 
protects the products of the reaction from degradation by other enzymes 
present in the crude preparation, improving yields and removing the 
necessity of purifying the enzyme, greatly simplifying the procedure. 
This crude enzyme preparation was then assayed for its protein 
concentration using the dye-binding BioRad protein assay and assayed to 
determine the number of units present. 
The enzymatic transfer reaction involves the exchange of the base moiety 
in the nucleoside with a free base molecule to yield a new nucleoside 
(Scheme 3.1). 
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Scheme 3.1 Standard enzymatic transfer reaction 
The standard assay system used to calculate the number of units present is 
as shown in Scheme 3.1: 2'-deoxycytidine (dC) as the glycosyl donor while 
adenine (A) acts as the glycosyl acceptor. The rate at which the new 
nucleoside, 2'-deoxyadenosine (dA), was produced was followed by reverse- 
phase HPLC, detected by UV at 254 nm. The units and specific activity of a 
sample of enzyme will vary with the assay system used. Therefore, a unit 
of enzyme must be defined for the particular assay system used, as can be 
found in General Materials and Methods (Chapter Five). 
The transfer reaction is reversible. Accordingly, if it is to have any use as 
a synthetic tool it must be displaced as fully as possible in the direction of 
the products. The adaptations which are generally used to push the 
equilibrium to the right-hand-side are: 
0a ratio of 3: 1 donor nucleoside to acceptor base; 
0a donor nucleoside which has a high affinity for the enzyme; 
"a donor nucleoside in which the base is a good leaving group. 
For the synthesis of 2'-deoxynucleosides, a glycosyl donor is required 
which will give a high levels of transfer with a large number of acceptor 
bases. From substrate specificity studies performed it has been shown that 
68 
2'-deoxycytidine is a better 2-deoxyribosyl donor than thymidine, 2'- 
deoxyuridine or any of the other naturally occuring nucleosides. 88' 206 
Synthesis of Triazole Nucleoside Analogues 
Using a crude preparation of N-deoxyribosyltransferase from 
Lactobacillus leichmannii the transfer of 2-deoxyribose from 2'- 
deoxycytidine or thymidine to the triazole bases in the presence of 
ethylene glycol was followed on an analytical scale. The progress of the 
reaction was monitored by reverse phase HPLC detected by UV at 214 nm. 
Transfer reactions were followed until equilibrium was attained or, in the 
case of unsuccessful reactions, until complete hydrolysis of the donor 
nucleoside occurred. Table 3.1 shows the nucleosides made using the N- 
deoxyribosyltransferase catalysed reactions. When transfer occurred, 
only one new compound was detected by HPLC. 
69 
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Table 3.1 Triazole nucleosides synthesised 
Discrepancies between the percentage conversion and the final yield are 
explained by the difficulties encountered in the work -up procedure. 
Similarities in the Rfs of some reactants and products required final 
purification by semipreparative HPLC, after incomplete separation by 
flash chromatography. In most cases the percentage conversion was 
70 
higher in the analytical than in the preparative N- 
deoxyribosyltransferase reaction. The difficulty of removing ethylene 
glycol at the end of the reaction made it necessary to reduce the overall 
amount used. The consequent increase in the concentration of the 
substrates and products, in comparison to that used on the analytical scale, 
led to problems of solubility and appeared to decrease the reaction rate. 
The enzymatic glycosylation of triazoles can, in theory, lead to three 
products depending on the position of glycosylation. However, only one 
product was produced. A combination of 1H and 13C NMR together with 
nuclear Overhauser enhancement (nOe) experiments was used to 
determine the site of attachment of the sugar residue in 1,2,3-triazole and 
1,2,4-triazole nucleosides. The site of glycosylation at N-1 agrees with 1H 
and 13C chemical shift NMR studies on 1-ß -D-ribofuranosyl-1,2,4- 
triazoles. 207 The data suggests, allowing for the difference in machines 
and solvents, that the deoxynucleosides synthesised are glycosylated at N-1 
and not N-4 of the 1,2,4-triazole base (Table. 3.2). Thus N-1 is the site of 
attachment of all the triazole nucleosides synthesised. 
71 
13C NMR 1HNMR 
Compound C-3 C-5 C=O H-5 
N MHz 
N 75* N 151.2 148.5 159.7 8.16 
R 
N1Hz 
7* 158.1 158.1 146.0 161.5 8.91 N 
R 
rý OONH2 
65 fN N 157.19 144.83 160.60 8.81 
CR 
ooNH2 
65 (N 158.1 146.1 163.4 8.74 
dR 
R= ribose 
dR = 2-deoxyribose 
* Figures from Kreishman et a! 207 in DMSO-d6 
Figures from Sanghvi et a1135 in DMSO-d6 
In MeOH-d4 
Table 3.2 Comparison of 13C and IH NMR data to confirm N-1 
glycosylation of the triazole nucleoside 
Nuclear Overhauser enhancement (nOe), whereby a chosen signal is 
irradiated and the percentage enhancement of the other signals in the 
spectrum are observed, utilises the through-space interaction between 
protons. Holzer has developed a method for the assignment of triazole 
proton resonances in 1-substituted 1-H-1,2,3-triazoles208 and 1-substituted 
1-H -1,2,4-triazoles. 
209 Upon the irradiation of the proton on the N-1- 
substituent of the 1,2,4-triazole 76 a marked enhancement of the H-5 was 
observed but the H-3 remained nearly unaffected. The same was 
found to 
be true with the 1,2,3-triazoles 77 (Fig. 3.2). Studies on a series of 1- 
72 
substituted triazoles confirmed this to be a general and unambiguous 
method of assignment. 
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Fig. 3.2 Sites of nuclear Overhauser enhancements in the IH NMR 
spectrum of 1,2,4-triazoles and 1,2,3-triazoles 
In the area of nucleosides, the anomeric configuration has been assigned 
by the use of nOe spectroscopy. 210,211 It is easy to distinguish the a- and 
ß-anomers by saturating H-1' and measuring the nOe enhancement at H-3' 
and H-4'. Enhancement at H-4' proves the ß-configuration at the anomeric 
centre 78 while a- anomers show an nOe at H-3' upon irradiation of H-1'. 
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Fig. 3.3 Sites of nuclear Overhauser enhancements in the IH NMR 
spectrum of 2'-deoxyribavirin 
Irradiation at H-5 
73 
In all but one case, irradiation at H-1' gave enhancement of the signal due 
to H-4' and H-2'b 78 (Fig. 3.3). Therefore, H-1', H-2'b and H-4' must be on 
the same side of the ring, that is the underside, confirming the -- 
orientation of the glycosidic linkage. The syn and anti conformations of 
nucleosides in solution have been analysed by the same method. 212,213 
Irradiation of the signal due to H-5 of the triazole ring only showed 
enhancement of the signal at H-1'79 (Fig. 3.3). 
Irradiation 
at H-1' 
Irradiation 
at H-5 
% Enhancement at 
Compound H-5 H-2'b (down) H-4' H-1' 
65 4.35 - 1.16 5.66 
66 3.00 6.20 - - 
67 2.40 4.50 1.00 2.90 
68* 4.59 7.89 1.15 2.31 
69* 6.25 7.42 1.56 6.02 
70 2.01 3.27 1.12 4.40 
71 - 6.43 1.17 - 
72 - 6.50 1.10 - 
* D20 as solvent 
Table 3.3 Nuclear Overhauser enhancements (%) caused by irradiating 
signals in the 1H NMR spectrum of the 2'-deoxyribonucleoside analogues 
of ribavirin 
As the triazole ring is on the topside of the glycosyl ring, enhancements 
of the signals due to H-2'a and H-3'a would be expected on irradiation of H- 
5 on the triazole ring. 
213 This lack of enhancement implies that the 
74 
proton on the triazole ring is not positioned over the sugar moiety, in the 
anti conformation 80 (Fig. 3.4). In fact, H-5 is close to the H-2'a sitting 
over the top side of the glycosyl ring in the high syn conformation 81 
(Fig. 3.4). As previously mentioned in Chapter One, theoretical studies 
have shown that ribavirin is in a high syn 81 conformation in solution. It 
appears that the conformation of these novel nucleosides adopted in 
solution remains the same as ribavirin. 
H 
HOH2 
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NHZ 
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HOH2 
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HO 
O 
N NH2 
H- 
ý 1N 
N, 
-O 
OFi 
ANTI 
81 
Fig. 3.4 Two conformations of ribavirin 
The structure of the benzotriazole-2'-deoxynucleoside was confirmed by 
comparison of 1H and 13C NMR and nOe data previously published (Fig. 
3.5a) (Table 3.4). 202 
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H4 
N 
H5 
N 
H5'a 
%\H5'b 
%N 
O Hs 
HO J H7 
Ha' Hl, 
HO H2'ß 
Irradiation at H-1' 
H5'a 
HO 
Fig. 3.5a Sites of nuclear Overhauser enhancements in the IH NMR 
spectrum of benzotriazole-2'-deoxynucleoside in DMSO-d6 
When the nOe is measured in D20, 
due to H-4' 83 (Fig. 3.5b). A signal 
underside of the ring (Table 3.4). 
H4 
N 
H5 
N" 
H5'a H5'b N HO 6 >,:: ý 3. H7 HO 
Ha, Hi- 
HO Heb 
Irradiation at H-1' 
82 
which 
83 
Fig. 3.5b Sites of nuclear Overhauser enhancements in the IH NMR 
spectrum of benzotriazole-2'-deoxynucleoside D20 
This appears to break the rules stated previously, 
no enhancement is seen of the signal 
is seen at 
H4 
N 
N 
N 
Irradiation at H-7 
H-2'b, which is on the 
H4 
N 
H5 
Ni 
. 100 
HO H7 
H4- Hl, 
HO Hrb 
H5'b 
21 
Irradiation at H-4' 
that irradiation at H-1' 
is on 
76 
will always produce enhancement at the signal due to H-4'. Exceptions to 
this rule are nucleosides with 0 -4'-exo conformation of the glyconic 
moiety. 212 Maybe the nucleoside adopts a different conformation in water 
to that in DMSO. 
Irradiation at H-1' of 73 
% Enhancement at 
Solvent H-7 H-2'b H-4' 
DMSO-d6* 6.0 7.0 1.6 
DMSO-d6 5.3 7.5 1.4 
D20 4.7 6.5 - 
* Figures from Kazimierczuk et a1202 
Table 3.4 Nuclear Overhauser enhancements (%) caused by irradiating 
signals in the IH NMR spectrum of the 2'-deoxyribonucleoside of 
benzotriazole 
The position of glycosylation was established by nOe experiments. Due to 
the symmetry of benzotriazole there are only two possible products of the 
N-deoxyribosyltransferase reaction, substitution of the 2'-deoxyribose at 
N-1 73 or N-2 84 of the benzotriazole base (Fig. 3.6). 
3N \ 
2 N% 
/ 
1 
HO 
3N 
2N 
Hp pN 
HO 
73 84 
Fig. 3.6 Two possible sites of glycosylation 
77 
Glycosylation at N-2 84 is known to give no enhancement at H-7 on 
irradiation of H-I', 202 so the sugar moiety must be attached at N-1 73 (Fig. 
3.6). 
Inhibition Studies 
The possible inhibitory effects of two triazole bases ethyl-5-hydroxy-1,2,3- 
triazole-4-carboxylate 55 and N-ethyl-1,2,3-triazole-4-carboxamide 39 
(Fig. 3.7) were investigated by incubating the compound with the crude N- 
deoxyribosyltransferase and then assaying the enzyme for activity after 
certain intervals of time. No loss in activity was observed so inhibition did 
not appear to be a factor for the lack of transfei. 
0 
/\O 
/N \N 
HO Ný 
H 
55 39 
Fig. 3.7 Triazole bases used in inhibition studies 
Discussion 
The following three tables (Tables 3.5,3.6,3.7) show the triazole bases 
synthesised and their 
deoxyribosyltransferase reaction. 
success as 
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is an acceptor in the N-deoxyribosyltransferase reaction 
x is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.5 Results with 1,2,4-triazole bases used as acceptors in the N- 
deoxyribosyltransferase reaction 
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is an acceptor in the N-deoxyribosyltransferase reaction 
X is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.6 Results with 1,2,3-triazole bases used as acceptors in the N- 
deoxyribosyltransferase reaction 
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V is an acceptor in the N-deoxyribosyltransferase reaction 
X is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.7 Results with benzotriazole bases used as acceptors in the N- 
deoxyribosyltransferase reaction 
The discussion will be divided into three parts: 
" an outline of the specificity studies carried out by other workers on N- 
deoxyribosyltransferases from Lactobacillus helveticus and L. 
leichmannii, 
0a discussion on the previous work done by Hutchinson et al on the N- 
deoxyribosyltransferases from L. leichmannii, 
" the results of the triazole bases in the N-deoxyribosyltransferase 
reaction. 
Specificity Studies on N -Deoxyribosyltransferases 
Lactobacillus helveticus and L. leichmannii 
from 
As previously discussed in the introduction in Chapter One, the N- 
deoxyribosyItransferases from Lactobacillus helveticus and L. 
1eichmannii have been purified. The substrate specificities for the bases 
and the sugars have been investigated. 
81 
Two distinct enzymes were characterised, N-deoxyribosyltransferase I and 
N-deoxyribosyltransferase H (Fig. 3.8). 
N-Deoxyribosyltransferase I 
dRib-Pur(l) + Pur(2) dRib-Pur(2) + Pur(1) 
N-Deoxyribosyltransferase H 
dRib-Pur(1) + Pur(2) dRib-Pur(2) + Pur(1) 
dRib-Pur + Pyr dRib-Pyr + Pur 
dRib-Pyr(1) + Pyr(2) dRib-Pyr(2) + Pyr(1) 
dRib = 2-deoxy-D-ribose 
Pur = Purine 
Pyr = Pyrimidine 
Fig. 3.8 Activities shown by the two transferase enzymes 
Holguin et a, 97 concluded that (Fig. 3.9): 
S 
. 
S 
S 
S 
the positions 1,2 and 6 are of minor importance, 
only minor modifications can be tolerated on the imidazole ring, 
a tautomeric proton must be present on the imidazole moiety, 
the position of the tautomeric proton governs the site of substitution, 
for steric reasons, no substituent is allowed on position 8. 
82 
67 
N 
1NI \\ 
218 Ný NH 
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Fig. 3.9 Purine and pyrimidine bases 
The same rules applied to the N-deoxyribosyltransferases isolated from L. 
leichmannii. 91, 107,110 However, some purines substituted at position 8 
did act as acceptors for the enzyme (Fig. 3.10 and 3.11). 110 The reaction 
rates were much slower and, in some cases, two products were formed. The 
formation of the 3-linked product was thought to be associated with the 
electronegativity of the substituent in the purine ring rather than the 
size of the group. 8-Methyl adenine gave solely the 9-glycosylated product, 
whereas replacement with the bromo or chloro group gave a mixture of 
the 3- and 9-glycosylated nucleosides (Fig. 3.10). 
NH2 
Bd CI 
N 
L:: 
jIIIIII, 
N 
1 
dR 
NH2 
N 
ý>--Br/Cl 
dR = 2'-deoxyribose 
Fig. 3.10 Two products formed in the N-deoxyribosyltransferase reaction 
The trifluoromethyl group, the most electronegative substituent, gave 
only the 3-glycosylated product (Fig. 3.11). 
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NN 
CF3 
N 
dR 
dR = 2'-deoxyribose 
Fig. 3.11 Different N-glycosylated products in the N- 
deoxyribosyltransferase reaction 
Previous Work Carried Out by Hutchinson et al on N- 
Deoxyribosyltransferases from Lactobacillus leichmannii 
Two N-deoxyribosyltransferase activities have been isolated from 
Lactobacillus leichmannii by Hutchinson et al, as mentioned in Chapter 
One. 98 The substrate specificities of the N-deoxyribosyltransferases will be 
discussed in the following groups: modified purine bases, imidazole bases, 
modified pyrimidine bases and finally, the triazole bases. The Michaelis 
constants determined were 4gM and 10 µM in the transfer reaction for N- 
deoxyribosyItrans ferases I and II, respectively. 9 8 The work on the 
modified purine bases, imidazole bases and modified pyrimidine bases has 
been previously published or is about to be published by a number of 
workers, all part of this group. The following seven tables (Tables 3.8-3.14) 
summarise their findings. 
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is an acceptor in the N-deoxyribosyltransferase reaction 
X is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.8 Modification on position 1,2 and 3 of the purine 
ring65,98,108,109,206,214,216 
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is an acceptor in the N- deoxyribosyltransferase reaction 
x is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.9 Modification on position 6 of the purine 
ring65,98,109,114,216 
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Table 3.10 Modification on position 7 of the purine ring98,109 
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Table 3.11 Modification on position 8 of the purine ring98,109,217 
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Table 3.12 Modification of the purine ring98,111 
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Table 3.13 Modification on positions 2,4,5 and 6 of the pyrimidine 
ring98,206 
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Table 3.14 Modification on position 5 of the pyrimidine ring98 
In general, the rules previously established for the N- 
deoxyribosyltransferases from L. helveticus97 were found to apply to the 
N-deoxyribosyltransferases from L. leichmannii. 
Modification of the Purine Ring at Positions 1,2 and 3 
The positions 1 and 2 of the purine ring can tolerate substitution of 
nitrogen for CH and vice versa (Table 3.8). A third ring can be 
accommodated, as in the tricyclic bases 90,95 and 108 (Fig. 3.12). 
However, changes at position 3 can result in bases that do not act as 
acceptors, such as 3-deazaadenine 98, though other bases, benzotriazole 61 
and benzimidazole 6 2, lacking the nitrogen atom at position 
3, are 
90 
acceptors (Fig. 3.12). Substitution at the 3 position has been reported to 
give either slow or non active substrates. 97 
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Fig. 3.12 Bases modified at positions 1,2 and 3 of the purine ring 
The 2,6-disubstituted purines, diaminopurine 91 and xanthine 96 (Table 
3.8) (Fig. 3.13) have slower velocities than the corresponding 
monosubstituted bases, adenine 99 and hypoxanthine 115 (Table 3.9). 
Xanthine 96 gave two products, thought to be the 3-ß -D- 
deoxyribonucleoside and the 9-0-D-deoxyribonucleoside (Fig. 3.13). The 
base seeks an alternative access to normal binding, docking into the 
protein catalytic site via the pyrimidine rather than the purine ring. 9 8 
Though the presence of a nitrogen at position 1 or 3 is not vital for the 
ability to act as a substrate, weak interactions could come into play 
between the nitrogens of the purine ring and the active site helping the 
base to bind, to the active site. It would be interesting to see if tricyclic 
compounds lacking nitrogens in the ring are active as substrates. 
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Fig. 3.13 Comparison of 6-mono- and 2,6-disubstituted purine bases 
Modification of the Purine Ring at Position 6 
All the 6-substituted purines tested proved to be substrates for the N- 
deoxyribosyltransferases (Table 3.9). The rate of the reaction decreases 
with the increasing size of the dialkylsubstituent at position 6.9 8 
Replacement of the amino group, such as 104, with the hydrophobic ethyl 
107 or phenyl 114 group at position 6 does not significantly affect the 
reaction rate (Fig. 3. 14). 215 These results show that the 1,2 and 6 part of 
0 
H 
115 
O 
HN N 
+OHN 
d3 
the purine ring resides in a large pocket in the active site. 
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Fig. 3.14 6-Substituted purine bases 
92 
Modification of the Purine Ring at Position 7 
The results in Table 3.10 show that a tautomeric proton is required in the 
imidazole ring. The 7-substituted purines, 7-methylguanine 119 and 1,7- 
deazaadenine 120 are not acceptors where the tautomeric shift is not 
possible. 98 The nitrogen atom at N-7 is not essential for binding as the 
three 7-deaza-8-azapurines 116,117 and 118 are acceptors. 
O NH2 0 CH3 
116 
HN 
ýIN 
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118 NN 119 
N 
N N H NH ºipN N 
\N / NH2 
N 
117 JL N 120 
N NH H 
is an acceptor in the N-deoxyribosyltransferase reaction 
X is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.10 Modification on position 7 of the purine ring 
Modification of the Purine Ring at Position 8 
All but one of the 8-modified analogues tested were substrates (Table 3.11). 
8-Bromoadenine 121 reacted very slowly and gave two products, probably 
the 3-ß -D-deoxyribonucleoside and the 
9-ß-D-deoxyribonucleoside (Fig. 
3.15), 98 which agrees with results published by Huang et al. 
' 10 
93 
NH2 NH2 
NN Enzyme NN 
Br Br 
NHNN 
cR 
121 dR = 2-deoxyribose 
NH2 
NN 
dR 
Fig. 3.15 The two possible products of the transferase reaction with 8- 
bromoadenine as acceptor base 
Uric acid 125 was not a substrate, which indicates that the 8-substituted 
analogues have difficulty in entering the active site due to steric 
hindrance (Fig. 3.16). 
O 
,, I N 
X 
0HH 
125 
Fig. 3.16 Uric acid is not an acceptor in the N-deoxyribosyltransferase 
reaction 
The 8-aza analogues, benzotriazole 61 and 123 were competent acceptors, 
but had reduced velocities compared to their 8-deaza analogues, 
benzimidazole 62 and adenine 99 (Fig. 3.17). Thus, though the presence of 
the extra nitrogen in the ring at position 8 does not prevent the base 
acting as an acceptor, it does hinder the reaction. 
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Fig. 3.17 Comparison of purine bases modified at position 8 
It is unclear why the 4-nitrobenzotriazole 63 and 4-aminobenzotriazole 64 
are not substrates in the transfer reaction. It has been shown that the 
active site is big enough to accommodate the amino and nitro groups 
(Table 3.9). Other 6-aminopurine analogues such as 2,6-diaminopurine 91, 
adenine 99,7-deaza-8-azaadenine 118 and 8-azaadenine 123 are all 
acceptors, though 3-deazaadenine 98 is not (Fig. 3.18). 
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Fig. 3.18 Comparison of 6-amino-substituted purine bases modified at 
position 8 
Benzotriazole 61 is an acceptor, even though the base lacks the nitrogens 
in the 6-membered ring and has an extra nitrogen at position 
2 
NH2 
Ný 
N 
95 
(the equivalent to position 8 in the purine ring). The presence of a 
substituent at position 4 of the benzotriazole base (the equivalent of the 6 
position in the purine ring) 63,64, coupled with the other changes 
within the ring, might put the molecule under some conformational 
strain. This prevents the 4-substituted benzotriazole from either entering 
the active site or being able to bind. The substituents at positions 4 and 5, 
for steric reasons, prevent the base from docking in the active site in the 
same way as the parent compound, benzotriazole 61. 
Modification of the Purine Ring 
The incomplete purine structure can participate in the transfer reaction 
(Table 3.12). The three imidazole bases tested, 4-amino-imidazole-5- 
carboxamide 126, ethyl-4-hydroxy-imidazoIe-5-carboxylate 127 and 
ethyl -4-amino-imidazole-5-carboxyIate 128, were all acceptors, though 
with a slower rate of transfer compared with the natural substrates. 
98 The 
1,2,4-triazole base 129 was found to be an acceptor, however the imidazole 
base 130 was not. Previous studies have found imidazole to be an inhibitor 
of the N-deoxyribosyltransferases. 
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Table 3.12 Modification of the purine ring 
96 
From these results the following rules can be established and a model of 
the active site proposed (Fig. 3.19): 
Summary: 
0 positions 1,2 and 6 are of little importance, 
" large groups can be accommodated at position 6 of the purine ring, 
"a tautomeric proton is necessary on the imidazole ring, 
0 only minor modifications can be tolerated at positions 3 and 8, for 
steric reasons, 
0 the imidazole moiety alone can act as an acceptor. 
Fig. 3.19 Model of the enzyme active site for purine bases 
Modification of Positions 2,4,5 and 6 of the Pyrimidine Ring 
N-Deoxyribosyltransferase II has a much narrower specificity for the 
pyrimidine ring. Tautomerism is necessary between N-1 and N-3 of the 
pyrimidine ring (Fig. 3.20). Substitutions at position 2 and 6 result in non 
acceptors (Table 3.13). However, position 5 on the pyrimidines seems to be 
analogous to position 6 on the purines in regard to its versatility. 
Substituents such as halides and small alkyl groups were substrates. Any 
substituent on position 5 bigger than the ethyl group resulted in an 
inactive compound, for steric reasons. 
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Fig. 3.20 Pyrimidine base 
The following conclusions can be drawn from these results and a model of 
the active site proposed (Fig. 3.21): 
Summary: 
" positions 1,2 and 6 are crucial for activity, 
9 tautomerism between positions 1 and 3 is necessary, 
0 small substituents at position 5 are tolerated. 
Fig. 3.21 Model of enzyme active site for pyrimidine bases 
Results 
Thirty two triazole bases were investigated as possible acceptors for the N- 
deoxyribosyltransferase from Lactobacillus leichmannii. Of these thirty 
two, twelve were found to act as acceptors and nine were isolated and fully 
characterised (Table 3.1). 
1,2,4-Triazole Bases 
98 
Only the carboxamides of the 1,2,4-triazoles 13,14,18-22,25 and 26 
synthesised were acceptors for the N-deoxyribosyltransferase (Table 3.5). 
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is an acceptor in the N-deoxyribosyltransferase reaction 
X is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.5 Results with 1,2,4-triazole bases used as acceptors in the N- 
deoxyribosyltransferase reaction 
The rate of the reaction decreased with the increasing size of alkyl group 
on the amide. The methyl 11 and 16, ethyl 12 and 17 or benzyl 27 esters 
were not acceptors, nor were the carboxylic acids 10 and 15. This led to 
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the conclusion that the hydrogen bonding properties of the amide were 
essential for binding. However, the N, N-dimethyl-1,2,4-triazole 25 was 
found to act as an acceptor and the nucleoside 70 was isolated. The rates of 
transfer of the N-butyl-1,2,4-triazole-3-carboxamide 22 and N-methyl, N- 
butyl-1,2,4-triazole-3-carboxamide 26 and were compared and the rates 
were found to be the same. This proved that the amide proton was not 
essential for binding. Replacing the amide with an ester or carboxylate 
group led to an inactive base. The nitrogen atom must be necessary for 
binding, anchoring the base in the active site. Loss of the amide group 
might prevent the triazole ring from docking correctly in the active site. 
Not all the 1,2,4-triazole-3-carboxamides synthesised acted . as acceptors. 
Alkyl substituents on the carboxamide of the 1,2,4-triazole base as big as n- 
butyl 22 were acceptors in the N-deoxyribosyltransferase reaction. Steric 
factors might explain the lack of transfer with N-benzyl-1,2,4-triazole-3- 
carboxamide 24 and N-cyclohexyl-1,2,4-triazole-3-carboxamide 23. 
Previous studies with N-deoxyribosyltransferases from Lactobacillus 
hel ve ti cus have shown that bases with bulkier substituents at position 6 
can act as acceptors (Fig. 3.22). 
a 
NH 
NN 
H 
CNH 
ýý 
NN 
H 
Fig. 3.22 Purines with bulky substituents on position 6 which are 
acceptors for the N-deoxyribosyltransferases from L. helveticus 
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The triazole probably docks in the enzyme site in the same way as the 
purines do. In this way the bulky substituents on the carboxamide can be 
accommodated, which roughly corresponds to position 6 on the purine 
base (Fig. 3.23). 
99 18 
Fig. 3.23 Possible position of the triazole base within the active site of the 
enzyme 
1,2,3-Triazole Bases 
The pattern of transfer with the 1,2,3-triazoles is not so straightforward. 
The only bases that were substrates for the N-deoxyribosyltransferase 
reaction were the 1,2,3-triazole-4-carboxamide 30 and the 5-amino-1,2,3- 
triazole-4-carboxamide 60. More notable is that the N -methyl -1 , 2,3 - 
triazole-4-carboxamide 38 and N-ethyl-1,2,3-triazole-4-carboxamide 39 
(Table 3.6) do not act as acceptors for the enzyme, whereas the equivalent 
1,2,4-triazole-3-carboxamides were substrates (Table 3.5). 
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x is not an acceptor in the N-deoxyribosyltransferase reaction 
Table 3.6 Results with 1,2,3-triazole bases used as acceptors in the N- 
deoxyribosyltransferase reaction 
Clearly, the enzyme can differentiate between the 1,2,3-triazole and the 
1,2,4-triazole bases. The positions of the nitrogen atoms within the 1,2,3- 
triazole ring must hinder its approach to the active site. The 1,2,3-triazole 
base could bind in such a way in the active site as to make it incapable of 
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reacting with the glycosyl-enzyme intermediate. This could be due to a 
mixture of hydrogen bonding and hydrophobic interactions within the 
active site. 
The 1,2,3-triazole esters 35,55,56 and 59 do not transfer (Table 3.6). This 
is consistent with the results obtained for the 1,2,4-triazole bases (Table 
3.5). However, ethyl-5-amino-imidazole-4-carboxylate 128 and ethyl-5- 
hydroxyl-imidazole-4-carboxylate 127 have been shown to be acceptors 
for N -deoxyribosyltransferase from Lactobacillus leichmannii (Fig. 
3.24). 98 How can these facts be reconciled? The 1,2,3-triazole and the 
imidazole bases only differ in the presence of a nitrogen at position 2, 
corresponding to position 8 on the purine ring (Fig. 3.24). 
/"%XOý N9 J 
HzN H 
ý N/ Hc)l 
/\O1 NNX 
HO H 
128 127 55 
Fig. 3.24 Comparison of the structures of the 1,2,3-triazole and imidazole 
bases 
As previously mentioned, purine bases substituted at position 8 act as 
acceptors but at much slower rates. The presence of a nitrogen at position 
8 results in lower reaction velocities. Thus it might 
be favourable for the 
4-substituted- 1,2,3-triazole base to bind as shown in (Fig. 3.25), where N-2 
is not close to the active site. 
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/0 
55 
Fig. 3.25 An alternative way for the 1,2,3-triazole to bind in the enzyme 
active site 
However, in this position the base cannot act as a substrate for the 
enzyme. With the 1,2,3-triazole-4-carboxamide 30 and the 5-amino-1,2,3- 
triazole-4-carboxamide 6 0, the only bases that acted as acceptors, it 
appears that the amide protons are crucial. The strong hydrogen bonding 
of the amide protons might overcome the tendency of the 1,2,3-triazole to 
minimise the interactions between N-2 and the active site. The 5-amino- 
1,2,3-triazole-4-carboxamide 60 could then dock in the same way in the 
active site as 5-amino-1,2,4-triazole-3-carboxamide 13 (Fig. 3.26). 
13 60 
Fig. 3.26 Model of 1,2,4-triazole and 1,2,3-triazole bases in the enzyme 
active site 
Thus, with the N-substituted-1,2,3-triazole-4-carboxamides lacking an 
hydrogen, the 1,2,3-triazole base reverts back to the inactive way of 
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binding. 
Another factor is the nucleophilicity of the base. The base acts as a 
nucleophile in the transfer reaction, a reduction in nucleophilicity could 
render the base inactive as a substrate. Imidazole has a pKa of 14.44 
compared with 1,2,3-triazole which has a significantly lower pKa of 9.26 
(Table 3.15). The presence of the third nitrogen in the ring pulls electron 
density from the ring causing a marked decrease in basicity. Equating 
basicity with nucleophilicity, imidazole is a much better nucleophile than 
1,2,3-triazole and thus would be a better acceptor in the transferase 
reaction. Esters are electron acceptors and reduce the basicity of the 
triazole even more making the triazole ester 55 inactive compared to the 
imidazole ester 127. 
Heterocyclic base Basic pKa 
Imidazole 6.95 
1,2,3-Triazole 1.17 
1,2,4-Triazole 2.20 
Table 3.15 pKa values of 5-membered heterocyclic bases218 
With 5-amino-1,2,3-triazole-4-carboxamide 60, replacing the amino group 
with a chloro 58 at position 5 rendered the base inactive as a substrate for 
the enzyme. 
0 
Fi2N 
F12N ii 
60 
0 
FýNýN 
N 
pýýH 
58 
X 
Fig. 3.25 Comparison of 5-substituted-1,2,3-triazole-4-carfioxamides 
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The amino group is an electron resonance donor and thus base 
strengthening whereas the halogens are inductive acceptors and hence 
decrease the basicity of the triazole. The chloro triazole 58 could be too 
weak a nucleophile to react with the enzyme. Another reason could be that 
steric factors might hinder the base from binding to the active site. 
Conclusion 
It is difficult to formulate an overall theory encompassing the results of 
the purine, imidazole and triazole bases. A combination of steric, hydrogen 
bonding and electronic factors have been used to explain most of the 
observations. The triazole bases synthesised are small enough to fit in the 
active site. However, it is clear that the N-deoxyribosyltransferases are 
sensitive to changes within the imidazole moiety of the ring. It would be 
useful to compare these findings with the X-ray crystal structure of a 
recombinant Lactobacillus leichmannii nucleoside 
deoxyribosyItransferase which has been reported. Unfortunately, only 
the preliminary findings have been published100 and it is unclear 
whether this enzyme is like N -deoxyribosyltransferase I or N- 
deoxyribosyltransferase H. 
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CHAPTER 4 
CHEMICAL SYNTHESIS OF NUCLEOSIDE ANALOGUES 
The 1,3-Dich Ioro-1,1,3,3-tetraisopropyldisiI oxane (TDPS) 
Protection Group 
There are many procedures for the modification of the sugar moiety of the 
intact nucleoside. 4 7,21 9 The regiospecific deoxygenation of 
ribonucleosides had been impeded by the difficulty in differentiating 2'- 
and 3'-hydroxyl groups. This problem was solved by Markiewicz, who 
developed the selective protection of the 3'-hydroxyl and 5'-hydroxyl 
functions of nucleosides by 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane 
15 6 (Scheme 4.1). 220 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane 156 
reacts rapidly with the primary hydroxyl group on C-5' 157. This is 
followed by the slower intramolecular ring closure with the secondary 3'- 
hydroxyl, to give the 3'-5'-O-protected nucleoside 158 (Scheme 4.1). 
The tetraisopropyldisiloxane (TPDS) group is stable under a wide range of 
conditions and so has been extensively used in the 2'-hydroxyl 
modification of nucleosides. 210 The 3'- and the 5'- ends can be cleaved 
selectively under appropriate conditions. 
220 However, isomerisation is 
known to occur in acid where the protected nucleoside undergoes 5'-end 
cleavage to give the 2'-3'-O-TPDS derivative 159 (Scheme 4.1). 
221 The 
reaction only occurs in dimethylformamide (DMF) with mesitylene 
sulfonic acid (MSA) as catalyst. 
107 
G'O CI 
156 
Base 
HO Kinetic 
HO OH 
Base o 0 
i-ý ö HO OH 
>//CI 
157 
Thermodynamic 
Base 
HO 
Z, \ 
159 
Base 
DMF, MSA 
OZp OH 
Si 
158 
Scheme 4.1 Reaction of 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane with 
a ribonucleoside 
Other solvents, such as, dioxane, acetonitrile, tetrahydrofuran or 
chloroform are not effective. This flexible property of the TPDS group has 
been exploited in the synthesis of carbohydrates where the TPDS group 
was used first to protect the primary and secondary alcohols 160 (Scheme 
4.2). Later on in the synthesis, using acid catalysis, the TPDS group was 
redirected to protect two secondary alcohols 161.222 
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Scheme 4.2 Manipulation of the TPDS protection group222 
Absence of the primary hydroxyl function at C-5' (if one of the protons is 
replaced by a methyl group) completely changes the course of the 
reaction affording exclusively 2', 3'-O-(tetraisopropyldisiloxane-1,3-diyl) 
derivative, the thermodynamic product. 223 
Deprotection of the silyl-protected nucleosides is effected by ammonium 
fluoride in methanol in quantitative yield (Scheme 4.3). 224 
H3C- 0\ 
% 
H' 
_ /H F -------- si - O, + ." """/ "H_ NH3 
/H. 
H3C-O 
1F- Si + ROH + NH3 
Scheme 4.3 Deprotection of silyl ethers with ammonium fluoride224 
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Ammonium fluoride provides an economical, effective alternative to 
tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) which 
until recently, has been the most common way to deprotect silyl ethers. 
The phase transfer properties of the tetrabutylammonium cation often 
cause difficulties in the workup and purification of products. 
Synthesis of 2'-Deoxyribosylnucleosides 
Robins et al were the first to report a general four step regiospecific 
stereoselective procedure for the conversion of ribonucleosides to 2'- 
deoxyribonucleosides (Scheme 4.4). 225,226 The first step incorporates the 
Markiewicz protection of the ribonucleoside as its 3', 5'-O -TPDS derivative 
162, phenoxythiocarbonylation of its 2'-hydroxyl group to give the 
xanthate ester 163, deoxygenation 164 and deprotection using TBAF to 
give the 2'-deoxynucleoside 165 (Scheme 4.4). 
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Scheme 4.4 The regiospecific and stereoselective conversion of 
ribonucleosides to 2'-deoxynucleosides226 
A variant of the procedure by Watanabe and coworkers utilises the 
deoxygenation of the 2'-O-(imidazol-l-yl) thionocarbonyl derivative 166 
(Scheme 4.5). 227 
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Scheme 4.5 The synthesis of 2'-deoxyribonucleosides via the 2'-O- 
{ (imidazol-1-yl)thiocarbonyl } nucleoside227 
Sanghvi et a1135 were able to apply this method, using the 3'-O-(imidazol- 
1-yl) thiocarbonyl of 5'-protected-2'-deoxyribavirin, in the synthesis of 
2', 3'-dideoxyribavirin. 
Synthesis of 5'-Deoxyribavirin 
The chemical synthesis of 2'-deoxyribavirin was attempted because the 2'- 
deoxyribavirin, synthesised enzymatically, was found to possess some 
antiviral activity. The difficulties with the actual purification of 2'- 
deoxyribavirin in the enzymatic synthesis led to the exploration of 
112 
chemical routes to this product. The deoxygenation of ribavirin at C-2' 
seemed to be an easy procedure with plenty of precedence for this type of 
transformation. The first step was the selective protection of the the 3', 5'- 
hydroxyl groups of ribavirin as outlined by Robins. 2 26 Ribavirin 7and 
1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane 156 in either anhydrous 
pyridine or DMF and imidazole gave 66% of the protected nucleoside. This 
was assumed to be the 1-(3', 5'-O-(tetraisopropyldisilox-1,3-diyl)-p-D- 
ribofuranosyI)-1,2,4-triazole-3-carboxamide 167. However, acetylation of 
the 0 -TPDS-protected ribavirin 168 showed that the 2'- and 3'-hydroxyl 
functions of the nucleoside were protected as in compound 169 (Scheme 
4.6). The electron withdrawing effect of the acetyl group causes the 
protons attached to shift to lower field in the 1H NMR. 228 The chemical 
shift of the protons at C-5' were 3.56 ppm in the 0-TPD-protected d 
ribavirin 16 8 which shifted to 4.34 ppm 169 on acetylation. Thus the 
product was 1-(2', 3'-O-(tetraisopropyldisilox-1,3-diyl)-ß -D-ribofuranosyl)- 
1,2,4-triazole-3-carboxamide 168. The chemical shifts of the protons on C- 
2' and C-3' were unchanged. 
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Scheme 4.6 Protection of ribavirin with 1,3-dichloro-1,1,3,3- 
tetraisopropyldisiloxane 
Maintaining the temperature at 0°C in pyridine in the initial stages of the 
reaction229 ensured that the kinetic product, 3', 5'-O-TPDS-ribavirin 167, 
and not the thermodynamic 2'-3'-O -protected nucleoside 168, was formed 
in 41 % yield. 
Attempts to form the phenyl thiocarbonylxanthate ester226,230 of either 
the 2', 3'-O-TPDS-ribavirin 168 or 3', 5'-O-TPDS-ribavirin 167 were not 
successful (Scheme 4.7). When dry dichloromethane was used as solvent 
no reaction occurred, whereas reaction in acetonitrile gave a range of 
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products, the number of which increased with time, but the starting 
material was always present by TLC. 
Reaction of 2', 3'-O-TPDS-ribavirin 168 and 3', 5'-O-TPDS-ribavirin 167 with 
methyloxalyl chloride in dichloromethane gave no reaction by TLC and 
only starting material was isolated in the workup (Scheme 4.7). 
Formation of the 2'-O -(imidazol-l-yl) thiocarbonyl of 3', 5'-O -TPDS- 
ribavirin in dichloromethane231 was not successful (Scheme 4.7). No 
reaction seemed to occur by TLC. 
o 
HZ Ný-- N 
N, 
N 
or 
O 
H2 NN 
N 
N 
>-/c:: O O OH Si 
S 
+\/ 
OxG 
0 
Act 
+ Me0 
0 
DMAP 
IN. Starting 
CH2CI2 material 
or and mixture 
MeCN of products 
DAP No reaction 
CH2Cl2 
S 
+NrN 
DMAP No reaction 
ý' 
N 
CH2C12 
Scheme 4.7 Attempts at the modification of the free hydroxyl group of 
TPDS protected ribavirin 
The successful synthesis of 2', 3'-dideoxyribavirin from 
2'-deoxyribavirin 
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using an excess of N, N"-thiocarbonyldiimidazole in DMF, followed by 
reductive deoxygenation has been reported. 135 It is difficult to explain the 
lack of success with this reagent. The use of dichloromethane instead of 
DMF and possible steric factors could account for this. 
Another approach was tried. A wide range of 2'-deoxynucleosides has been 
prepared via either reduction of 2'-halogenated compounds or 
desulfurisation of various thio derivatives. 47 A procedure by Verheyden et 
a1232 was used to iodinate the remaining hydroxyl group of 2', 3'-O-TPDS- 
ribavirin 168 with methyltriphenoxyphosphonium iodide (Rydon's 
reagent) 170 in anhydrous DMF. It is thought to react with alcohols in the 
following way (Scheme 4.8). 
CH3 
RCH2OH + (PhO)3P-CH3 (PhO)2P I 
170 OCH2R 
0 
11 
RCH2I + (PhO) 2P-CH 3 
Scheme 4.8 Iodination of the hydroxyl group using Rydon's 
reagent47,232 
This gave the expected product 171 in 62% yield (Scheme 4.9). The 
palladium-catalysed reduction148 of the iodo protected nucleoside gave the 
5'-deoxy-2', 3'-O-TPDS-ribavirin 172 in 63% yield. Deprotection with 
ammonium fluoride in methanol resulted in 5'-iodo-5'-deoxyribavirin 173 
and 5'-deoxyribavirin 174 in yields of 91.5% and 84% respectively. 
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Scheme 4.9 Synthesis of 5'-iodo-5'-deoxyribavirin and 5'-deoxyribavirin 
from 2', 3'-O-TPDS-ribavirin 
Iodination, followed by reduction of 3', 5'-O-TPDS-ribavirin 167, in exactly 
the same procedure as detailed above, gave after work up, the 5'- 
deoxyribavirin 174 (Scheme 4.10). Further investigations showed that the 
iodo-protected derivative was the 5'-iodo-5'-deoxy-2', 3'-O-TPDS-ribavirin 
171, identical, by IH NMR and TLC, with that previously made from 3', 5'-0- 
TPDS-ribavirin 168. Iodination caused isomerisation of the TPDS group 
from the 3'- and 5'- position to the 2'- and 3'- position and the only product 
of this reaction was the 5'-iodo-5'-deoxy-2', 3'-O -TPDS-ribavirin 171 
(Scheme 4.10). 
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Clearly, the difference in stability between 3', 5'-O-TPDS-ribavirin 167 and 
2', 3'-O -TPDS-ribavirin 168 is far greater than in other TPDS protected 
nucleosides. At room temperature, the protection of ribavirin by 1,3- 
dichloro-1,1,3,3-tetraisopropyldisiloxane is governed by thermodynamic 
rather than kinetic factors. Conducting the reaction at 0°C gives only the 
kinetic product, which is stable indefinitely in the solid form. Difficulties 
have been reported in the synthesis of 2'- and 3'- derivatives of 
ribavirin. 229 After the synthesis of the 3', 5'-O-TPDS-ribavirin 167, careful 
manipulation of the reaction conditions was required to give the desired 
2'-ester. The removal of the protective disiloxyl group gave a range of 
products. Finally, the desired products were synthesised by the non- 
selective acylation of ribavirin followed by chromatographic separation 
and purification. 
Another protection procedure has been reported in the synthesis of a 
range of deoxygenated ribavirin derivatives. 134 Acylation of ribavirin 
with a-acetoxyisobutyryl bromide gave a mixture of intermediate isomers, 
which were not characterised. On reduction only the 3'-deoxyribavirin 
was isolated. 
Other protective groups were tried (Scheme 4.11). Protection with the 
trityl group233 gave a complex mixture of products. Three were partially 
isolated by flash chromatography but not properly identified. A test 
reaction was followed by TLC over time to see the order in which the 
products emerged. The aim was to optimise the product ratio by carefully 
picking the time when the reaction was quenched. Unfortunately, what 
appeared to be the monoprotected ribavirin- as it was the first product to 
appear in the reaction, was still present when the third spot appeared- 
that is the triprotected ribavirin. The products were difficult to separate as 
the Rfs were very close. This procedure was abandoned as it was too 
wasteful. 
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Protection with trimethylorthobenzoate gave a mixture of products in 3: 1 
ratio (20.2% : 7.6%) of the 2', 5'-O-phenylesters and 3', 5'-O-phenylesters 
(Scheme 4.11). 234 The two products, having identical Rf values, could not 
be separated by flash chromatography. 
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Scheme 4.11 Protection of the hydroxyl groups of ribavirin 
The synthesis of 2'-deoxyribavirin was repeated using thymidine and N- 
deoxyribosyltransferase, which, though it presented difficulties in 
purification, was less troublesome than the chemical procedures. This is a 
classic example of the advantages of the enzymatic over purely chemical 
methods. 
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Results of Viral Assays 
Nucleoside 
HCMV 
/µM 
HSV-2 
/µM 
VZV 
/µM 
Flu A 
/µM 
HIV 
/µM 
Flu B 
/µM 
CC1C50 
Vero 
/gm 
7 - - - 30 - 13 
65 49 >10 >40 3.3 - IC50= 
1.9µM 
- 
66 >100 >100 >40 >100 - - - 
67 >100 >100 >40 >100 >50 - >500 
68 >100 >100 >100 >100 >50 - >500 
174 >100 >100 >100 >100 ST50 - >500 
173 >10 
<100 
ST10 >40 >10 
<100 
>50 - 196 
Table 4.1 The EC50 values of some of the nucleosides synthesised 
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Fig. 4.1 Nucleoside analogues tested for antiviral activity 
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EC50 represents the concentration of the compound that inhibits the virus 
in infected cells to 50% of the control. CC1C50 Vero is the measure of the 
cell toxicity, representing the concentration of the nucleoside that kills 
50% of the cells. 2'-Deoxyribavirin 65 showed significant antiviral 
activity. This is in contrast to findings by Sidwell et al, who reported that 
the 2'-deoxyribofuranosyl analogue was inactive against both RNA and 
DNA viruses. 43 Compared to ribavirin 7 the remainder of the nucleosides 
synthesised showed little antiviral activit y (Table 4.1). Alkyl substitution 
of the carboxamide group renders the 2'-deoxyribavirin analogues 
inactive. 
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CHAPTERS 
GENERAL MATERIALS AND METHODS 
Materials 
Chemicals and starting materials were either commercially available or 
synthesised as described in the text. Chemicals were either purified using 
literature methods235 or purchased as the highest available grade. All 
solvents were dried and distilled before use. 
Methods 
iH NMR spectra were recorded at 250 MHz on a Bruker ACF250 
spectrometer or at 400 MHz on a Bruker WH400 spectrometer. Chemical 
shifts are given in ppm relative to tetramethlysilane (TMS) (0.00ppm). 
Multiplicities of 1H NMR signals, where applicable, are abbreviated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublets), ddd (doublet of doublet of doublets) and m (multiplet). 
13C NMR spectra were recorded at 100.62 MHz on a Broker WH400 
spectrometer or at 62.89 MHz on a Bruker ACF250 spectrometer with CHC13, 
(CH3)2SO and CH3OD as internal standards. 
Nuclear Overhauser enhancement spectra were measured on a solution 
that had not been deoxygenated and were acquired with an irradiation 
time of 2 seconds. 
Mass spectra were recorded using a Kratos MS80 instrument. Electron 
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impact (EI) spectra were recorded at 70 eV and for chemical ionisation (CI) 
spectra ammonia was used as the carrier gas. 
Accurate mass spectra were recorded on either a Kratos MS80 instrument 
or were carried out by the SERC Mass Spectrometry Service Centre, 
Swansea. 
CHN analysis was carried out at the University of Warwick or The 
Wellcome Research Laboratories, Beckenham, Kent. 
Melting points are uncorrected. 
High-Performance Liquid Chromatgraphy (HPLC) analysis was performed 
on a Waters machine, 501 solvent delivery system. The concentration of 
nucleosides and bases present in the reaction mixture was determined 
using reverse phase HPLC on a Techsphere 5C8 or a Techsphere 100DS 
column (25 cm x 4.6 mm and a precolumn, 5 cm x 4.6 mm; HPLC Technology 
Ltd, Macclesfield, Cheshire, UK). The samples were eluted from the column 
using a mobile phase of acetonitrile and 10 mM ammonium acetate with 
doubly distilled water at a flow rate of 1.0 ml/min and detected by UV at 214 
nm. 
TLC analyses were run on aluminium plates coated with silica gel (Merck 
60F 254,0.20 mm) and eluted in the solvent systems given in the text. 
Visualisation was achieved by UV or by spraying the plate with p- 
anisaldehyde in ethanol and acetic acid followed by heating to observe the 
sugars. Compounds were purified by recrystallisation or by flash 
chromatography on silica gel. 
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Microorganisms and Media 
Lactobacillus leichmannii was obtained from the American Type Culture 
Collection (ATCC, Rochville, Maryland, USA). The growth media MRS 
Broth236 was purchased from Oxoid, Basingstoke, Hampshire, UK and was 
used as instructed on the bottle. The Biorad protein assay was purchased 
from BioRad, Watford, Hertfordshire, UK. 
The symbol * indicates the synthesis of a new compound. 
EXPERIMENTAL 
Synthesis of 1,2,4-Triazole Bases 
Synthesis of 5-amino-1,2,4-triazole-3-carboxylic acid 10165,166 
0 
N\ OH 
I-12W/ \ý/N 
Oxalic acid (100.8 g, 1.12 mol) was dissolved by heating in water (800 ml). 
To the cooled solution was slowly added aminoguanidine bicarbonate (95.2 
g, 0.68 mol). The mixture was refluxed for 6h and a precipitate was 
formed. On cooling, aqueous sodium hydroxide (400 ml, 2.5 M) was added to 
dissolve the precipitate and the solution was refluxed for 1 h. When cooled 
the mixture was adjusted to pH 3.0 with concentrated hydrochloric acid. 
The colourless precipitate was filtered, washed with water and dried to 
give 5-amino-1,2,4-triazole-3-carboxylic acid 10 (85.0 g, 98%), m. p. 183°C 
(lit., 165 182_3°C); vmax (nujol mull)/cm-1 1684 (C=O); m/z (FAB) 128 
125 
((M+H)+, 7%), 58 (28) and 46 (27). 
Synthesis of methyl 5-amino-1,2,4-triazole-3-carboxylate 11166 
N 
H2N Ni 
H 
5-Amino-1,2,4-triazole-3-carboxylic acid 10 (5.00 g, 39.0 mmol) was 
suspended in methanol (50 ml) and saturated with hydrogen chloride gas 
at 0°C. The solution was left stirring at room temperature for 7 d. Nitrogen 
gas was bubbled through the solution to remove the excess hydrogen 
chloride gas. The solution was filtered, the filtrate evaporated to dryness 
and the residue recrystallised from methanol giving methyl 5-amino- 
1,2,4-triazole-3-carboxylate 11 (4.345 g, 78.4%) as colourless crystals, m. p. 
220°C (lit., 166 220°C); vmax (KBr)/cm-1 3371-2982 (C-H), 1707 (C=O) and 
1672 (C=O); 8H (250 MHz; MeOH-d4) 4.04 (3 H, s, OMe) and 5.17 (1 H, br s, 
NH2); 6C (250 MHz; MeOH-d4) 53.96 (OMe), - 143.33 (C-5), 153.73 (C-3) and 
157.54 (C=O); m/z (CI) 160 ((M+NH4)+, 27%), 143 ((M+H)+, 100), 128 (3), 112 
(1), 99 (2), 85 (23) and 56 (1); m/z (EI) 142 (M+-, 27%), 100 (10), 97 (3), 82 
(26), 69 (8), 57 (18), 54 (25), 43 (32) and 36 (100). 
Synthesis of ethyl 5-amino-1,2,4-triazole-3-carboxylate 12167* 
N\O` 
K2N H 
126 
5-Amino-1,2,4-triazole-3-carboxylic acid 10 (8.0 g, 62.5 mmol) was 
suspended in ethanol (150 ml) cooled to 0°C by an ice/water bath and 
saturated with hydrogen chloride gas for 30 min, then sealed and left 
stirring at room temperature for 11 d. The reaction was monitored by 
reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 4.6 mm, 
elution with 2% acetonitrile/10 mM ammonium acetate). The solvent was 
removed in vacuo, the residue was treated with saturated aqueous sodium 
hydrogen carbonate (41 ml) and the white precipitate collected, washed 
with water and dried to give ethyl 5 -amino-1,2,4-triazole-3-carboxylate 12 
(5.155 g, 53%) as a colourless solid, m. p. 280-283°C (decomp); (Found: C, 
38.465; H, 5.165; N, 35.27. C5H8N402 requires C, 38.26; H, 5.40; N, 35.02); 6H 
(250 MHz; DMSO-d6) 1.25 (3 H, t, J 6.98, Me), 3.51 (2 H, br s, NH2), 4.22 (2 H, q, 
J 7.17, CH2) and 12.67 (1 H, br s, H-1); 8C (250 MHz; DMSO-d6) 14.15 (Me), 
60.43 (CH2), 151.78 (C-5), 157.63 (C-3) and 160.33 (C=O); m/z (Cl) 174 
((M+NH4)+, 7%), 157 ((M+H)+, 30), 96 (100) and 79 (91); m/z (EI) 156 (M+", 
20%), 128 (9), 78 (100) and 45 (57). 
Synthesis of 5-amino-1,2,4-triazole-3-carboxamide 13 
0 
N NH2 
H2 NNx 
H 
Methyl 5-amino-1,2,4-triazole-3-carboxylate 11 (0.66 g, 4.65 mmol) was 
dissolved in methanol (175 ml), cooled to 0°C and saturated with ammonia 
gas. The suspension was left stirring at room temperature 
for 8 d. The 
reaction was monitored by reverse phase 
HPLC analysis (Techsphere 5C8 
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column, 25 cm x 4.6 mm, elution with 3% acetonitrile/10 mM ammonium 
acetate). The solvent was removed in vacuo and the residue recrystallised 
from water to give 5-amino-1,2,4-triazole-3-carboxamide 13 (0.53 g, 90%) 
as a colourless crystalline solid, m. p. 295-298°C (decomp); (Found: C, 28.04; 
H, 3.98; N, 54.83. C3H5N50 requires C, 28.35; H, 3.98; N, 55.09); vmax (KBr 
disc)/cm-1 3342,3352, (NH-amide) and 1707,1691,1655 (C=O); SH (250 MHz; 
DMSO-d6) 3.49 (2 H, br s, NH2/H20), 6.14 (1 H, br s, NH-amide), 7.44 (1 H, br 
s, NH-amide) and 12.52 (1 H, s, H-1); SC (250 MHz; DMSO-d6) 154.51 (C-5), 
157.33 (C-3) and 161.75 (C=O); m/z (CI) 128 ((M+H)+, 45%), 111 (25), 85 (7), 
69 (2), 56 (18), 45 (13), 41 (100) and 33 (13); m/z (EI) 127 (M+-, 47%), 107 
(18), 77 (34), 56 (100), 44 (93) and 39 (20). 
Synthesis of N-methyl-5-amino-1,2,4-triazole-3-carboxamide 
14166* 
0 
H2N Ni 
H 
Ethyl 5-amino-1,2,4-triazole-3-carboxylate 12 (0.224 g, 1.56 mmol) was 
dissolved in methylamine (20 ml, 25-30% w/v solution in water) and the 
solution was left at room temperature for 4 d. The reaction was monitored 
by reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 4.6 mm, 
elution with 4% acetonitrile/10 mM ammonium acetate). The solvent was 
evaporated in vacuo and the residue gave on recrystallisation from water 
N-methyl-5-amino-1,2,4-triazole-3-carboxamide 14 (0.197 g, 97.5%) as 
colourless crystals, m. p. 153-155°C; (Found: C, 34.32; H, 4.95; N, 49.99. 
C4H7N50 requires C, 34.05; H, 5.00; N, 49.61); SH (250 MHz; D20) 2.53 (1.5 H, s, 
128 
Me) and 2.83 (1.5 H, s, Me); 8C (250 MHz; D20) 25.36 (Me), 26.55 (Me), 154.41 
(C-5), 158.15 (C-3) and 162.61 (C=O); m/z (CI) 159 ((M+NH4)+, 40%), 142 
((M + H) +, 100), 112 (2), 102 (2) and 85 (13); n/z (EI) 141 (M+", 38%), 112 
(13), 98 (8), 84 (20), 69 (5), 56 (16), 43 (17) and 36 (100). 
Synthesis of 1,2,4-triazole-3-carboxylic acid 15165,166 
0 
N OH 
N 
N 
H 
5-Amino-1,2,4-triazole-3-carboxylic acid 10 (8.5 g, 66 mmol) was heated to 
50°C in water (52 ml) and concentrated hydrochloric acid (20 ml), cooled 
to 0°C with an ice/water bath, ice (60 g) was added and a precipitate 
formed. A solution of sodium nitrate (9.10 g, 130 mmol) in water (20 ml) 
was added dropwise maintaining the temperature below 5°C and left 
stirring for 1 h. The white solid was filtered off, pressed dry and 
immediately suspended in methanol (60 ml) and heated carefully with 
stirring to 40°C when a very exothermic reaction occurred and the 
solution was rapidly cooled in an acetone/dry ice bath. The solid was 
filtered off and dried to give 1,2,4-triazole-3-carboxylic acid 15 (7.07 g, 
94%) of a colourless powder, m. p. 136-137°C (lit., 
166 137°C). 
Synthesis of methyl 1,2,4-triazole-3-carboxylate 16166 
O 
NO 
N 
N1-1 
H 
129 
1,2,4-Triazole-3-carboxylic acid 15 (1.60 g, 14 mmol) was dissolved in 
methanol (30 ml) and the solution was saturated with hydrogen chloride 
gas at 0°C. The reaction was stirred at room temperature for 3d and 
followed by reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 
4.6 m, elution with 2% acetonitrile/10 mM ammonium acetate). Nitrogen 
was bubbled through the solution to remove excess hydrogen chloride gas. 
The solvent was removed in vacuo and the hydrogen chloride salt of the 
product was recrystallised from water to give methyl 1,2,4-triazole-3- 
carboxylate 16 (1.60 g, 89%) as colourless crystals, m. p. 198°C (lit., 164 
198°C); vmax (nujol mull)/cm-1 1724 (C=O); 8H (400 MHz; DMSO-d6) 4.13 (3 H, 
s, Me) and 8.67 (1 H, s, H-5); SC (400 MHz; DMSO-d6) 52.16 (Me), 146.10 (C-5), 
159.97 (C-3) and 163.07 (C=O); m/z (CI) 145 ((M+NH4)+, 12%), 128 ((M+H)+, 
100), 116 (14), 70 (34), 58 (11) and 41 (3); mlz (EI) 127 (M+", 21%), 97 (58), 
69 (100), 58 (26) and 42 (38). 
Synthesis of ethyl 1,2,4-triazole-3-carboxylate 17167 
N\O, \ 
H 
1,2,4-Triazole-3-carboxylic acid 15 (7.01 g, 62.5 mmol) was suspended in 
ethanol (100 ml) cooled to 0°C by an ice/water bath and saturated with 
hydrogen chloride gas for 30 min, then sealed and left stirring at room 
temperature for 7 d. The reaction was monitored by reverse phase HPLC 
analysis (Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 2% 
acetonitrile/10 mM ammonium acetate). The solvent was removed in 
va cuo, the residue was treated with saturated aqueous sodium 
hydrogen 
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carbonate (41 ml) and the white precipitate collected, washed with water 
and recrystallised from ethanol to give 1.98 g of colourless crystals. The 
filtrate was extracted with ethyl acetate (3 x 50 ml), the organic extracts 
combined and dried over sodium sulfate, filtered and evaporated to give on 
recrystallisation 2.85 g. The total yield of ethyl 1,2,4-triazole-3-carboxylate 
17 was 4.83 g (50%), m. p. 177°C (lit., 167 178°C); Amax (H20)/nm 192.3; 8H 
(250 MHz; DMSO-d6) 1.29 (3 H, t, J 7.11, Me), 4.32 (2 H, q, J 7.07, CH2), 8.71 (1 
H, br s, H-5) and 14.96 (1 H, br s, H-1); SC (250 MHz; DMSO-d6) 14.28 (Me), 
61.20 (CH 2C H3), 145.31 (C-5), 154.29 (C-3) and 159.96 (C=O); m/z (CI) 142 
((M+H)+, 100%), 128 (10), 114 (9), 96 (11) and 70 (10); m/z (EI) 141 (M+", 
10%), 114 (33), 96 (90), 69 (100), 55 (10), 45 (10) and 42 (54). 
Synthesis of 1,2,4-triazole-3-carboxamide 18166 
N\ Nhlp 
,N 
H 
Ethyl 1,2,4-triazole-3-carboxylate 17 (0.210 g, 1.49 mmol) was dissolved in 
methanol (10 ml) and saturated aqueous ammonia (20 ml, d=0.88) was 
added and the solution stirred at room temperature for 4 d. The reaction 
was monitored by reverse phase HPLC analysis (Techsphere 5C8 column, 
25 cm x 4.6 mm, elution with 2% acetonitrile/10 mM ammonium acetate). 
The solvent was evaporated in vacuo and the residue gave on 
recrystallisation from methanol and water 1,2,4-triazole-3-carboxamide 
18 (0.157 g, 94%) as colourless crystals, m. p. 312°C (lit., 
166 312°C); vmax 
(nujol mull)/cm-1 3327 (NH-amide), 3123 (NH-amide) and 1699 (C=O); SH 
(250 MHz; DMSO-d6) 7.73 (1 H, br s, NH-amide), 8.00 (1 H, br s, NH-amide), 
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8.43 (1 H, s, H-5) and 14.59 (1 H, br s, H-1); m/z (CI) 130 ((M+NH4)+, 33%), 
113 ((M+H)+, 100), 96 (2), 84 (2) and 70 ({ (M+H)+ - CONH 21,3); m/z (EI) 112 
(M+", 33%), 96 (1), 84 (13), 69 ((M+- - CONH2), 100), 57 (18) and 42 (34). 
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Synthesis of N-methyl-1,2,4-triazole-3-carboxamide 19* 
0 
NýH 
ýN N 
H 
Methyl 1,2,4-triazole-3-carboxylate 16 (0.099 g, 0.78 mmol) was dissolved 
in methanol (10 ml) cooled to 0°C and saturated with methylamine gas. The 
solution was stirred at room temperature for 11 d and the reaction was 
monitored by reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm 
x 4.6 mm, elution with 10 mM ammonium acetate). The solvent was 
evaporated in vacuo and the residue gave on recrystallisation from 
methanol N-methyl-1,2,4-triazole-3-carboxamide 19 (0.79 g, 81%) as 
colourless crystals, m. p. 253-255°C; (Found: C, 37.86; H, 4.77; N, 44.13. 
C4H6N40 requires C, 38.13; H, 4.80; N, 44.41); SH (250 MHz; DMSO-d6) 2.75 (1.5 
H, s, Me), 2.77 (1.5 H, s, Me), 8.40 (1 H, s, H-5), 8.55 (0.5 H, br s, NH-amide) 
and 8.57 (0.5 H, br s, NH-amide); SC (250 MHz; DMSO-d6) 25.72 (Me), 147.25 
(C-5), 153.70 (C-3) and 158.65 (C=O); m/z (CI) 144 ((M+NH4)+, 5%), 127 
((M+H)+, 23), 35 (8) and 18 (100); m/z (EI) 126 (M+", 75%), 98 (32), 96 (53), 
83 (25), 69 (97), 58 (81), 42 (100), 28 (87) and 17 (10). 
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Synthesis of N-ethyl-1,2,4-triazole-3-carboxamide 20* 
0 
N\H` 
ýN N 
H 
Methyl 1,2,4-triazole-3-carboxylate 16 (0.40 g, 3.147 mmol). and 
ethylamine (2 ml, 70% (w/v) solution in water) were dissolved in 
methanol (2 ml) and stirred at 50°C for 3 d. The reaction was monitored by 
reverse phase HPLC (Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 
2% acetonitrile/10 mM ammonium acetate). The solvent was removed in 
vacuo and the residue recrystallised from methanol and dichioromethane 
to give N-ethyl-1,2,4-triazole-3-carboxamide 20 (0.41 g, 92%) as colourless 
crystals, m. p. 188-190°C ; (Found: M+ 140.0689. C5H8N40 requires 140.0699); 
5H (250 MHz; MeOH-d4) 1.25 (3 H, t, J 7.25, Me), 3.46 (2 H, q, J 7.25, CH2) and 
8.49 (1 H, s, H-5); 8C (250 MHz; MeOH-d4) 14.84 (Me), 35.20 (CH2), 146.99 (C- 
5), 156.43 (C-3) and 160.84 (C=O); m/z (CI) 158 ((M+NH4)+, 7%), 141 ((M+H)+, 
100), 113 (5), 96 (3) and 44 (14); m/z (EI) 140 (M+-, 3%), 125 (12), 96 (45), 83 
(12), 69 (63), 44 (100) and 42 (84). 
Synthesis of N-n-propyl-1,2,4-triazole-3-carboxamide 21* 
0 
N\H 
\ /N N 
H 
Methyl 1,2,4-triazole-3-carboxylate 16 (0.40 g, 3.147 mmol) and n- 
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propylamine (2 ml) were dissolved in methanol (2 ml) and stirred at 50°C 
for 6 d. The reaction was monitored by reverse phase HPLC (Techsphere 
5C8 column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 mM 
ammonium acetate). The solvent was removed in vacuo and the residue 
recrystallised from methanol to give N-n-propyl-1,2,4-triazole-3- 
carboxamide 21 (0.35 g, 72%) as colourless crystals, m. p. 189-190°C; 
(Found: M+ 154.0851. C6H 10N40 requires 154.0856); SH (250 MHz; MeOH-d4) 
0.86 (3 H, t, J 7.43, Me), 1.53 (2 H, sextet, J 7.31, CH2CH3), 3.25 (2 H, t, J 7.03, 
CH2CH2CH3) and 8.33 (1 H, s, H-5); SC (250 MHz; MeOH-d4) 11.65 (Me), 23.67 
(CH2CH3), 42.07 (CH2CH2CH3), 147.06 (C-5), 156.35 (C-3) and 160.97 (C=O); 
m/z (CI) 172 ((M+NH4)+, 3%), 155 ((M+H)+, 100), 141 (2), 125 (8), 113 (7), 96 
(4), 70 (3) and 58 (7); m/z (EI) 154 (M+", 12%), 125 (97), 96 (100), 91 (10), 83 
(12), 81 (14), 69 (37), 58 (41), 55 (23) and 41 (33). 
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Synthesis of N-n-butyl-1,2,4-triazole-3-carboxamide 22* 
0 
a 
N\ Hý 
N 
H 
Ethyl 1,2,4-triazole-3-carboxylate 17 (0.210 g, 1.49 mmol) was dissolved in 
methanol (10 ml) and freshly distilled n-butylamine (20 ml) was added and 
the solution stirred at room temperature for 4 d. The reaction was 
monitored by reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm 
x 4.6 mm, elution with 2% acetonitrile/10 mM ammonium acetate). The 
solution was evaporated in vacuo to give on recrystallisation from 
methanol and dichloromethane N-n-butyl-1,2,4-triazole-3-carboxamide 22 
(0.198 g, 79%) as colourless crystals, m. p. 185-187°C; (Found: C, 50.01; H, 
7.09; N, 33.12. C7H 12N40 requires C, 49.99; H, 7.19; N, 33.30); SH (250 MHz; 
MeOH-d4) 1.00 (3 H, t, J 7.26, Me), 1.44 (2 H, sextet, J 7.32, CH2-y), 1.64 (2 H, 
quintet, J 7.33, CH2-0), 3.43 (2 H, t, J 7.11, CH2-a) and 8.46 (1 H, s, H-5); 6C 
(250 MHz; MeOH-d4) 14.09 (Me), 21.09 (CH2-y), 32.57 (CH2-ß), 40.09 (CH2-a), 
147.08 (C-5), 156.33 (C-3) and 160.89 (C=O); m/z (EI FAB) 169 ((M+H)+, 75%), 
110 (11) and 58 (48). 
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Synthesis of N-cyclohexyl-1,2,4-triazole-3-carboxämide 23* 
0 Y 
a 
N\ 
S 
ý 
H 
Ný, 
N 
H 
Methyl 1,2,4-triazole-3-carboxylate 16 (50 mg, 0.39 mmol) and 
cyclohexylamine (0.047 ml, 0.39 mmol) were dissolved in methanol (5 ml) 
and refluxed for 2 d. The reaction was monitored by reverse phase HPLC 
(Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 
mM ammonium acetate). The solvent was removed in vacuo and the 
residue recrystallised from methanol to give N-cyclohexyl-1,2,4-triazole- 
3- carboxamide 23 (28 mg, 37%) as light yellow crystals, m. p. 162-164°C; 
(Found: C, 55.38; H, 7.48; N, 29.06. C9H 14N40 requires C, 55.66; H, 7.27; N, 
28.84); SH (250 MHz; MeOH-d4) 1.39 (4 H, M, CH2-y, CH2-5), 1.72 (2 H, m as d, 
CH2-y), 1.86 (2 H, m, CH2-0), 2.05 (2 H, m, CH2-0), 3.13 (1 H, nonet, CH-a) and 
8.17 (1 H, s, H-5); SC (250 MHz; MeOH-d4) 25.42 (CH2-8), 25.95 (CH2-y), 31.97 
(CH2-0), 51.43 (CH-a), 149.12 (C-5), 157.03 (C-3) and 164.38 (C=O); m/z (CI) 
195 ((M+H)+, 38%), 166 (2), 151 (3), 137 (4), 98 (8) and 18 (100); m/z (EI) 
194 (M+", 23%), 166 (30), 151 (67), 137 (82), 123 (23), 98 (100), 69 (58) and 28 
(15). 
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Synthesis of N-benzyl-1,2,4-triazole-3-carboxamide 24* 
0 
NN 
\ 
\N 
H 
Ný 
H 
m 
r 
Methyl 1,2,4-triazole-3-carboxylate 16 (50 mg, 0.39 mmol), benzylamine 
(0.043 ml, 0.39 mmol) were dissolved in methanol (8 ml) and refluxed for 3 
d. The reaction was monitored by reverse phase HPLC (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 mM ammonium 
acetate). The solvent was removed in vacuo and the residue suspended in 
methanol. The colourless solid was filtered off and washed with methanol 
to give N-benzyl-1,2,4-triazole-3-carboxamide 24 (20 mg, 25%) as a 
colourless powder, m. p. 238-240°C; (Found: M+- 202.0850. C10H l ON40 
requires 202.0856); 5H (400 MHz; TFA) 5.22 (2 H, s, CH2), 7.80 (6 H, m, H- 
aromatic, H-5) and 10.14 (1 H, br s, H-1); SC (400 MHz; TFA) 44.83 (CH2), 
127.75 (C-aromatic-o), 128.59 (C-aromatic-m), 128.95 (C-aromatic-p), 134.49 
(C-aromatic-1), 143.28 (C-5), 148.45 (C-3) and 155.01 (C=O); m/z (CI) 203 
((M+H)+, 100%), 159 (13), 106 (100), 96 (9), 91 (46), 77 (13), 65 (21) and 39 
(13); m/z (EI) 202 (M+", 11%), 159 (17), 106 (100), 96 (5), 91 (19), 77 (13), 69 
(17) and 39 (7). 
138 
Synthesis of NN-dimethyl-1,2,4-triazole-3-carboxamide 25* 
0 
N\ N\ 
N ýN 
H 
Methyl 1,2,4-triazole-3-carboxylate 16 (0.40 g, 3.15 mmol), dimethyl-amine 
(10 ml) and methanol (4 ml) were stirred at 50°C for 6 d. The reaction was 
monitored by reverse phase HPLC (Techsphere 5C8 column, 25 cm x 4.6 
mm, elution with 2% acetonitrile/10 mM ammonium acetate). The solvent 
was removed in vacuo and the residue recrystallised from methanol and 
dichloromethane to give N, N-dimethyl-1,2,4-triazole-3-carboxamide 25 
(0.30 g, 68%) as colourless crystals, m. p. 163-165°C; (Found: M+" 140.0697. 
C5H8N40 requires 140.0697); (Found: C, 42.67; H, 5.72; N, 40.22. C5H8N40 
requires C, 42.86; H, 5.76; N, 39.97); SH (250 MHz; MeOH-d4) 3.13 (3 H, s, Me, 
syn), 3.30 (3 H, s, Me, anti) and 8.48 (1 H, s, H-5); SC (250 MHz; MeOH-d 4) 
36.11 (Me, syn), 39.09 (Me, anti), 146.58 (C-5), 156.02 (C-3) and 162.92 (C=O); 
m/z (CI) 158 ((M+NH4)+, 7%), 141 ((M+H)+, 64), 124 (35), 96 (10), 79 (100), 
61 (27) and 44 (15); m/z (EI) 140 (M+", 10%), 111 (5), 96 (10), 83 (17), 72 
(15), 69 (20) and 41 (100). 
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Synthesis of N-methyl-N-n-butyl-1,2,4-triazole-3-carboxamide 26* 
0 
N 
N 
H 
Ethyl 1,2,4-triazole-3-carboxylate 17 (99 mg, 0.70 mmol) and freshly 
distilled N-methyl-n-butylamine (5 ml) was kept at 60°C for 10 d. The 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 5% acetonitrile/l0 mM ammonium 
acetate) the solvent was removed in vacuo and the residue was 
recrystallised from methanol and dichloromethane to give N-methyl-N-n- 
butyl-1,2,4-triazole-3-carboxamide 26 (51 mg, 40%) of a white powder, 
(Found: C, 52.52; H, 7.65; N, 31.02. C8H 14N40 requires C, 52.74; H, 7.75; N, 
30.74); SH (250 MHz; MeOH-d4) 1.02 (3 H, t, J 7.25, Me-S), 1.46 (2 H, sextet, J 
6.98, CH2-y), 1.65 (2 H, quintet, J 7.02, CH2-ß), 3.29 (3 H, s, Me-N), 3.43 (2 H, t, 
J 6.98, CH2 -a) and 8.47 (1 H, s, C-5); SC (250 MHz; MeOH-d4) 14.15 (me-8), 
21.13 (CH2-y), 32.62, (CH2-0), 40.13 (CH2-(x), 51.71 (Me-N), 147.11 (C-5), 
150.43 (C-3) and 160.98 (C=O); m/z (CI) 219 ( (M+H)+, 100%), 173 (15), 133 
(9), 112 (21), 91 (83), 65 (9) and 41 (12). 
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Synthesis of benzyl 5-amino-1,2,4-triazole-3-carboxylate 27181* 
0 
0 N 
Nm 
HzN N/ 
H 
5-Amino-1,2,4-triazole-3-carboxylic acid 10 (0.64 g, 5 mmol) was 
suspended in phosphorous oxychloride (25 ml). Phosphorous 
pentachloride (1.25 g, 6 mmol) was added, the solution was stirred at room 
temperature for 2.5 h and then at 55°C for 45 min. The phosphorous 
oxychloride was removed under vacuum distillation. Benzyl alcohol (20 
ml) and dimethylaminopyridine (10 mg) were added to the dry yellow solid 
and the suspension was left stirring at room temperature for 12 h. The 
remaining benzyl alcohol was removed under vacuum at room 
temperature and a white solid gradually formed, which was filtered off, 
dried and recrystallised from methanol to give benzyl 5-amino-1,2,4- 
triazole-3-carboxylate 27 (163 mg, 15%) as a colourless crystalline solid, 
(Found: M+" 218.0816. C1 OH 1 ON402 requires 218.0805); SH (250 MHz; DMSO- 
d6) 4.99 (2 H, br s, NH2/H20), 5.32 (2 H, s, CH2) and 7.31-7.41 (5 H, m, H- 
aromatic); 8C (250 MHz; DMSO-d6) 66.30 (CH2), 128.36-128.60 (C-aromatic- 
o/m/p), 135.84 (C-aromatic-1), 150.52 (C-5), 153.30 (C-3) and 159.43 (C=O); 
m/z (CI) 219 ((M+H)+, 100%), 173 (15), 133 (9), 112 (12), 91 (83), 65 (9) and 
41 (12). 
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Synthesis of 1,2,3-Triazole Bases 
Synthesis of 5-diazo-6-methoxy-1,6-dihydropyrimidin- 
2,4(1H, 3H, 6H)dione (5-diazouracil-6-methanolate) 29182 
0 
N 
HN + 
H 
ON OMe 
H 
5-Aminouracil (0.173 g, 1.35 mmol) was dissolved in hydrochloric acid (3.4 
ml, 1 M) cooled to 0°C with an ice/salt ' bath. Sodium nitrite (1.36 ml, 1 M) 
was added dropwise maintaining the temperature between 0°-3°C. The 
solution was stirred at room temperature for 1.5 h, then cooled to -10°C by 
an ice/salt bath and ethanol (2 x 9.50 ml, 95%) at -10°C was added. Rapid 
filtration of the precipitate and recrystallisation from boiling methanol 
(12 ml) gave 5-diazouracil-6-methanolate 29 (0.182 g, 79%) as yellow 
crystals, m. p. 198°C (lit., 
182 198°C); kmax (MeOH)/nm 210.9 and 263, (lit., 18 2 
262 nm); 8H (250 MHz; DMSO-d6) 3.19 (3 H, s, OMe), 5.75 (1 H, d, J 4.07, H-6), 
8.70 (1 H, br d, J 2.33, H-1) and 10.35 (1 H, s, H-3); 8C (250 MHz; DMSO-d6) 
51.83 (OMe), 57.55 (C-6), 77.38 (C-5), 152.01 (C-2) and 162.88 (C-4); nJz (EI) 
137 ((M+- - OMe), 43%), 112 ((M+- - 
N2 - OMe), 52), 66 (42) and 31 (OMe+", 
100). 
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Synthesis of 1,2,3-triazole-4-carboxamide 30184 
0 
N\ NHp 
Ný 
N 
H 
5-Diazouracil-6-methanoIate 29 (1 g, 5.9 mmol) was dissolved in a mixture 
of acetonitrile (250 ml) and water (10 ml) at 50°C. The solution was sealed 
in a stainless steel reaction vessel heated at 100°C (internal temperature 
and pressure) for 18 h. When cooled, the solution and washings were 
filtered and the filtrate evaporated in vacuo. The yellow solid was 
recrystallised from glacial acetic acid (15 ml) to give 1,2,3-triazole-4- 
c arb ox am i de 30 (0.28 g, 84.7%) as yellow crystals, m. p. 256-258°C (lit., 18 4 
256-259°C); %max (H20)/nm 199 (lit., 184 197nm); SH (400 MHz; DMSO-d6) 
7.49 (1 H, br s, NH-amide), 7.86 (1 H, br s, NH-amide), 8.30 (1 H, s, H-5) and 
15.44 (1 H, br s, H-1); 8C (400 MHz; DMSO-d6) 129.48 (C-5), 141.81 (C-4) and 
161.65 (C=O); nVz (CI) 130 ((M+NH4)+, 8%), 113 ((M+H)+, 20), 35 (6) and 18 
(100); Wz (EI) 112 (M+", 87%), 96 (85), 69 (22) and 17 (100). 
Synthesis (1) of methyl 1,2,3-triazole-4-carboxylate 35188 
0 
N\ O/ 
// 
Ný 
N 
H 
'Amberlyst' 15 strong acid cation exchange resin (1.4 g) was rinsed with 
methanol until the washings were neutral and dried in vacuo. 1,2,3- 
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triazole-4-carboxamide 30 (100 mg, 0.892 mmol), methanol (8 ml) and the 
resin were gently stirred at reflux for 24 h. The progress of the reaction 
was monitored by reverse phase HPLC (Techsphere 5C8 column, 25 cm x 4.6 
mm, elution with 2% acetonitrile/10 mM ammonium acetate). The solution 
was cooled, the resin collected in a column and eluted with methanol. The 
solvent was removed in vacuo to give after recrystallisation from water 
methyl 1,2,3-triazole-4-carboxylate 35 (64 mg, 56%) as colourless crystals, 
m. p. 145°C (lit., 184 144-145°C); 8H (250 MHz; MeOH-d4) 3.96 (3 H, s, Me) and 
8.40 (1 H, s, H-5); m/z (CI) 145 ((M+NH4)+, 28%), 128 ((M+H)+, 100), 110 (2) 
and 96 (10); m/z (EI) 127 (M+", 14%), 96 (94), 69 (44), 59 (15) and 40 (100). 
Synthesis (2) of methyl 1,2,3-triazole-4-carboxylate 35189 
0 
N\ O/ 
// 
Ný 
N 
H 
Trimethylsilyl azide (4.5 ml, 34 mmol) and methyl propiolate (2.0 ml, 23 
mmol) were heated in a stainless steel autoclave at 130°C 
(internal 
pressure) for 19 h. After cooling, the trimethylsilyl group was 
hydrolysed 
by methanol (10 ml ) and white crystals gradually 
formed. Evaporation of 
the mixture to dryn ess and recrystallisation of the residue 
from methanol 
with charcoal gave methyl 1,2,3-triazole-4-carboxylate 
35 (2.38 g, 83%) as 
colourless crystals. NMR and analytical 
data was identical with methyl 
1,2,3-triazole-4-carboxylate 35 synthesised from 1,2,3-triazole-4- 
carboxamide 30. 
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Synthesis of N-methyl-1,2,3-triazole-4-carboxamide 38 
O 
NH 
Ný\ 
N 
H 
Methyl 1,2,3-triazole-4-carboxylate 35 (107 mg, 0.84 mmol) in 
methylamine (5 ml, 30-40% (w/v) solution in water) was left at room 
temperature for 7 d. The reaction was monitored by reverse phase HPLC 
(Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 
mM ammonium acetate). The solvent was removed in vacuo and the 
residue recrystallised from methanol and dichloromethane to give N- 
methyl-1,2,3-triazole-4-carboxamide 38 (0.77 g, 76%) as colourless 
crystals, m. p. 260°C (lit., ' 84 258-261°C); SH (250 MHz; DMSO-d6) 2.75 (1.5 H, 
s, Me), 2.77 (1.5 H, s, Me), 8.32 (1 H, s, H-5) and 8.47 (1 H, br s, NH-amide); & 
(250 MHz; DMSO-d6) 25.64 (Me), 128.83 (C-5), 142.09 (C-4) and 160.34 (C=O); 
m/z (CI) 144 ((M+NH4)+, 26%), 127 ((M+H)+, 100), 96 (5), 84 (18) and 55 (5); 
m/z (EI) 126 (M+", 90%), 100 (10), 96 (100), 82 (90), 69 (50), 54 (43) and 40 
(38). 
Synthesis of N-ethyl-1,2,3-triazole-4-carboxamide 39* 
0 
N\H` 
// 
Ný 
b 
Methyl 1,2,3-triazole-4-carboxylate 35 (0.51 g, 4.01 mmol) and ethylamine 
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(3 ml, 70% (w/v) solution in water) were dissolved in methanol (2 ml) and 
stirred at 50°C for 2 d. The reaction was monitored by reverse phase HPLC 
(Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 
mM ammonium acetate). The solvent was removed in vacuo and the 
residue recrystallised from methanol and dichloromethane to give N- 
ethyl-1,2,3-triazole-4-carboxamide 39 (0.50 g, 89.5%) as colourless 
crystals, m. p. 148-150°C; (Found: M+- 140.0698. C5H8N40 requires 140.0699); 
(Found: C, 42.56; H, 5.69; N, 39.73. C5H8N40 requires C, 42.86; H, 5.76; N, 
39.97); SH (250 MHz; MeOH-d4) 1.26 (3 H, t, J 7.25, Me), 3.43 (2 H, q, J 7.23, 
CH 2C H 3) and 8.23 (1 H, s, H-5); 8C (250 MHz; MeOH-d4) 14.95 (Me), 35.11 
(C H 2C H3), 130.30 (C-5), 142.93 (C-4) and 162.95 (C=O); m/z (CI) 158 
((M+NH4)+, 11%), 141 ((M+H)+, 10), 128 (8), 113 (3), 85 (3), 79 (5), 58 (6) and 
44 (7); m/z (EI) 140 (M+", 38%), 125 (23), 96 (90), 83 (6), 77 (51), 69 (29), 57 
(8), 44 (100) and 40 (18). 
Synthesis of p-toluenesulfonylazide 40237 
0 
--a 
II 
11 
0 
Sodium azide (4.13 g, 63.5 mmol) and p-toluenesulfonylchloride (10 g. 
52.5 
mmol) and ethanol (60 ml, 95%) were stirred at room temperature 
for 1 h, 
then poured into water (200 ml). The separated oily sulfonylazide was 
washed with water and dried over sodium sulfate to give p- 
toluenesulfonylazide 40 (5.53 g, 54%) as a clear, colourless oil which was 
used without further purification. 
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Synthesis of 1,2,3-triazole-4-cyano-5-N -to 1uenesu1f on yI -amine 
48191,192 
CN 
N 
N NHTs 
H 
Ts = CH3C6H4SO2- 
To a cooled solution (0°C) of malononitrile (0.66 g, 10 mmol) and sodium 
hydroxide (7.22 ml, 20 mM) was added dropwise p-toluenesulfonyl azide 40 
(1.97 g, 10 mmol) in ether (8 ml). The mixture was stirred vigorously for 1 
h. The reaction was washed with ether (3 x 20 ml) and the aqueous layer 
was brought to pH 0.75 with concentrated sulfuric acid. The precipitate 
formed was filtered off and recrystallised from water to give 1,2,3-triazole- 
4-cyano-5-N-toluenesulfonylamine 48 (2.15 g, 82%) as colourless crystals, 
m. p. 190°C (lit., 191 190°C); SH (250 MHz; MeOH-d4) 2.44 (3 H, s, Me) and 7.56 
(4 H, ABq, J 8.30, H-aromatic); 8C (250 MHz; MeOH-d4) 21.48 (Me), 111.82 (C- 
5), 115.60 (CN), 128.32 (C-aromatic-o), 130.75 (C-aromatic-m), 137.61 (C- 
aromatic-p), 145.79 (C-aromatic-1) and 146.14 (C-4); m/z (CI) 281 
((M+NH4)+, 100%), 264 ((M+H)+, 37), 238 (43), 155 (58), 139 (44), 124 (10), 
108 (32) and 91 (43); Wz (EI) 263 (M+", 12%), 155 (50), 124 (3), 91 (100), 77 
(3), 65 (28), 53 (9) and 39 (12). 
Synthesis of 4-methoxybenzyl azide 49197 
Meo -0--\N3 
Sodium azide (2.15 g, 33 mmol) was stirred for 24 hrs at 20°C with a solution 
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of 4-methoxybenzyl chloride (5.18 g, 33 mmol) in dry DMF (20 ml). The 
reaction was quenched with water (20 ml). The organic azide was extracted 
into ether and the extracts were washed well with water and dried with 
magnesium sulfate. Evaporation in vacuo (<20°C) afforded the title azide, 4- 
methoxybenzyl azide 49 (5.12 g, 95%) as a colourless, clear oil which was 
used without further purification, vmax (film)/cm-1 2000. 
Synthesis of ethyl 5-hydroxy-l-(4-methoxybenzyl)-1,2,3- 
triazole-4carboxylate 50197 
O 
N OEt 
N OH 
Ar 
Ar = 4-CH3OC6H4CH2- 
Sodium (6.03 g, 0.26 mol) was added to dry ethanol (450 ml) followed by 
diethyl malonate (41.9 g, 0.26 mol). After 30 min a solution - of 
4- 
methoxybenzyl azide 49 (42.5 g, 0.26 mol) in ethanol (50 ml) was added 
dropwise with stirring and the mixture was gently refluxed for 18 h. 
When cool, most of the solvent was removed in vacuo and water was added. 
Acidification to pH 2 with dilute hydrochloric acid gave a crystalline 
precipitate. The solid was filtered off, washed with water, dried in an 
evacuated desiccator over phosphorous pentoxide and recrystallised from 
chloroform and petroleum ether (40°-60°C) to give ethyl 5-hydroxy-l-(4- 
methoxybenzyl)-1,2,3-triazole-4-carboxylate 50 (45.0 g, 65%) as colourless 
crystals, m. p. 116°C (lit., 
197 117°C); SH (250 MHz; MeOH-d4) 1.36 (3 H, t, J 
7.11, Me), 3.77 (3 H, s, OMe), 4.31 (2 H, q, J 7.17, CH2CH3), 5.12 (2 H, s, CH2N) 
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and 7.06 (4 H, ABq, J 8.73, H-aromatics); 5C (250 MHz; MeOH-d4) 14.89 (Me), 
47.36 (CH2N), 55.62 (OMe), 60.42 (CH2CH3), 114.77 (C-aromatic-m), 118.81 (C- 
4), 129.90 (C-aromatic-o), 130.66 (C-aromatic-1), 160.47 (COMe), 161.18 (C-5) 
and 165.28 (C=O); m/z (CI) 295 ((M+NH4)+, 20%), 278 ((M+H)+, 100), 252 
(81), 206 (5), 176 (5), 136 (18) and 121 (25); m/z (EI) 277 (M+-, 8%), 205 
((M+- - COOEt), 33), 176 (43), 136 (33), 121 (100) and 78 (18). 
Synthesis of ethyl 5-chloro-1-(4-methoxybenzyl)-1,2,3- 
triazole-4-carboxylate 51197 
0 
N\ OEt 
N \N Ci 
Ar 
Ar = 4-CH3OC6H4CH2- 
Phosphorous pentachloride (1.90 g, 9.12 mmol) was added to a stirred 
solution of the hydroxy ester 50 (2.34 g, 8.44 mmol) in dry toluene (25 ml) 
and the mixture was stirred at 40°C for 90 min. The solvent was removed in 
vacuo and the residue taken up in ether and washed well with saturated 
sodium hydrogen carbonate, water, dried over magnesium sulfate and 
evaporated to give on recrystallisation from ether and petroleum ether 
(40°-60°C) ethyl 5-chioro-l-(4-methoxybenzyl)-1,2,3-triazole-4- 
carboxylate 51 (1.66 g, 68%) as colourless crystals, m. p. 76°C (lit., 
197 77°C); 
8H (250 MHz; CDC13) 1.38 (3 H, t, J 7.13, Me), 3.78 (3 H, s, OMe), 4.41 (2 H, q, J 
7.13, CH2CH3), 5.48 (2 H, s, CH2N) and 7.05 (4 H, ABq, J 8.73, H-aromatic); SC 
(250 MHz; CDC13) 14.17 (Me), 51.84 (CH2N), 55.26 (OMe), 61.43 (CH 2C H3), 
114.35 (C-aromatics-m), 125.04 (C-aromatics-o), 129.52 (C-aromatics-1), 
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135.07 (C-4/5), 159.63 (COMe) and 159.95 (C=O); m/z (CI) 315 ((M+2+NH4)+, 
3%), 313 ((M+NH4)+, 9), 298 ((M+2+H)+, 10), 296 ((M+H)+, 33), 278 (3), 138 
(9) and 121 (100); mlz (EI) 297 ((M+2)+", 2%), 295 (M+-, 5), 223 (10), 194 (5), 
178 (37), 160 (17), 137 (13), 121 (100) and 78 (13). 
Synthesis of ethyl 5-cyano- l-(4-methoxybenzy1)-1,2,3- 
triazole-4-carboxylate 52197 
0 
N OEt 
N CN 
Ar 
Ar = 4-CH3OC6H4CH2- 
Sodium cyanide (0.187 g, 3.80 mmol) was added to a solution of the chloro 
ester 51 (1.06 g, 3.66 mmol) in dry DMF (10 ml) and stirred at 80°C for 24 h. 
When cool, the solvent was removed in vacuo and the oil partitioned 
between ethyl acetate (100 ml) and water (25 ml). The organic layer was 
washed with water (3 x 25 ml), brine (25 ml), dried over magnesium 
sulfate and evaporated to give on recrystallisation from ethanol ethyl 5- 
cyano-l-(4-methoxybenzyl)-1,2,3-triazole-4-carboxylate 52 (0.54 g, 52%) 
as colourless crystals, m. p. 82°C (lit., 
197 81-83°C); 8H (250 MHz; CDC13) 1.41 
(3 H, t, J 7.08 , Me), 
3.81 (3 H, s, OMe), 4.46 (2 H, q, J 7.06, CH2CH3), 5.65 (2 H, s, 
CH 2N) and 7.13 (4 H, ABq, J 8.55, H-aromatic); SC (250 MHz; CDC13) 13.83 
(Me), 54.30 (CH2N), 55.08 (OMe), 62.25 (CH2CH3), 107.17 (CN), 114.41 (C- 
aromatic-m), 124.07 (C-aro matic-o), 124.87 (C-5), 129.97 (C-aromatic-1), 
141.01 (C-4), 157.92 (C=O) an d 160.50 (COMe); m/z (CI) 287 ((M+H)+, 5%), 185 
(5) and 121 (100); m/z (EI) 286 (M+', 25%), 229 (11), 185 (22), 121 
(100) and 
150 
78 (32). 
Synthesis of 5-chloro-1-(4-methoxybenzyl). 1,2,3-triazole-4. 
carboxamide 53* 
0 
N NHZ 
N 
NG 
Ar 
Ar =4 -CH3 OC6H4CH 2- 
The chloro ester 51 (0.100 g, 0.361 mmol) was dissolved in methanol 
previously saturated with ammonia at 0°C. The solution was left at room 
temperature for 6d and monitored by TLC. The solvent was removed in 
vacuo to give after recrystallisation from dichloromethane and petroleum 
ether (40°-60°C) 5-chloro-1-(4-methoxybenzyI)-1,2,3-triazole-4- 
c arb oxamide 53 (0.076 g, 79%) as colourless crystals, m. p. 168-169°C; 
(Found: (M+2)+" 268.0542. C 11 Hil N40237C1 requires 268.0542); 8H (250 MHz; 
CDC13) 3.72 (3 H, s, OMe), 5.41 (2 H, s, CH2N), 6.63 (1 H, br s, NH-amide), 6.98 
(I H, br s, NH-amide) and 7.00 (4 H, ABq, J 14.5, H-aromatic); 8C (250 MHz; 
CDC13) 51.71 (CH2N), 55.29 (OMe), 114.40 (C-aromatic-m), 125.10 (C- 
aromatic-o), 129.58 (C-aromatic-1), 136.23 (C-4/5), 159.98 (COMe) and 161.02 
(C=O); m/z (CI) 286 ((M+2+NH4)+, 6%), 284 ((M+NH4)+, 25), 269 ((M+2+H)+, 
8), 267 ((M+H)+, 17), 157 (25), 138 (20), 121 (100), 96 (60) and 79 (65); m/z 
(EI) 268 ((M+2)+", 15%), 266 (M+., 50), 237 (17), 203 (42), 159 (30), 133 (50), 
121 (100) and 78 (35). 
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Synthesis of 5-cyano-1-(4-methoxybenzyl)-1,2,3-triazole-4- 
carboxamide 54* 
N NH2 
N 
N CN 
Ar 
Ar =4 -CH30C6H4CH2- 
Ethyl 5-cyano-l-(4-methoxybenzyl)-1,2,3-triazole-4-carboxylate 52 (190 
mg, 0.66 mmol), concentrated aqueous ammonia (10 ml, d=0.88) and 
methanol (5 ml) were left at room temperature in a sealed flask for 2 d. 
The reaction was monitored by TLC. The solvent was removed and the 
residue was recrystallised from acetone and petroleum ether (40°-60°C) to 
give 5-cyano-l-(4-methoxybenzyl)-1,2,3-triazole-4-carboxamide 54 (85 
mg, 50%) as light yellow crystals, m. p. 113-115°C; (Found: M+- 257.0904. 
C 12H 11 N502 requires 257.0914); SH (250 MHz; CDC13) 3.89 (3 H, s, OMe), 5.77 
(2 H, s, CH2N), 6.33 (1 H, br s, NH-amide), 6.97 (4 H, ABq, J 8.70, H-aromatic) 
and 7.40 (1 H, br s, NH-amide); SC (250 MHz; CDC13) 54.87 (CH2N), 55.22 
(OMe), 114.12-158.29 (C-aromatic/C-4/5/CN), 159.57 (COMe) and 162.74 (C=O); 
m/z (CI) 275 ((M+NH4)+, 15%), 258 ((M+H)+, 10) and 121 (100); m/z (EI) 
257 (M+", 20%), 229 (8) and 121 (100). 
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Synthesis of ethyl 5-hydroxy-1,2,3-triazole-4-carboxylate 55197 
N OEt 
N 
N OH 
H 
Ethyl 5 -hydroxy-1 -(4-methoxybenzyI)-1,2,3-triazole-4-carboxyIate 50 
(200 mg, 0.72 mmol) in trifluoroacetic acid (2 ml) was stirred at 65°C (bath 
temperature) for 6 h. The course of the reaction was followed by TLC. The 
solution was cooled and the solvent removed in vacuo. Water (20 ml) was 
added to the brown residue, the solid was filtered and the filtrate was 
evaporated to dryness. Recrystallisation from ethyl acetate and petroleum 
ether (40°-60°C) to give ethyl 5-hydroxy-1,2,3-triazole-4-carboxylate 55 
(52 mg, 46%) as colourless crystals, m. p. 143-145°C (lit., 197 145-146°C); 8H 
(250 MHz; MeOH-d4) 1.38 (3 H, t, J 7.10, Me) and 4.31 (2 H, q, 1 7.10, CH2CH3); 
SC (250 MHz; MeOH-d4) 14.92 (Me), 60.90 (CH2CH3), 118.69 (C-4), 162.82 (C-5) 
and 165.21 (C=O); m/z (CI) 175 ((M+NH4)+, 28%), 158 ((M+H)+, 100), 149 (6), 
132 (17), 86 (2) and 44 (2); m/z (EI) 157 (M+", 38%), 136 (3), 112 (6), 69 (18), 
58 (12) and 44 (100). 
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Synthesis of ethyl 5-chloro-1,2,3-triazole-4-carboxylate 59197 
0 
N\ OEt 
N ýN d 
H 
The chloro ester 51 (3.16 g, 10.7 mmol) in trifluoroacetic acid (25 ml) was 
heated at 67°C (oil bath temperature) for 3h and the course of the 
reaction was followed by TLC. The solvent was removed in vacuo and water 
was added to the residue. The brown solid was filtered off and the filtrate 
evaporated to dryness and recrystallised from toluene and petroleum 
ether (40°-60°C) to give ethyl 5-chloro-1,2,3-triazole-4-carboxylate 59 
(1.50 g, 90%) as colourless crystals, m. p. 77-79°C (lit., 197 78-81 °C); 8H(250 
MHz; MeOH-d4) 1.42 (3 H, t, J 7.12, Me) and 4.42 (2 H, q, J 7.08, CH2CH 3 ); SC 
(250 MHz; MeOH-d4) 14.43 (Me), 62.68 (CH2CH3), 133.94 (C-4), 139.15 (C-5) 
and 160.47 (C=O); m/z (CI) 195 ((M+2+NH4)+, 33%), 193 ((M+NH4)+, 100), 178 
((M+2+H)+, 11), 176 ((M+H)+, 40), 158 (22) and 148 (15); m/z (EI) 177 
((M+2)+", 10%), 175 (M+", 28), 147 (75), 130 ((M+- - OEt), 100), 103 (32), 91 
(11), 74 (34) and 47 (29). 
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Synthesis of ethyl 5-cyan-1,2,3-tciazole-4-carboxylate 56197 
0 
N OEt 
N ýN CN 
H 
Ethyl 5-cyano-1-(4-methoxybenzyl)-1,2,3-triazoIe-4-carboxylate 52 (40 
mg, 0.17 mmol) in trifluoroacetic acid (3 ml) was refluxed at 65°C (bath 
temperature) for 3.5 h. The reaction was followed by TLC. The solvent was 
removed in vacuo and the brown oil was suspended in water (20 ml). The 
brown solid was filtered and the filtrate was evaporated to dryness and 
recrystallised from ether and petroleum ether (40°-60°C) to give ethyl 5- 
cyano-1,2,3-triazole-4-carboxylate 56 (56 mg, 78%) as colourless crystals, 
m. p. 111-112°C (lit., 197 111°C-113°C); 8H (250 MHz; CDC13) 1.46 (3 H, t, J 7.08, 
Me) and 4.56 (2 H, q, J 7.18, CH2CH3); 8C (250 MHz; CDC13) 13.95 (Me), 63.55 
(CH2CH3), 109.98 (CN), 122.96 (C-5), 141.54 (C-4) and 158.77 (C=O); m/z (CI) 
184 ((M+NH4)+, 100%), 167 ((M+H)+, 13) and 121 (90); m/z (EI) 166 (M+", 
12%), 139 (38), 121 (80) and 69 (38). 
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Synthesis of 5-chloro-1,2,3-triazole-4-carboxamide 58197 
O 
N NHp 
N 
N CI 
H 
5-Chloro-1-(4-methoxybenzyl)-1,2,3-triazole-4-carboxamide 53 (67 mg, 
0.23 mmol) in trifluoroacetic acid (3 ml) was refluxed at 65°C (bath 
temperature) for 3 h. The reaction was followed by TLC. The solvent was 
removed in vacuo and the solid residue was suspended in water (30 ml). 
The pale brown solid was filtered and the filtrate was evaporated to 
dryness to give on recrystallisation from methanol and dichloromethane 
5-chloro-1,2,3-triazole-4-carboxamide 58 (28 mg, 82%) as colourless 
crystals, m. p. 158-161°C (decomp); kmax (H20)/nm 192.1 and 232.0; SH (250 
MHz; MeOH-d4) 7.53 (1 H, br s, NH-amide) and 7.88 (1 H, br s, NH-amide); SC 
(250 MHz; MeOH-d4) 137.26 (C-4), 137.69 (C-5) and 163.33 (C=O); m/z (CI) 166 
((M+2+NH4)+, 6%), 164 ((M+NH4)+, 18), 149 ((M+2+H)+, 25) and 147 
((M+H)+, 100); Wz (EI) 148 ((M+2)+", 71%), 146 (M+", 24), 132 (83), 130 (27) 
and 44 (100). 
Synthesis of 5-amino-1,2,3-triazole-4-carboxamide 60 
0 
N NH2 
N 
N NH2 
I 
H 
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Ethyl 5-chloro-1,2,3-triazole-4-carboxylate 59 (128 mg, 1.24 mmol) was 
dissolved in methanol (50 ml), cooled to 0°C and saturated with ammonia 
gas. The solution was sealed and left for 10 d at room temperature. The 
solvent was evaporated and the residue was recrystallised from methanol 
to give 5-amino-1,2,3-triazole-4-carboxamide 60 (107 mg, 68%) as a 
colourless powder, m. p. 224°C (lit., 198 224-225°C); 5H (400 MHz; MeOH-d4) 
7.33 (1 H, br s, NH-amide) and 7.64 (1 H, br s, NH-amide); SC (400 MHz; 
MeOH-d 4) 135.31 (C-4), 136.09 (C-5) and 165.34 (C=O); m/z (CI) 145 
((M+NH4)+, 13%), 128 ((M+H)+, 100), 85 (5) and 58 (5); m/z (EI) 127 (M+", 
15%), 91 (10), 56 (63) 44 (65) and 28 (100). 
Synthesis of 4-nitro-benzotriazole 63203 
NO2 
N 
N 
H 
Benzotriazole (10.0 g, 83 mmol) was dissolved in concentrated sulfuric acid 
(33 ml). The solution was cooled and concentrated nitric acid (6 ml) was 
added dropwise keeping the temperature below 30°C. The mixture was 
heated at 60°C (bath temperature) for 1 h. When cooled, water was added 
until no more precipitate developed. The solid was filtered off giving on 
recrystallisation from methanol and acetone 4-nitro-benzotriazole 63 
(11.0 g, 84%) as light yellow crystals, m. p. 228°C (lit., 
203 229°C); )-max 
(H20)/nm 199.2 and 225.9; 8H (400 MHz; DMSO-d6) 7.63 (1 H, dd appears as t, 
J 8.00, H-6), 8.46 (1 H, d, J 7.80, H-5) and 8.59 (1 H, d, J 8.20, H-7); m/z (C I) 
182 ((M+NH4)+, 3%), 165 ((M+H)+, 12), 135 (100) and 52 (5); mnz (EI) 164 
(M+-, 37%), 105 (25), 91 (38), 77 (38), 69 (53), 63 (96), 52 (60), 43 (100) and 38 
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(33). 
Synthesis of 4-amino-benzotriazole 64202 
NH2 
N 
\\ 
N 
N 
H 
A solution of 4-nitro-benzotriazole 63 (0.40 g, 2.98 mmol) in ethanol (40 
ml) containing 10% palladium on carbon (80 mg) was hydrogenated at 
atmospheric pressure and temperature for 4 h. The catalyst was removed 
by filtration through a pad of celite and washed with ethanol. The solvent 
was removed in vacuo and the residue was recrystallised from ethanol and 
dichloromethane to give 4-amino-benzotriazole 64 (0.23 g, 70%) as yellow 
crystals, m. p. 149°C (lit., 203 149°C); . max (H20)/nm 191.1 and 218.9; SH (400 
MHz; MeOH-d4) 6.59 (1 H, d, J 7.50, H-5), 6.98 (1 H, d, J 8.10, H-7) and 7.25 (1 
H, dd appears as t, J 7.81, H-6); m/z (EI) 134 (M+", 100%), 105 (95), 79 (82), 
69 (9), 57 (12), 52 (87) and 41 (12). 
Enzymatic Synthesis of Nucleoside Analogues 
Purification of Nucleoside N -Deoxyribosyltransferases (E. C. 
2.4.2.6. ) from Lactobacillus leichmannii 
Lactobacillus leichmannii ATCC 4797 was grown in an MRS (DeMan- 
Rogosa-Sharpe) medium (52 g1-1) previously sterilised by autoclaving at 
120°C. The medium was inoculated with a 24 h starter culture (1%) grown 
in the same medium and incubated at 37°C for 24 h without aeration or 
agitation. The bacterial suspension was harvested by centrifugation (10 
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000 g) for 15 min at 4°C. The pellet produced was washed twice with 0.02 M 
PIPES buffer (pH 6.5) containing 0.02% (w/v) sodium azide and the cell 
paste stored at -20°C. Thawed cells were disrupted by three passes through 
a French pressure cell (20 000 psi) keeping the temperature below 10°C 
and the cell debris was removed by centrifugation (20 000 g) for 30 min at 
4°C. Cell-free extracts were dialysed overnight against 100 volumes of 0.02 
M PIPES buffer (pH 6.5) containing 0.02% (w/v) sodium azide. The final 
preparation could be stored at -20°C for up to 3 months without significant 
loss of activity. 
Protein Determination 
The concentration of protein was estimated using the dye-binding BioRad 
protein assay according to the method of Bradford. 238 The colorimetric 
property of Coomassie blue G-250 was employed. When bound to protein 
the absorbance maximum of the dye changes from 465 nm to 595 nm. 
Bovine serum albumin was used as the standard. 
Definition of Unit and Specific Activity 
One unit of enzyme activity was defined as the amount of enzyme 
catalysing the formation of 1.0 µ mol of product (2'-deoxyadenosine) 
formed in 1 min in the assay conditions from 2'-deoxycytidine and 
adenine. Specific activity was defined as units per milligram of protein. 
Standard Assay of N-Deoxyribosyltransferase 
The standard reaction assay mixture contained 2'-deoxycytidine (1.5 mM) 
and adenine (0.5 mM) as donor and acceptor, respectively, 
in citrate 
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buffer (50 mM, pH 6.0). The reactions were initiated by the addition of a 
volume of the crude enzyme preparation equivalent to 50 µg/ml of 
protein. The final volume of the reaction mixture was 0.5 ml and it was 
incubated at 40°C with no shaking. At intervals of 0,5,10,15,20 and 30 
min a 20 gl aliquot was removed from the reaction mixture and analysed 
by HPLC. The rate of deoxyribosyl transfer from the pyrimidine 
nucleoside to the purine base was measured by following the formation of 
2'-deoxyadenosine. The concentration of nucleosides and bases present in 
the reaction mixture was determined using reverse phase HPLC on a 
Techsphere 5C8 column (25 cm x 4.6 mm and a precolumn, 5 cm x 4.6 mm), 
using a mobile phase of acetonitrile and doubly distilled water (5: 95) at a 
flow rate of 1.2 ml/min and detected by UV at 254 nm. 
Analytical Studies 
The triazole base (0.05 ml, l0mM), 2'-deoxycytidine or thymidine (0.15 ml, 
10mM) in citrate buffer (0.20 ml, 50 mM, pH 6.0 containing 0.05% sodium 
azide) and ethylene glycol (0.05 ml, 10% (v/v)) was allowed to equilibrate 
for 10 min at 40°C. The reaction was initiated by the addition of the crude 
N-deoxyribosyltransferase extract (0.05 ml, 15.8 mgml-1 protein, 0.04 U) to 
give a final volume of 0.5 ml. The reaction was followed by reverse phase 
HPLC on a Techsphere 5C8 column (25 cm x 4.6 mm and a precolumn, 
5 cm 
x 4.6 mm, elution with acetonitrile/10 mM ammonium acetate). 
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Synthesis of 1-0 -D-2'-deoxyribofuranosyl-1,2,4-triazole-3- 
carboxamide, 2'-deoxyribavirin 65 
0 
N-, 
ýNFiZ 
kIJ 
FIO" "ýI 
HO 
1,2,4-Triazole-3-carboxamide 18 (42 mg, 0.37 mmol) and thymidine (198 
mg, 0.82 mmol) were dissolved in citrate buffer (22 ml, 20 mM, pH 6.0 
containing 0.05% sodium azide) and ethylene glycol (2.5 ml, 10%). The 
crude N-deoxyribosyltransferase extract (1.0 ml, 16.3 mgml-1,9 U) was 
added and the mixture incubated for 8d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 10 mM ammonium acetate). When the 
reaction had reached equilibrium (62% conversion), the solution was 
lyophilised and the residue purified by flash chromatography on silica 
gel (methanol: dichloromethane, 10: 90). Final purification was by 
preparative reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 
20 mm, elution with 10 mM ammonium acetate, 8 mlmin-1) to give 1-ß-D-2'- 
deoxyribofuranosyl-1,2,4-triazole-3-carboxamide, 2'-deoxyribavirin 65 
(29 mg, 35%) as a colourless solid, m. p. 111-112°C (lit., 
58 112-113°C); [a]p3o 
-0.6 (c 0.75 in MeOH); 6H (400 MHz; 
MeOH-d4) 2.50 (1 H, ddd, J 5.18,6.68, 
13.57, H-2'b), 2.80 (1 H, ddd, J 5.08,6.25,13.45, H-2'a), 3.69 (1 H, dd, J 5.38, 
12.03, H-5'b), 3.79 (1 H, dd, J 4.10,12.08, H-5'a), 4.05 (1 H, ddd appears as q, J 
2x4.19,5.35, H-4'), 4.59 (1 H, ddd appears as q, J 4.15,2 x 5.15, H-3'), 6.34 (1 
H, dd, J 5.00,6.53, H-1') and 8.74 (1 H, s, H-5); 8C (250 MHz; MeOH-d4) 41.22 
(C-2'), 63.23 (C-5'), 71.98 (C-3'), 89.70 (C-1'), 89.82 (C-4'), 146.11 (C-5), 158.08 
(C-3) and 163.44 (C=O); m/z (CI) 229 ((M+H)+, 7%), 211 (2), 130 (44), 113 
161 
((base+H)+, 100), 98 (17) and 81 (19). The 1H and 13C NMR data compared 
favourably with that published by Sanghvi et al. 135 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 8.74 ppm (H-5) caused enhancement due to H-1' (5.66%). Irradiation of 
the signal at 6.34 ppm (H-1') caused enhancement due to H-5 (4.35%) and 
H-4' (1.16%). 
Synthesis of 1-0 -D-2'-deoxyribofuranosyl-N-methyl- 1,2,4- 
triazole-3-carboxamide 66* 
0 
N- (ý N 
NH 
jN 
HO O 
N-Methyl-1,2,4-triazole-3-carboxamide 19 (40 mg, 0.32 mmol) and 2'- 
deoxycytidine (154 mg, 0.63 mmol) were dissolved in citrate buffer (22 ml, 
20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol (2.5 ml, 
10%). The crude N-deoxyribosyltransferase extract (0.5 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 7d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 2% acetonitrile/l0 mM ammonium 
acetate). When the reaction had reached equilibrium (62% conversion), 
the solution was lyophilised and the residue purified by flash 
chromatography on silica gel (methanol: dichloromethane, 5: 95) to give 1- 
ß-D-2'-deoxyribofuranosyl-N-meth yl-1,2,4-triazole-3-carboxamid e 66 (19 
mg, 24%) as a colourless powder, Rf 0.38 (methanol: dichloromethane, 1: 5); 
m. p. 173-179°C; [aID30 +10.35 (c 1.5 in MeOH); (Found: M+ 243.1093. 
C9H 14N4O4+H+ requires 243.10945); SH (250 MHz; MeOH-d4) 2.45 (1 H, ddd, i 
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5.20,6.65,13.55, H-2'b), 2.74 (1 H, ddd, J 5.10,6.25,13.58, H-2'a), 2.96 (3 H, s, 
Me), 3.64 (1 H, dd, J 5.38,12.05, H-5'b), 3.75 (1 H, dd, J 4.08,12.05, H-5'a), 4.00 
(1 H, ddd appears as q, J2x4.15,5.28, H-4'), 4.55 (1 H, ddd appears as q, J3x 
5.19, H-3'), 6.34 (1 H, dd, J 5.08,6.58, H-1') and 8.74 (1 H, s, H-5); SC (250 MHz; 
MeOH-d4) 26.33 (Me), 41.18 (C-2'), 63.21 (C-5'), 71.98 (C-3'), 89.65 (C-1'), 89.77 
(C-4'), 146.10 (C-5), 158.20 (C-3) and 162.03 (C=O); nVz (CI) 243 ((M+H)+, 
15%), 193 (4), 144 (23), 127 (100) and 117 (8). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 6.29 ppm (H-1') caused enhancement due to H-5 (3.0%) and H-2'b (6.2%). 
Synthesis of 1-0 -D-2'-deoxyribofuranosyl-N-ethyl- 1,2,4- 
triazole-3-carboxamide 67* 
0 
NýN"'Ný 
HO 
(NH 
ýN 
HO O 
FIO 
N-Ethyl-1,2,4-triazole-3-carboxamide 20 (20 mg, 0.14 mmol) and 2'- 
deoxycytidine (144 mg, 0.55 mmol) were dissolved in citrate buffer (22 ml, 
20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol (2.5 ml, 
10%). The crude N-deoxyribosyltransferase extract (0.5 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 4d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 10 mM ammonium acetate). When the 
reaction had reached equilibrium (95% conversion), the solution was 
lyophilised and the residue purified by flash chromatography on silica 
gel (methanol: dichloromethane, 2: 98) to give 1-0 -D - 2' - 
deoxyribofuranosyl-N-ethyl-1,2,4-triazole-3-carboxamide 67 (33 mg, 89%) 
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as a colourless oil, (a 1D30 +8.30 (c 2.6 in MeOH); (Found: M+ 257.125. 
C 10H 16N404 + H+ requires 257.125); SH (400 MHz; MeOH-d4) 1.26 (3 H, t, i 
7.24, Me), 2.50 (1 H, ddd, J 5.16,6.60,13.56, H-2'b), 2.80 (1 H, ddd, J2x6.16, 
13.64, H-2'a), 3.46 (2 H, q, J 7.24, C H2 ), 3.69 (1 H, dd, J 5.40,12.04, H-5'b), 3.79 
(1 H, dd, J 4.04,12.00, H-5'a), 4.05 (1 H, ddd appears as q, J 4.20,2 x 4.72, H- 
4'), 4.60 (1 H, ddd appears as q, J 4.95,2 x 5.30, H-3'), 6.34 (1 H, dd, J 5.04,6.56, 
H-1') and 8.73 (1 H, s, H-5); 8C (400 MHz; MeOH-d4) 14.9 (Me), 35.3 (CH2), 41.2 
(C-2'), 63.2 (C-5'), 72.0 (C-3'), 89.6 (C-1'), 89.75 (C-4'), 146.0 (C-5), 158.3 (C-3) 
and 161.2 (C=O); m/z (CI) 274 ((M+NH4)+, 8%), 257 ((M+H)+, 27), 158 (100) 
and 141 (85). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 8.73 ppm (H-5) caused enhancement due to H-1' (2.9%). Irradiation of 
the signal at 6.34 ppm (H-i') caused enhancement due to H-5 (2.4%), H-4' 
(1.0%) and H-2'b (4.5%). 
Synthesis of 1-0 -D-2'-deoxyribofuranosyl-N-n-propyl-1,2,4- 
triazole-3-carboxamide 68* 
0 
Ný 
H N 
HO ý"y 
N-n-Propyl-1,2,4-triazole-3-carboxamid e 21 (60 mg, 0.39 mmol) and 2'- 
deoxycytidine (191 mg, 0.78 mmol) were dissolved in citrate buffer (22 ml, 
20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol (2.5 ml, 
10%). The crude N-deoxyribosyltransferase extract (0.75 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 3d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 
5C8 
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column, 25 cm x 4.6 mm, elution with 4% acetonitrile/10 mM ammonium 
acetate). When the reaction had reached equilibrium (54% conversion), 
the solution was lyophilised and the residue purified by flash 
chromatography on silica gel with a gradient 
(methanol: dichloromethane, 10: 90). Final purification was by preparative 
reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 20 mm, 
elution with 8% acetonitrile/10 mM ammonium acetate, 8 mlmin-1) to give 
1-ß-D-2'-deoxyribofuranosyl-N-n-propyl-1,2,4-triazole-3-carboxamide 68 
(30 mg, 29%) as a clear, colourless oil, (a ID30 +3.07 (c 3.8 in MeOH); (Found: 
M+ 271.1406. C 11 H 18N4O4+H+ requires 271.1408); 'max (H20)/nm 209.6; SH 
(400 MHz; D20) 0.89 (3 H, t, J 7.44, Me), 1.58 (2 H, sextet, J 7.26, CH2CH3), 2.53 
(1 H, ddd, J 5.24,6.72,14.00, H-2'b), 2.79 (1 H, ddd, J 5.36,6.16,14.08, H-2'a), 
3.32 (2 H, t, J 7.04, CH2CH2CH3), 3.66 (1 H, dd, J 6.16,12.32, H-5'b), 3.76 (1 H, 
dd, J 3.88,12.36, H-5'a), 4.09 (1 H, ddd appears as q, J2x4.04,6.08, H-4'), 4.60 
(1 H, ddd appears as q, J2x4.88,5.72, H-3'), 6.35 (1 H, dd, J 5.24,6.60, H-1') 
and 8.64 (1 H, s, H-5); SC (400 MHz; D20) 11.25 (Me), 22.55 (CH2CH3), 39.51 
(CH2CH2CH3), 41.93 (C-2'), 62.14 (C-5'), 71.27 (C-3'), 88.16 (C-1'), 88.63 (C-4'), 
146.19 (C-5), 157.32 (C-3) and 174.16 (C=O); m/z (CI) 271 ((M+H)+, 12%), 155 
((base+H)+, 100), 117 (13), 99 (9) and 58 (11). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 8.65 ppm (H-5) caused enhancement due to H-1' (2.3%). Irradiation of 
the signal at 6.35 ppm (H-1') caused enhancement due to H-5 (4.59%), H-4' 
(1.15%) and H-2'b (7.89%). Irradiation of the signal at 3.75 ppm (H-5'a) 
caused enhancement due to H-3' (3.77%), H-4' (11.32%) and H-5'b (16.23%). 
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Synthesis of 1-o-D-2'-deoxyribofuranosy l-N-n-butyl-1,2,4- 
triazole-3-carboxamide 69* 
0 
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N-n-Butyl-1,2,4-triazole-3-carboxamide 22 (40 mg, 0.26 mmol) and 2'- 
deoxycytidine (184 mg, 0.78 mmol) were dissolved in citrate buffer (9 ml, 
10 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol (1 ml, 
10%). The crude N-deoxyribosyltransferase extract (0.75 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 3d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 10% acetonitrile/10 mM ammonium 
acetate). When the reaction had reached equilibrium (73% conversion), 
the solution was lyophilised and the residue purified by flash 
chromatography on silica gel (methanol: dichloromethane, 5: 95) to give 1- 
ß-D-2'-deoxyribofuranosyl-N-n-butyl-1,2,4-triazole-3-carboxamide 69 (46 
mg, 62%) as a clear, colourless oil, [0X]D30 +9.64 (c 1.4 in MeOH); (Found: M+ 
285.1563. C 12H2ON404+H+ requires 285.1564); 8H (400 MHz; D20) 0.87 (3 H, t, 
J 7.40, Me), 1.31 (2 H, sextet, J 7.44, CH2-y), 1.54 (2 H, quintet, J 7.27, CH2-0), 
2.52 (1 H, ddd, J 5.12,6.84,14.00, H-2'b), 2.78 (1 H, ddd, J 5.24,6.24,14.08, H- 
2'a), 3.34 (2 H, t, J 7.02, CH2-a), 3.65 (1 H, dd, J 6.08,12.32, H-5'b), 3.75 (1 H, 
dd, J 3.92,12.36, H-5'a), 4.08 (1 H, ddd appears as q, J2x4.04,6.16, H-4'), 4.44 
(1 H, ddd appears as q, J3x4.65, H-3'), 6.34 (1 H, dd, J 5.20,6.68, H-1') and 
8.63 (1-H, s, H-5); SC (400 MHz; D20) 13.68 (Me), 20.57 (CH 2-y), 31.19 (CH 2-ß), 
39.56 (CH2-a), 39.98 (C-2'), 62.17 (C-5'), 71.30 (C-3'), 88.20 (C-1'), 88.66 (C-4'), 
146.18 (C-5), 157.33 (C-3) and 161.30 (C=O); m/z (CI) 285 ((M+H)+, 11%), 186 
166 
(40), 169 ((base+H)+, 100), 117 (5), 98 (21) and 72 (5). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 8.63 ppm (H-5) caused enhancement due to H- l' (6.00%) and H-2'a 
(0.91%). Irradiation of the signal at 6.34 ppm (H-1') caused enhancement 
due to H-5 (6.25%), H-4' (1.56%), CH2-a (0.78%), H-2'a (0.40%) and H-2'b 
(7.42%). 
Synthesis of 1-0 -D-2'-deoxyribofuranosyl-V, N. dimetbyl-1,2,4. 
triazole-3-carboxamide 70* 
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N, N-Dimethyl-1,2,4-triazole-3-carboxamide 25 (45 mg, 0.32 mmol) and 2'- 
deoxycytidine (210 mg, 0.86 mmol) were dissolved in citrate buffer (22 ml, 
20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol (2.5 ml, 
10%). The crude N-deoxyribosyltransferase extract (0.75 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 11 d at 40°C. The progress of 
the reaction was monitored by reverse phase HPLC analysis (Techsphere 
5C8 column, 25 cm x 4.6 mm, elution with 4% acetonitrile/10 mM 
ammonium acetate). When the reaction had reached equilibrium (50% 
conversion), the solution was lyophilised and the residue purified by 
flash chromatography on silica gel with a gradient 
(methanol: dichloromethane, 3: 97 to methanol, 100). The last methanol 
fraction contained the product. Final purification was by preparative 
reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 20 mm, 
elution with 5% acetonitrile/10 mM ammonium acetate, 8 m1min-1) to give 
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1-ß-D-2'-deoxyribofuranosyl-N, N-dimethyl-1,2,4-triazole-3-carboxamide 
70 (36 mg, 43%) as a clear, colourless oil, [aID30 +25.0 (c 1.4 in MeOH); 
(Found: M+ 257.1250. C 1OH 16N4O4+H+ requires 257.1251); Amax (H20)/nm 
201.6; 8H (400 MHz; MeOH-d4) 2.52 (1 H, ddd, J 5.28,6.72,13.64, H-2'b), 2.78 (1 
H, ddd, J 4.84,6.28,13.64, H-2'a), 3.17 (3 H, s, Me, syn), 3.33 (3 H, s, Me, anti), 
3.68 (1 H, dd, J 5.48,11.96, H-5'b), 3.78 (1 H, dd, J 4.20,11.96, H-5'a), 4.05 (1 H, 
ddd appears as q, J2x4.24,4.32, H-4'), 4.59 (1 H, ddd appears as q, J2x5.60, 
7.08, H-3'), 6.36 (1 H, dd, J 4.80,6.64, H-1') and 8.77 (1 H, s, H-5); SC (250 MHz; 
MeOH-d4) 36.25 (Me, syn), 39.26 (Me, anti), 41.15 (C-2'), 63.26 (C-5'), 72.64 
(C-3'), 89.63 (C-1'/C-4'), 145.45 (C-5), 158.35 (C-3) and 163.38 (C=O); mlz (CI) 
257 ((M+H)+, 6%), 193 (3), 141 (100), 99 (12) and 81 (13). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 8.77 ppm (H-5) caused enhancement due to H-1' (4.40%). Irradiation of 
the signal at 6.35 ppm (H-1') caused enhancement due to H-5' (2.01%), H-4' 
(1.12%), H-2'a (0.45%) and H-2'b (6.27%). Irradiation of the signal at 3.67 
ppm (H-5'b) caused enhancement due to H-3' (3.36%), H-4' (5.67%) and H- 
5'a (9.24%). 
Synthesis of 1-ß -D-2'-deoxyribofuranosyl-5-amino-1,2,4- 
triazole-3-carboxamide 71* 
0 
N NHp 
ý 
N 
H2 
HO O 
HO 
5-Amino-1,2,4-triazole-3-carboxamide 13 (18 mg, 0.14 mmol) and 2'- 
deoxycytidine (198 mg, 0.82 mmol) were dissolved in citrate buffer (4.5 ml, 
20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol 
(0.5 ml, 
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10%). The crude N-deoxyribosyltransferase extract (0.5 ml, 16.3 mgml-1,9 
U) was added and the mixture incubated for 9d at 40°C. The progress of the 
reaction was monitored by reverse phase HPLC analysis (Techsphere 5C8 
column, 25 cm x 4.6 mm, elution with 10 mM ammonium acetate). When the 
reaction had reached equilibrium (75% conversion), the solution was 
lyophilised and the residue dissolved up in water and filtered under 
centrifugation to remove the protein. Purification was by preparative 
reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm x 20 mm, 
elution with 10 mM ammonium acetate, 8 mlmin-1) to give 1-0-D-2'- 
deoxyribofuranosyl-5-amino-1,2,4-triazole-3-carboxamide 71 (22mg, 64%) 
as a colourless solid, m. p. 178°C (decomp); [a]D30 +29.7 (c 8.0 in MeOH); 
(Found: M+ 244.1046. C8H 13N504+H+ requires 244.1(486); 8H (400 MHz; 
MeOH-d4) 2.32 (1 H, ddd, J 4.00,6.52,13.48, H-2'b), 2.83 (1 H, ddd appears as 
quintet, J 6.32,6.52,13.48, H-2'a), 3.67 (1 H, dd, J 5.00,11.84, H-5'b), 3.75 (1 H, 
dd, J 3.96,11.84, H-5'a), 4.00 (1 H, ddd appears as q, J2x3.80,4.76, H-4'), 4.58 
(1 H, ddd appears as quintet, J 2x3.80,6.24, H-3') and 6.14 (1 H, dd appears 
as t, J 6.36, H-1'); 8C (250 MHz; MeOH-d4) 39.59 (C-2'), 63.52 (C-5'), 72.60 (C- 
3'), 87.44 (C-1'), 89.17 (C-4'), 153.92 (C-5), 157.88 (C-3) and 164.37 (C=O); m 1z 
(CI) 244 ((M+H)+, 67%), 226 (3), 145 (51), 128 ((base+H)+, 100), 112 (7), 98 
(46) and 81 (48); m/z (EI) 177 (4%), 154 (11), 127 (base+", 80), 97 (30) and 69 
(100). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 6.14 ppm (H-1') caused enhancement due to H-4' (1.17%) and 
H-2'b 
(6.43%). Irradiation of the signal at 4.57 ppm (H-3') caused enhancement 
due to H-4' (1.64%), H-5'b (1.18%), H-5'a (1.77%), H-2'a (4.40%) and H-2'b 
(1.10%). 
169 
Synthesis of 1-ß -D-2'-deoxyribofuranosyl-5-amino-N-methyl - 
1,2,4-triazole-3-carboxamide 72* 
0 
N-ý 
ANH 
H2N N 
HO 
FIS 
5-Amino-N-methyl- 1,2,4-triazole-3-carboxamide 14 (43 mg, 0.31 mmol) 
and 2'-deoxycytidine (160 mg, 0.65 mmol) were dissolved in citrate buffer 
(22 ml, 20 mM, pH 6.0 containing 0.05% sodium azide) and ethylene glycol 
(2.5 ml, 10%). The crude N-deoxyribosyltransferase extract (0.5 ml, 16.3 mg 
ml-1,9 U) was added and the mixture incubated for 11 d at 40°C. The 
progress of the reaction was monitored by reverse phase HPLC analysis 
(Techsphere 5C8 column, 25 cm x 4.6 mm, elution with 2% acetonitrile/10 
mM ammonium acetate). When the reaction had reached equilibrium (66% 
conversion), the solution was lyophilised and the residue purified by flash 
chromatography on silica gel with a gradient 
(methanol: dichloromethane, 1: 99 to 20: 80) to give 1-ß -D- 2' - 
deoxyribofuranosyl-5-amino-N-methyl-1,2,4-triazole-3-carboxamide 72 
(35 mg, 43%) as a colourless powder, Rf 0.22 (methanol: dichloromethane, 
1: 9); m. p. 125-127°C; [a]D3o -8.5 (c 1.0 in MeOH); (Found: M+ 258.1203. 
C9H 15N5O4+H+ requires 258.1204); SH (400 MHz; MeOH-d4) 2.31 (1 H, ddd, J 
4.04,6.56,13.48, H-2'b), 2.84 (1 H, ddd, J 6.32, 6.56,13.48, H-2'a), 2.92 (3 H, s, 
Me), 3.66 (1 H, dd, J 5.08,11. 76, H-5'b), 3.75 (1 H, dd, J 4.00,11.76, H-5'a), 4.00 
(1 H, ddd appears as q, J3x 3.80, H-4'), 4.58 (1 H, ddd appears as quintet, J2 
x 3.80,6.20, H-3') and 6.13 (1 H, dd appears as t, J 6.36, H-1'); 
6C (250 MHz; 
MeOH-d4) 26.02 (Me), 39.59 (C-2'), 63.57 (C-5' ), 72.60 (C-3'), 87.13 (C-1'), 89.27 
(C-4'), 154.27 (C-5), 157.71 (C-3) and 162.63 (C=O); m/z (CI) 258 ((M+H)+, 
170 
25%), 220 (5), 168 (8), 142 ((base+H)+, 100), 117 (11), 98 (13) and 43 (27). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 6.13 ppm (H- l') caused enhancement due to H-4' (1.10%), H-2'a (1.10%) 
and H-2'b (6.50%). Irradiation of the signal at 4.00 ppm (H-4') caused 
enhancement due to H-1' (1.3 %), H-3' (2.10%) and H-5' (6.1 %). 
Synthesis of 1-ß-D-2'-deoxyribofuranosylbenzotriazole 73 
ý 
N' 
NN 
ý 
HO 
HO 
Benzotriazole 61 (43 mg, 0.36 mmol) and 2'-deoxycytidine (180 mg, 0.74 
mmol) were dissolved in citrate buffer (45 ml, 0.2M, pH 6.0 containing 
0.05% sodium azide) and ethylene glycol (5 ml, 10%). The crude N- 
deoxyribosyltransferase extract (0.5 ml, 16.3 mgml-1,9 U) was added and 
the mixture incubated for 7d at 40°C. The progress of the reaction was 
monitored by reverse phase HPLC analysis (Techsphere 5C8 column, 25 cm 
x 4.6 mm, elution with 2% - 10% acetonitrile/10 mM ammonium acetate). 
When the reaction had reached equilibrium, the solution was lyophilised 
and the residue purified by flash chromatography on silica gel 
(methanol: dichloromethane, 3: 97) to give 1-ß -D-2'- 
deoxyribofuranosylbenzotriazole 73 (42 mg, 50%) as a colourless solid, 
m. p. 149-150°C (lit., 
202 150-151°C); Xmax (H20)/nm 211.7,257.7 and 280.0 
(lit., 202 257 and 281 nm); 8H (400 MHz; D20) 2.61 (1 H, ddd, J 5.64,6.40, 13.80, 
H-2'b), 3.20 (1 H, ddd, J2 x 5.92,13.92, H-2'a), 3.51 (1 H, dd, J 6.16,12.32, H- 
5b), 3.65 (1 H, dd, J 4.04, 12.28, H-5'a), 4.10 (1 H, ddd as appears q, J2x4.32, 
6.00, H-4'), 4.69 (1 H, ddd appears as q, J2x5.08,6.04, H-3'), 6.72 (1 H, dd 
appears as t ,J5.80,6.24, 
H-1'), 7.42 (1 H, dd appears as t, J 7.56,7.84, H-6), 
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7.55 (1 H, dd appears as t, J 7.40,8.00, H-5), 7.74 (1 H, d, J 8.50, H-7) and 7.92 
(1 H, d, J 8.52, H-4); SH (400 MHz; DMSO-d6) 2.45 (1 H, ddd, J 4.40,6.60,13.34, 
H-2'b), 3.04 (1 H, ddd, J 6.16,6.61,13.35, H-2'a), 3.37 (1 H, dd, J 5.60,11.56, H- 
5'b), 3.51 (1 H, dd, J 5.00,11.56, H-5'a), 3.93 (1 H, ddd appears as br q, J3x 
5.16, H-4'), 4.53 (1 H, ddd appears as m, J2x4.12, 6.00, H-3'), 4.83 (1 H, br s, 
OH-2'), 5.45 (1 H, br s, OH-3'), 6.77 (1 H, dd appears as t, J 6.32, H-1'), 7.43 (1 
H, dd appears as t, J 7.52,7.76, H-6), 7.57 (1 H, dd appears as t, J 7.24,7.96, H- 
5), 7.99 (1 H, d, J 8.36, H-7) and 8.07 (1 H, d, J 8.32, H-4); 8C (400 MHz; DMSO- 
d6) 40.59 (C-2'), 61.93 (C-5'), 70.79 (C-3'), 86.41 (C-1'), 88.30 (C-4'), 111.31 (C- 
7), 119.34 (C-4), 124.45 (C-5), 127.77 (C-6), 132.56 (C-8) and 145.5 (C-9); m /z 
(CI) 236 ((M+H)+, 7%), 220 ((base+H)+, 17), 172 (3), 155 (45), 120 (100), 98 
(7) and 65 (12). 
Nuclear Overhauser enhancement experiments (D20): Irradiation of the 
signal at 6.72 ppm (H-i') caused enhancement due to H-7 (4.7%) and H-2'b 
(6.5%). Irradiation of the signal at 4.10 ppm (H-4') caused no enhancement 
of any signals. 
Nuclear Overhauser enhancement experiments (DMSO-d6): Irradiation of 
the signal at 7.98 ppm (H-7) caused enhancement due to H-6 (9.23%), H-1' 
(5.06%) and H-2'a (1.79%). Irradiation of the signal at 8.06 (H-4) caused 
enhancement due to H-5 ppm (7.63%). Irradiation of the signal at 6.77 ppm 
(H-1') caused enhancement due to H-7 (5.31%), H-4' (1.36%) and H-2'b 
(7.48%). 
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Chemical Synthesis of Nucleoside Analogues 
Synthesis of 2', 3'-O -1,1,3,3 -tetraisopropy1disj1oxyI. rj rin 
168226* 
O 
HpNý N 
N, 
N 
HO 
0 
0.0. O 
si 19 
le 
To a suspension of ribavirin 7 (0.317 g, 1.3 mmol) and imidazole (0.219 g, 
3.22 mmol) (previously freeze dried) in anhydrous DMF (10 ml) was added 
1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (0.48 ml, 1.5 mmol). The clear 
mixture was stirred at room temperature under a nitrogen atmosphere for 
12 h. The solvent was removed in vacuo and the residue was purified by 
flash chromatography on silica gel (methanol: dichloromethane, 3: 97) to 
give 2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl-ribavirin 168 (0.705 g, 66%) as 
a colourless solid, m. p. 202-205°C (decomp); (Found: M+ 487.2402. 
C20H38N4O6Si2+H+ requires 487.2409); 8H (250 MHz; DMSO-d6) 0.96-1.08 (28 
H, m, Pr12Si), 3.53 (1 H, dd, J 4.83,11.90, H-5'a), 3.63 (1 H, dd, J 4.85,11.90, H- 
5'b), 4.04 (1 H, ddd appears as q, J3x4.47, H-4'), 4.61 (1 H, dd appears as t, i 
2x4.46, H-3'), 4.85 (1 H, dd appears as t, J2x4.83, H-2'), 5.07 (1 H, br t, J 
5.97, OH-5'), 5.93 (1 H, d, J 4.83, H-1'), 7.68 (1 H, br s, NH-amide), 7.86 (1 H, br 
s, NH-amide) and 8.94 (1 H, s, H-5); SC (250 MHz; 
DMSO-d6) 12.10-12.57 
(CHSi), 16.84-17.29 (CH3CHSi), 60.79 (C-5'), 72.32 (C-2'), 76.30 (C-3'), 86.03 (C- 
4'), 91.26 (C-1'), 145.47 (C-5), 157.56 (C-3) and 160.33 (C=O); mlz (EI FAB 
THIO) 487 ((M+H)+-, 15%), 391 (50), 357 (82) and 261 (100). 
173 
Synthesis of 5'-iodo-5'-deoxy-2', 3'-O -1,1,3,3-tetraisopropyldisiIoxyl- 
ribavirin 171232* 
0 
FLlN N 
N. 
N 
O, Oý 
A solution of 2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl-ribavirin 168 (100 mg, 
0.21 mmol) and freshly recrystallised239 methyltriphenoxyphosphonium 
iodide 170 (186 mg, 0.41 mmol) in anhydrous DMF (8 ml) was stirred for 1 
h at room temperature under a nitrogen atmosphere and covered to 
exclude light. The reaction was quenched with methanol (1 ml) and the 
solvent removed in vacuo. The residue was partitioned between ethyl 
acetate (40 ml) and sodium thiosulfate (2 x 7.5 ml, 10 M), washed with water 
(10 ml), brine (10 ml), dried over magnesium sulfate and the solvent 
removed in vacuo to give a clear colourless oil. Purification by flash 
chromatography on silica gel (methanol: dichloromethane, 2: 98) and 
recrystallisation from methanol and dichloromethane gave 5'-iodo-5'- 
deoxy-2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl-ribavirin 171 (77 mg, 62%) of 
colourless crystals, Rf 0.35 (methanol: dichloromethane, 1: 10); m. p. 109- 
111°C; (Found: M+ 597.143. C2pH37N4O5Si2I+H+ requires 597.1424); SH (250 
MHz; DMSO-d6) 0.97-1.09 (28 H, m, Pr12Si), 3.39 (1 H, dd, J 5.93,10.47, H-5'a), 
3.56 (1 H, dd, J 4.00,10.48, H-5'b), 4.14 (1 H, ddd appears as q, J2x3.97,6.5 8, 
H-4'), 4.69 (1 H, dd appears as t, J2x4.25, H-3'), 5.00 (1 H, dd appears as t, J2 
x 4.60, H-2'), 6.01 (1 H, d, J 4.70, H-1), 7.70 (1 H, br s, NH-amide), 7.92 (1 H, 
br s, NH-amide) and 8.95 (1 H, s, H-5); SC (250 MHz; DMSO-d6) 6.15 (C-5'), 
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12.17-I2.51 (CHSi), 15.83-17.25 (CH3CHSi), 75.52 (C-3'), 76.35 (C-2'), 84.85 (C- 
4'), 91.25 (C-1'), 146.01 (C-5), 157.74 (C-3) and 160.27 (C=O); m/z (CI) 597 
((M + H) +, 42%), 553 (( M+ - CONH2), 100), 485 (30), 329 (52) and 113 
((base+H)+, 23). 
Synthesis of 5'-iodo-5'-deoxy-ribavirin 173224 
O 
hlZ Ný N 
N 
N 
HO OH 
5'-Iodo-5'-deoxy-2', 3'-0-1,1,3,3-tetraisopropvldisiIoxy I-ribavirin 171 (100 
mg, 0.17 mmol) and ammonium fluoride (104 mg, 2.8 mmol) was refluxed in 
methanol (4 ml) at 60°C (bath temperature) for 40 min. Silica gel was 
added and the solution was evaporated to dryness. The residue was applied 
to a short column (3.0 cm long) and eluted with ethyl acetate (50 ml) 
followed by (methanol: ethyl acetate, 10: 90). The product was recrystallised 
from methanol and dichloromethane to give 5'-iodo-5'-deoxy-ribavirin 
173 (55.1 mg, 91.5%) as colourless crystals, Rf 0.14 
(methanol: dichloromethane, 1: 10); m. p. 180-184°C; (Found: C, 26.95; H, 3.02; 
N, 15.90. C8H 11 N404I requires C, 27.13; H, 3.13; N, 15.82); SH (400 MHz; DMSO- 
d6) 3.33 (1 H, dd, J 7.44,10.54, H-51)), 3.53 (1 H, dd, J 5.24,10.56, H-5'a), 4.03 
(1 H. ddd appears as br q, J2x5.20,7.44, H-4'), 4.19 (1 H, dd appears as 
br q, 
J2x4.75, H-3'), 4.47 (1 H, dd appears as br q, J2x4.32, H-2'), 5.72 (1 H, br d, 
J 5.20, OH-2'), 5.89 (1 H, d, J 3.72, H-1'), 6.01 (1 H, br d, J 5.36, OH-3'), 7.65 (1 
H, br s, NH-amide), 7.88 (1 H, br s, NH-amide) and 
8.87 (1 H, s, H-5); SC (400 
MHz; DMSO-d6) 7.56 (C-5'), 73.45 (C-3'), 74.49 (C-2'), 84.20 (C-4'), 91.29 (C-1'), 
175 
145.66 (C-5), 157.52 (C-3) and 160.34 (C=O); rn/z (CI) 150 (11%), 130 (52), 113 
((base H)+, 100), 99 (6) and 70 (13). 
Nuclear Overhauser enhancement experiments: Irradiation of the signal 
at 5.88 ppm (H-1') caused enhancement due to H-5 (5.30%), H-2' (2.35%) 
and H-3' (1.47%). Irradiation of the signal at 4.48 ppm (H-2') caused 
enhancement due to H-5 (2.05%), H-1' (2.93%), OH-2' (1.76%), OH-3' (0.88%) 
and H-3' (6.45%). Irradiation of the signal at 4.19ppm (H-3') caused 
enhancement due to H-5 (0.70%), H-1' (0.30%), OH-2' (1.40%), OH-3' (1.74%), 
H-2' (6.60%), H-4' (2.1 %) and H-5'a (1.4%). 
Synthesis of 5'-deoxy-2', 3'-O -1,1,3,3-tetraisopropyldisiloxyl- 
ribavirin 172148* 
0 
I-hNýN 
N, 
N 
FI3C, %"l 0 
0. ý, 0 
--ý Ä 
A solution of 5'-iodo-5'-deoxy-2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl- 
ribavirin 171 (90 mg, 0.15 mmol), 10% palladium on carbon (40 mg) and 
sodium acetate (33 mg, 0.40 mmol) in aqueous ethanol (20 ml, 50%) was 
hydrogenated at 15 psi and room temperature for 12 h. The catalyst was 
removed by filtering through a pad of celite and washed with methanol. 
The solvent was evaporated to give 5'-deoxy-2', 3'-O -1 ,1,3,3 - 
tetraisopropyldisiloxyl-ribavirin 172 (45 mg, 63%) as a colourless powder, 
Rf 0.29 (methanol: dichloromethane, 1: 19); (Found: M+ 471.2459. 
C20H38N4O5Si2+H+ requires 471.2460); SH (250 MHz; CDC13) 1.02-1.05 (28 H, 
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m, Pr12 Si), 1.41 (3 H, d, J 6.40, Me-5'), 4.13 (1 H, dd, J 4.38,6.40, H-3'), 4.22 (1 
H, quintet, J 6.40, H-4'), 4.78 (1 H, dd, J 3.05,4.50, H-2'), 5.69 (1 H, br s, NH- 
amide), 5.81 (1 H, d, J 3.20, H-1'), 6.96 (1 H, br s, NH-amide) and 8.27 (1 H, s, 
H-5); SC (250 MHz; CDC13) 12.56-13.19 (CHSi), 16.83-17.32 (CH3CHSi), 18.60 (C- 
5'), 77.10 (C-2'/3'), 80.88 (C-4'), 93.12 (C-1'), 143.90 (C-5), 157.30 (C-3) and 
160.39 (C=O); m/z (CI) 471 ((M+H)+, 100%), 453 (25), 427 (50), 354 (51), 329 
(15) and 113 ((base+H)+, 8). 
Synthesis of 5'-deoxyribavirin 174148 
0 
1-ýNý- N 
N 
O H3C ý, N 
N 
HO OH 
A solution of 5'-iodo-5'-deoxyribavirin 173 (50 mg, 0.141 mmol) and 5% 
palladium on barium carbonate (32 mg) in aqueous ethanol (20 ml, 50%) 
was shaken in a Parr bombe hydrogenator at 18 psi for 16 h. The catalyst 
was removed by filtration through a pad of celite, washed with methanol 
and the filtrate was evaporated to dryness. Recrystallisation from 
methanol and dichloromethane gave 5'-deoxyribavirin 174 (27 mg, 84%) 
as colourless crystals, m. p. 131°C (lit., 
56 132°C); SH (250 MHz; MeOH-d4) 1.41 
(3 H, d, J 6.025, Me-5'), 4.20 (2 H, m, H-374'), 4.61 (1 H, dd, J 3.38,4.30, H-2'), 
5.96 (1 H, d, J 3.23, H-1') and 8.78 (1 H, s, H-5); 8C (250 MHz; MeOH-d4) 19.52 
(C-5'), 76.32 (C-3'), 76.45 (C-2'), 82.45 (C-4'), 94.04 (C-1'), 147.16 (C-5), 158.50 
(C-3) and 163.52 (C=O); m/z (CI) 246 ((M+NH4)+, 10%), 229 ((M+H)+, 100), 
145 (48), 130 (51) and 113 ((base+H)+, 88); m/z (EI) 228 (M+", 25%), 218 (28), 
200 (58) and 169 (100). 
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Synthesis of 3,5'-0 -1,1,3,3-tetraisopropyIdisiIoxyI-rib avirin 
167229 
0 
Fi2N N 
N, 
ý p 
S', 
0 OH 
Ribavirin 7 (1.5 g, 6.69 mmol) was made anhydrous by coevaporation with 
pyridine (10 ml). The residue was dissolved in anhydrous pyridine (45 ml) 
and cooled to 0°C with an ice/water bath. 1,3-Dichloro-1,1,3,3- 
tetraisopropyldisiloxane (1.06 ml, 3.35 mmol) was added dropwise under a 
nitrogen atmosphere and stirred at room temperature for 24 h. The 
reaction was quenched with 5% ammonium carbonate (75 ml) under ice 
cooling and extracted with dichloromethane (2 x 75 ml), the extracts were 
washed with water (150 ml) and brine (25 ml), dried over magnesium 
sulfate and evaporated in vacuo to give a clear oil. Purification by flash 
chromatography on silica gel with a gradient 
(methanol: dichloromethane, 0.5: 99.5 - 95: 5) gave 3', 5'-O -1,1,3 ,3- 
tetraisopropyldisiloxyl-ribavirin 167 (1.34g, 41%) as a colourless foam, 
m. p. 138°C, (lit., 
229 136-138°C); SH (250 MHz; CDC13) 0.98-1.00 (28 H, m, 
Pr'2Si), 3.98 (1 H, dd, J 3.20,15.20, H-5'a), 4.10 (1 H, dd, J 3.78,15.98, H-5'b), 
4.15 (1 H, ddd appears as q, J3x3.48, H-4'), 4.45 (1 H, d, J 4.65, H-3'), 4.60 (1 
H, dd, J 4.93,7.85, H-2'), 5.92 (1 H, s, H-1'), 6.48 (1 H, br s, NH-amide), 7.01 (1 
H, br s, NH-amide) and 8.40 (1 H, s, H-5); SC (250 MHz; CDC13) 12.562-13.22 
(CHSi), 16.79-17.30 (CH3CHSi), 61.36 (C-5'), 70.38 (C-2'), 75.53 (C-3'), 82.72 (C- 
4'), 92.15 (C-1'), 143.71 (C-5), 157.45 (C-3) and 160.86 (C=O); m/z (EI FAB 
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SODIUM THIOGLY) 509 ((M+H+Na)+", 100%), 487 ((M+H)+", 23) and 113 
((base+H)+", 60). The IH and 13C NMR data compared favourably with that 
published by Deyrup et al. 229 
Iodination 
ribavirin232* 
of 2', 3' -O -1,1,3,3-tetraisopropyldisiloxyl- 
0 
FipN) I- N 
N, 
0 -, 
J 
O OH 
H2Ný-ý 
A solution of 3', 5'-0-1,1,3,3-tetraisopropyldisiloxyl-ribavirin 167 (100 mg, 
0.21 mmol) and freshly recrystallised239 methyltriphenoxyphosphonium 
iodide 170 (186 mg, 0.41 mmol) in anhydrous DMF (8 ml) was stirred for 1 
h at room temperature under a nitrogen atmosphere and covered to 
exclude light. The reaction was quenched with methanol (1 ml) and the 
solvent removed in vacuo. The residue was partitioned between ethyl 
acetate (40 ml) and sodium thiosulfate (2 x 7.5 ml, 10 M), washed with water 
(10 ml), brine (10 ml), dried over magnesium sulfate and the solvent 
removed in vacuo to give a clear oil. Purification by flash 
chromatography on silica gel (methanol: dichloromethane, 3: 97) and 
recrystallisation from methanol and dichloromethane gave the iodinated 
21,3'-0-1,1,3,3-tetraisopropyldisiloxyl-ribavirin (74.5 mg, 61%) as 
colourless crystals, which was identical to that of 5'-iodo-5'-deoxy-2', 3'-O- 
1,1,3,3-tetraisopropyldisiloxyl-ribavirin 171 by NMR and TLC. 
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Hydrogenation of the iodination product of 
tetraisopropyidisiloxyl-ribavirin 148 
0 
IiZN N 
N, 
N 
I0 
--ý Ä 
-1,1,3,3- 
0 
1-I2N--N 
N, 
O Ha 
Oý Oý 
,p 
--ý Ä 
A solution of 5'-iodo-5'deoxy-2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl- 
ribavirin 171 (74.5 mg, 0.125 mmol) and 5% palladium on barium 
carbonate (50 mg) and sodium acetate (15 mg) in aqueous ethanol (15 ml, 
50%) was shaken in a Parr bombe hydrogenator at 18 psi for 5 h. The 
catalyst was removed by filtration through a pad of celite, washed with 
methanol and the filtrate was evaporated to dryness. Recrystallisation 
from methanol and dichloromethane gave the hydrogenated product (44.9 
mg, 76.3%) as white crystals, which was identical to 5'-deoxy-2', 3'-O - 
1,1,3,3-tetraisopropyldisdoxyl-ribavirin 172 by TLC and NMR. 
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Synthesis of 5'-D-acetyl-2', 3'-0-1,1,3,3-tetraisopropyl-disiloxyl. 
ribavirin 169* 
0 
H2N N 
O N, 
ON ý 
Oý Op 
To a cooled (0°C) suspension of 2', 3'-0-1,1,3,3-tetraisopropyldisiloxyl- 
ribavirin 168 (60 mg, 0.123 mmol) in dry pyridine (5 ml) was added acetic 
anhydride (0.2 ml, 2.3 mmol). The reaction mixture was stirred at room 
temperature for 3 h. The pyridine was removed in vacuo, the residue was 
dissolved in ethanol and again evaporated to dryness. The oil was 
dissolved in dichloromethane (20 ml) and washed with aqueous saturated 
sodium hydrogen carbonate, water, dried over sodium sulfate and 
evaporated to dryness to give 5'-O-acetyl-2', 3'-O-1,1,3,3- 
tetraisopropyldisiloxyl-ribavirin 169 (60.1 mg, 92.3%) as a colourless 
solid, m. p. 76-78°C; SH (250 MHz; DMSO-d6) 0.96-1.05 (28 H, m, Pr'2-Si), 4.12 
(1 H, dd, J 5.39,11.34, H-5'b), 4.18 (1 H, ddd as m, H-4'), 4.34 (1 H, dd, J 3.16, 
11.36, H-5'a), 4.74 (1 H, dd appears as t, J 4.85, H-3'), 4.85 (1 H, dd appears as 
t, J 4.10, H-2'), 6.04 (1 H, d, J 3.70, H-1'), 7.66 (1 H, br s, NH-amide), 7.85 (1 H, 
br s, NH-amide) and 8.98 (1 H, s, H-5); SC (250 MHz; DMSO-d6) 12.08-12.47 
(CH-Si), 16.76-17.13 (CH3CH-Si), 20.46 (Me), 63.23 (C-5'), 72.98 (C-3'), 76.05 
(C-2'), 82.30 (C-4'), 91.07 (C-1'), 145.88 (C-5), 157.77 (C-3), 160.20 (CONH2) 
and 170.08 (COOMe); m/z (CI) 529 ((M+H)+, 
10%), 537 (12), 253 (58), 155 
(100), 127 (75), 113 (13) and 85 (86). 
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